

# CITATION REPORT

List of articles citing

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

DOI: 10.1182/blood-2016-03-643544  
Blood, 2016, 127, 2391-405.

**Source:** <https://exaly.com/paper-pdf/64571328/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2239	Reply to: Correspondence Regarding the Study by Chen-Lu Yang et al. Published in the Chinese Medical Journal, 129(18):2258-9. <b>2016</b> , 129, 2898		
2238	Correspondence Regarding the Study by Chen-Lu Yang et al. Published in the Chinese Medical Journal, 129(18):2258-9. <b>2016</b> , 129, 2897		
2237	[Diagnosis and treatment of polycythaemia vera: state of the art]. <b>2016</b> , 157, 1743-1751		
2236	Monoclonal B-cell Lymphocytosis in a Patient with Wegener Granulomatosis: A Case Report and Update on 2016 World Health Organization Classification. <b>2016</b> , 129, 2258-9		1
2235	Reports of Oncological Societies. <b>2016</b> , 39, 560-567		
2234	Inherited and Acquired Bone Marrow Failure Syndromes: In the Era of Deep Gene Sequencing. <b>2016</b> , 04,		
2233	Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes. <b>2017</b> , 9, e2017017		2
2232	Molecular landscape in acute myeloid leukemia: where do we stand in 2016. <b>2016</b> , 13, 474-482		8
2231	Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. <b>2016</b> , 7, 205-215		5
2230	Treatment of Low-Blast Count AML using Hypomethylating Agents. <b>2017</b> , 9, e2017045		
2229	Myelodysplastic Syndromes and Other Precursor Myeloid Neoplasms in the Era of Genomic Medicine (Mini Review). <b>2016</b> , 04,		
2228	Targeted deep sequencing in primary myelofibrosis. <b>2016</b> , 1, 105-111		120
2227	A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry. <b>2017</b> , 9, e2017046		2
2226	Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing. <b>2016</b> , 7, 56746-56757		14
2225	Sjögren's Syndrome Complicated by Myeloid/Natural Killer Cell Precursor Acute Leukemia: Case Report and Review of the Literature. <b>2016</b> , 2016, 8261249		
2224	Mixed-phenotype acute leukemia: suboptimal treatment when the 2008/2016 WHO classification is used. <b>2016</b> , 51, 233-241		14
2223	Immune Mechanisms in Myelodysplastic Syndrome. <b>2016</b> , 17,		35

2222	Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features. <b>2016</b> , 7, 57021-57035	21
2221	Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. <b>2016</b> , 91, 918-22	40
2220	Epigenetically centered evolution in an example of myeloid malignancy. <b>2016</b> , 91, E361-2	
2219	Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group. <b>2016</b> , 30, 2248-2250	28
2218	'Acute myeloid leukemia: a comprehensive review and 2016 update'. <b>2016</b> , 6, e441	542
2217	The World Health Organization revisits the classification of the myelodysplastic syndromes: Improvement and insufficiencies. <b>2016</b> , 60, 12-5	2
2216	Early-age Acute Leukemia: Revisiting Two Decades of the Brazilian Collaborative Study Group. <b>2016</b> , 47, 593-606	6
2215	Molecular Characterization of Pediatric Acute Myeloid Leukemia: Results of a Multicentric Study in Brazil. <b>2016</b> , 47, 656-667	18
2214	Chronic neutrophilic leukemia in a child with a CSF3R T618I germ line mutation. <i>Blood</i> , <b>2016</b> , 128, 2097-2099	9
2213	Unusual lower back pain with monocytosis: A case report. <b>2016</b> , 12, 4048-4050	
2212	Myeloproliferative Neoplasms: Thrombosis and Hemorrhage. <b>2016</b> , 210-228	
2211	Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review. <b>2016</b> , 25, 501-509	5
2210	Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics. <b>2016</b> , 144, 437-484	5
2209	The Calreticulin gene and myeloproliferative neoplasms. <b>2016</b> , 69, 841-5	7
2208	Targeted therapies in the treatment of adult acute myeloid leukemias: current status and future perspectives. <b>2016</b> , 5, 143-164	5
2207	Coexistence of iAMP21 and fusion in an adolescent with B cell acute lymphoblastic leukemia: literature review of six additional cases. <b>2016</b> , 9, 84	5
2206	Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosis. <b>2016</b> , 6, e507	4
2205	Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. <b>2016</b> , 8, 133	95

2204	Chronische myeloische Leukämie âState of the Art. <b>2016</b> , 11, 48-57		
2203	When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia. <i>Blood</i> , <b>2016</b> , 128, 2381-2387	2.2	40
2202	Mutations in AML: prognostic and therapeutic implications. <b>2016</b> , 2016, 348-355		77
2201	Case 37-2016. An 86-Year-Old Woman with Leukocytosis and Splenomegaly. <b>2016</b> , 375, 2273-2282		1
2200	Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?. <b>2016</b> , 2016, 24-32		18
2199	Treatment of low-risk myelodysplastic syndromes. <b>2016</b> , 2016, 462-469		35
2198	Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <b>2016</b> , 14, 1572-1611		51
2197	Chronic myelomonocytic leukemia âmyelodysplastic typeâin transformation to acute myeloid leukemia âdiagnostic and therapeutic options: case report and literature review / Leucemie mielomonocitarâcronicâforma mielodisplazicâ n transformare spre leucemie acutâmieloidâ diagnostic si optiuni terapeutice: prezentare de caz si revizuirea literaturii. <b>2016</b> , 24, 263-277		
2196	Redefiniendo el plan: nuevas vÃ­as oncogÃ©nicas y nuevos paradigmas en leucemias agudas y crÃ³nicas. <b>2016</b> , 20, 147-149		
2195	How should quality of life assessment be integrated in the evaluation of patients with acute myeloid leukemia?. <b>2016</b> , 1, 373-387		3
2194	Chasing down the triple-negative myeloproliferative neoplasms: Implications for molecular diagnostics. <b>2016</b> , 5, e1248011		4
2193	The new provisional WHO entity 'RUNX1 mutated AML' shows specific genetics but no prognostic influence of dysplasia. <b>2016</b> , 30, 2109-2112		19
2192	Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes. <b>2016</b> , 30, 2322-2331		70
2191	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <b>2016</b> , 22, 1348-1356		51
2190	Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?). <b>2016</b> , 47, 63-9		16
2189	Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. <i>Blood</i> , <b>2016</b> , 128, 686-98	2.2	314
2188	Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts. <b>2016</b> , 11, 416-424		17
2187	Persistence of DNMT3A does not influence clinical outcome in acute myeloid leukaemia. <b>2016</b> , 175, 185-186		1

2186	Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. <i>Blood</i> , <b>2016</b> , 128, 1408-17	2.2	151
2185	[Predictive molecular pathological stratification of hematological neoplasms]. <b>2016</b> , 37, 210-216		
2184	New developments in the understanding and diagnosis of myelodysplastic syndromes with ring sideroblasts. <b>2016</b> , 38, 279-280		
2183	[Treatment of low-risk pediatric lymphocyte-predominant Hodgkin lymphoma]. <b>2016</b> , 192, 827-829		
2182	IRF3 is involved in human acute myeloid leukemia through regulating the expression of miR-155. <b>2016</b> , 478, 1130-5		14
2181	An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T. <b>2016</b> , 11, 425-433		15
2180	MYC rearranged B-cell neoplasms: Impact of genetics on classification. <b>2016</b> , 209, 431-439		12
2179	The role of the CCN family of proteins in blood cancers. <b>2016</b> , 10, 197-205		3
2178	Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian Mpn Group. <b>2016</b> , 146, 408-22		22
2177	Accurate Medicine: Indirect Targeting of NPM1-Mutated AML. <b>2016</b> , 6, 1087-1089		1
2176	Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms. <b>2016</b> , 91, 1277-1280		15
2175	The Pathology of Reactive Lymphadenopathies: A Discussion of Common Reactive Patterns and Their Malignant Mimics. <b>2016</b> , 140, 881-92		9
2174	The disappearance of acute erythroid leukemia: An act of legerdemain at the World Health Organization. <b>2016</b> , 61, 54-7		2
2173	Recent frustration and innovation in myelodysplastic syndrome. <b>2016</b> , 101, 891-3		2
2172	The prognostic impact of bone marrow fibrosis in primary myelofibrosis. <b>2016</b> , 91, E454		3
2171	The prognostic impact of bone marrow fibrosis in primary myelofibrosis. <b>2016</b> , 91, E454-5		10
2170	Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines. <b>2016</b> , 244, 149-156		15
2169	NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value. <b>2016</b> , 104, 582-590		5

2168	Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas. <b>2016</b> , 15, 2241-7		5
2167	Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature. <b>2016</b> , 58, 72-77		26
2166	Aberrations identified by genomic arrays in normal karyotype CMML can be detected in 40% of patients, but do not add prognostic information to molecular mutations. <b>2016</b> , 30, 2235-2238		1
2165	Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. <b>2016</b> , 142, 2041-9		9
2164	Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. <b>2016</b> , 29, 1541-1551		11
2163	Changes in the Updated 2016: WHO Classification of the Myelodysplastic Syndromes and Related Myeloid Neoplasms. <b>2016</b> , 16, 607-609		26
2162	How I treat essential thrombocythemia. <i>Blood</i> , <b>2016</b> , 128, 2403-2414	2.2	46
2161	Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study. <b>2016</b> , 95, 1819-23		8
2160	Treatment-related myelodysplastic syndrome (t-MDS)/acute myeloid leukemia (AML) in children with cancer: A single-center experience. <b>2016</b> , 29, 729-730		2
2159	Established and emerging targeted therapies in the myelodysplastic syndromes. <b>2016</b> , 9, 997-1005		1
2158	Evaluating Elevated Hemoglobin. <b>2016</b> , 316, 1114-5		
2157	Investigation and Management of Erythrocytosis. <b>2016</b> , 11, 342-7		23
2156	Improving prognostic tools in systemic mastocytosis: Insights from mutations. <b>2016</b> , 91, 867-8		
2155	Acute erythroid leukemia with . <b>2016</b> , 29, 1221-31		20
2154	Phenotypic and functional characterization of neutrophils and monocytes from patients with myelodysplastic syndrome by flow cytometry. <b>2016</b> , 308, 19-26		10
2153	Good riddance to the term "refractory anemia" in myelodysplastic syndromes. <b>2016</b> , 51, 22-26		3
2152	Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. <b>2016</b> , 91, 1262-1271		100
2151	Clinical manifestations and diagnosis. <b>2016</b> , 15-23		1

2150 Diagnostic criteria, classification, and prognosis of acute leukemias. **2016**, 25-39

2149 How I diagnose and manage individuals at risk for inherited myeloid malignancies. *Blood*, **2016**, 128, 1800-1813 106

2148 Handbook of Acute Leukemia. **2016**,

2147 Treatment of chronic myelomonocytic leukemia. **2016**, 9, 168-171 0

2146 Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia. **2016**, 8, 359ra129 43

2145 Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera. **2016**, 6, e459 2

2144 Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. *Blood*, **2016**, 128, 2096-2097 2.2 25

2143 Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia. **2016**, 6, e490 6

2142 High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression. **2016**, 6, e491 4

2141 Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. **2016**, 6, e472 32

2140 Cytophies chez le patient g: **2016**, 2016, 27-36

2139 Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists. **2016**, 9, 1189-1202 16

2138 Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. **2016**, 25, 1393-1403 21

2137 Adult Acute Lymphoblastic Leukemia. **2016**, 91, 1645-1666 97

2136 Acute myeloid leukemia with TP53 germ line mutations. *Blood*, **2016**, 128, 2270-2272 2.2 24

2135 Langerhans Cell Histiocytosis and Langerhans Cell Sarcoma: Current Understanding and Differential Diagnosis. **2016**, 56, 109-118 28

2134 Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis. **2016**, 6, e505 4

2133 Integrating cancer genomic data into electronic health records. **2016**, 8, 113 41

2132	Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3(-/dim)CD4(+) population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. <b>2016</b> , 29, 1173-82	21
2131	The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. <b>2016</b> , 30, 453-459	70
2130	BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features. <b>2016</b> , 95, 1211-21	46
2129	CEBPA mutation in a case of chronic myeloid leukemia presenting in myeloid blast crisis. <b>2017</b> , 58, 708-710	2
2128	Synchronous T lymphoblastic lymphoma and myeloid neoplasm with PDGFRA rearrangement. <b>2017</b> , 39, e28-e32	2
2127	Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version. <b>2017</b> , 92, E48-E51	13
2126	Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes. <b>2017</b> , 31, 1226-1229	37
2125	Biological and clinical consequences of NPM1 mutations in AML. <b>2017</b> , 31, 798-807	102
2124	Charakterystyka kliniczna i diagnostyka molekularna nadpłtkowości i nadkrwistości u dzieci. <b>2017</b> , 92, 1-10	
2123	Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms. <b>2017</b> , 96, 919-927	16
2122	Characterization of Mast Cell Activation Syndrome. <b>2017</b> , 353, 207-215	43
2121	Diagnostic work-up of acute myeloid leukemia. <b>2017</b> , 92, 317-321	14
2120	Absence of CALR mutations in JAK2-negative polycythemia. <b>2017</b> , 102, e15-e16	9
2119	Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012. <b>2017</b> , 46, 85-92	17
2118	The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia. <b>2017</b> , 39, 129-136	8
2117	Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling. <b>2017</b> , 15, 8	33
2116	Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia. <b>2017</b> , 56, 7-12	47
2115	Polycythemia Vera Management and Challenges in the Community Health Setting. <b>2017</b> , 92, 179-189	8



2114	Who to screen for calreticulin mutations? An audit of real-life practice and review of current evidence. <b>2017</b> , 40, e22-e23		2
2113	Molecular Analysis of Gene Rearrangements and Mutations in Acute Leukemias and Myeloid Neoplasms. <b>2017</b> , 92, 10.4.1-10.4.49		4
2112	MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia. <b>2017</b> , 58, 1-15		18
2111	Maturation-associated gene expression profiles along normal human bone marrow monopoiesis. <b>2017</b> , 176, 464-474		7
2110	[Hyperleucocytosis with acute uric acid nephropathy in a patient with hepatocellular carcinoma]. <b>2017</b> , 46, 238-239		
2109	Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and acute myeloid leukemia. <b>2017</b> , 102, e125-e128		3
2108	FISH identifies a KAT6A/CREBBP fusion caused by a cryptic insertional t(8;16) in a case of spontaneously remitting congenital acute myeloid leukemia with a normal karyotype. <b>2017</b> , 64, e26450		13
2107	Counting bone marrow blasts as a percentage of nonerythroid cells improves the prognostic evaluation of MDS with erythroid predominance. <b>2017</b> , 92, E55-E57		
2106	Gain-of-function mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. <i>Blood</i> , <b>2017</b> , 129, 2266-2279	2.2	104
2105	A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts. <b>2017</b> , 56, 82-87		4
2104	Neurological Complications of the Leukemias Across the Ages. <b>2017</b> , 17, 13		6
2103	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. <b>2017</b> , 10, 55		208
2102	Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology. <b>2017</b> , 141, 1342-1393		63
2101	Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. <b>2017</b> , 20, 315-328.e7		83
2100	The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia. <b>2017</b> , 92, 454-459		9
2099	Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes. <b>2017</b> , 7, e533		10
2098	The role of the extracellular matrix in primary myelofibrosis. <b>2017</b> , 7, e525		30
2097	Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. <b>2017</b> , 35, 934-946		257

2096	Changes in allele frequencies of and mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. <b>2017</b> , 102, e207-e209	22
2095	Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. <b>2017</b> , 56, 52-59	13
2094	Genetic Basis of Acute Lymphoblastic Leukemia. <b>2017</b> , 35, 975-983	237
2093	Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry. <b>2017</b> , 98, 577-583	17
2092	Diagnostic Liquid-Based Cytology. <b>2017</b> ,	13
2091	Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial. <b>2017</b> , 56, 524-534	12
2090	Atypical chronic myeloid leukemia in a German Shepherd Dog. <b>2017</b> , 29, 338-345	3
2089	Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. <b>2017</b> , 10, 54	30
2088	Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and - Rearrangement. <b>2017</b> , 22, 480-483	4
2087	Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Hematolymphoid Tumours. <b>2017</b> , 11, 96-109	15
2086	New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types. <b>2017</b> , 57, 78-84	18
2085	-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. <b>2017</b> , 102, 529-540	36
2084	Research in morphology and flow cytometry is at the heart of hematology. <b>2017</b> , 102, 421-422	2
2083	Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. <b>2017</b> , 31, 185-192	42
2082	Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. <i>Blood</i> , <b>2017</b> , 129, 1881-1883	2.2 45
2081	Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome. <b>2017</b> , 70, 435-442	13
2080	Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia. <b>2017</b> , 10, 41	24
2079	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. <b>2017</b> , 376, 536-547	383

2078	A novel molecular assay using hybridisation probes and melt curve analysis for exon 9 mutation detection in myeloproliferative neoplasms. <b>2017</b> , 70, 662-668		0
2077	Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis. <i>Blood</i> , <b>2017</b> , 129, 934-939	2.2	23
2076	Application of vitamin D and vitamin D analogs in acute myelogenous leukemia. <b>2017</b> , 50, 1-12		15
2075	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , <b>2017</b> , 129, 1753-1762	2.2	189
2074	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <b>2017</b> , 77, 1261-1270		162
2073	The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. <b>2017</b> , 102, 1035-1043		57
2072	Acute leukaemia with a pure erythroid phenotype: under-recognized morphological and cytogenetic signatures associated universally with primary refractory disease and a dismal clinical outcome. <b>2017</b> , 71, 316-321		3
2071	Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic work-up of 38 patients. <b>2017</b> , 72, 123-129		2
2070	Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. <b>2017</b> , 92, 297-310		39
2069	Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia. <b>2017</b> , 92, E66-E68		8
2068	Diagnostic impact of the 2016 revised who criteria for polycythemia vera. <b>2017</b> , 92, 417-419		18
2067	Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival. <b>2017</b> , 23, 782-789		5
2066	Regulation of Hematopoiesis and Hematological Disease by TGF- $\beta$ Family Signaling Molecules. <b>2017</b> , 9,		19
2065	Haematological cancers: improving outcomes. A summary of updated NICE service guidance in relation to Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS). <b>2017</b> , 70, 461-468		8
2064	Book Reviewâ€”Hematopathology, 2nd edition. <b>2017</b> , 470, 353-354		
2063	Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. <b>2017</b> , 7, e538		16
2062	Familial CEBPA-mutated acute myeloid leukemia. <b>2017</b> , 54, 87-93		35
2061	Mixed phenotype acute leukemia with t(9;22): success with nonacute myeloid leukemia-type intensive induction therapy and stem cell transplantation. <b>2017</b> , 5, 435-439		1

2060	Acute mast cell leukemia associated with t(4;5)(q21;q33). <b>2017</b> , 67, 198-204		6
2059	The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related Disorders. <b>2017</b> , 15, 131-135		4
2058	Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients. <b>2017</b> , 22, 599-606		5
2057	FMS-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD): a villain among others. <b>2017</b> , 39, 283-284		
2056	Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate. <b>2017</b> , 212-213, 38-44		3
2055	Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. <b>2017</b> , 177, 741-750		16
2054	A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia. <b>2017</b> , 39, 375-383		9
2053	Clinical significance of somatic mutation in unexplained blood cytopenia. <i>Blood</i> , <b>2017</b> , 129, 3371-3378	2.2	229
2052	Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. <b>2017</b> , 10, 90		72
2051	Therapy-related myeloid neoplasms. <b>2017</b> , 24, 152-158		22
2050	Response and progression on midostaurin in advanced systemic mastocytosis: D816V and other molecular markers. <i>Blood</i> , <b>2017</b> , 130, 137-145	2.2	64
2049	Generalized palisaded neutrophilic and granulomatous dermatitis-a cutaneous manifestation of chronic myelomonocytic leukemia? A clinical, histopathological, and molecular study of 3 cases. <b>2017</b> , 64, 198-206		9
2048	Implications of molecular genetic diversity in myelodysplastic syndromes. <b>2017</b> , 24, 73-78		35
2047	The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalities. <b>2017</b> , 178, 57-60		2
2046	MYB-GATA1 fusion promotes basophilic leukaemia: involvement of interleukin-33 and nerve growth factor receptors. <b>2017</b> , 242, 347-357		9
2045	Recognition of familial myeloid neoplasia in adults. <b>2017</b> , 54, 60-68		28
2044	Experience with ruxolitinib in the treatment of polycythaemia vera. <b>2017</b> , 8, 139-151		7
2043	Interleukin-1βs emerging therapeutic target in hematological malignancies and potentially in their complications. <b>2017</b> , 31, 306-317		46

2042	Frequency of polycythemia in individuals with normal complete blood cell counts according to the new 2016 WHO classification of myeloid neoplasms. <b>2017</b> , 39, 528-531	8
2041	Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. <b>2017</b> , 102, 1352-1360	37
2040	Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery. <b>2017</b> , 58, 2786-2798	12
2039	Mast cell diseases in patients with insect venom allergy: implications for diagnosis and therapy. <b>2017</b> , 26, 137-145	7
2038	The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes. <b>2017</b> , 58, 2582-2587	7
2037	MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy. <b>2017</b> , 58, 2895-2904	8
2036	Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome. <b>2017</b> , 92, E168-E171	3
2035	CMML: Clinical and molecular aspects. <b>2017</b> , 105, 711-719	26
2034	FLT3-ITD and its current role in acute myeloid leukaemia. <b>2017</b> , 34, 114	54
2033	Splicing factor mutations in MDS RARS and MDS/MPN-RS-T. <b>2017</b> , 105, 720-731	13
2032	Liver function test abnormalities and their clinical relevance in primary myelofibrosis. <b>2017</b> , 7, e557	1
2031	Advances in understanding the pathogenesis of familial myeloproliferative neoplasms. <b>2017</b> , 178, 689-698	25
2030	Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology. <b>2017</b> , 58, 63-72	15
2029	Management of venous thromboembolism in myeloproliferative neoplasms. <b>2017</b> , 24, 108-114	7
2028	Flow cytometry-Recognizing unusual populations in leukemia and lymphoma diagnosis. <b>2017</b> , 39 Suppl 1, 86-92	11
2027	A life-threatening ruxolitinib discontinuation syndrome. <b>2017</b> , 92, 833-838	26
2026	A novel germ-line mutation of c-mpl gene in a sporadic case of essential thrombocythemia. <b>2017</b> , 64, 51-52	4
2025	Imetelstat for treatment of myelofibrosis. <b>2017</b> , 5, 91-97	

2024	Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes. <b>2017</b> , 1541, 209-222	5
2023	NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors. <b>2017</b> , 31, 237-240	10
2022	Recurrent Cytogenetic Abnormalities in Acute Lymphoblastic Leukemia. <b>2017</b> , 1541, 257-278	17
2021	Modeling myeloproliferative neoplasms: From mutations to mouse models and back again. <b>2017</b> , 31, 139-150	6
2020	Mast Cell Leukemia: Review of a Rare Disease and Case Report of Prolonged Survival after Allogeneic Stem Cell Transplant. <b>2017</b> , 10, 46-49	1
2019	Current management of patients with chronic myelomonocytic leukemia. <b>2017</b> , 29, 79-87	6
2018	Frequency and Clinicopathologic Features of RUNX1 Mutations in Patients With Acute Myeloid Leukemia Not Otherwise Specified. <b>2017</b> , 148, 64-72	7
2017	Midostaurin for the treatment of acute myeloid leukemia. <b>2017</b> , 13, 1853-1871	7
2016	CD4-Negative Variant of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm With a Novel PBRM1 Mutation in an 11-Year-Old Girl. <b>2017</b> , 147, 453-460	4
2015	Emerging cell cycle inhibitors for acute myeloid leukemia. <b>2017</b> , 22, 137-148	8
2014	Clinical Significance of Isolated Myeloperoxidase Expression in Pediatric B-Lymphoblastic Leukemia. <b>2017</b> , 147, 374-381	24
2013	Congenital immature pure erythroid leukemia with E-cadherin expression. <b>2017</b> , 106, 711-717	3
2012	Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib. <b>2017</b> , 58, 2969-2972	11
2011	Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance. <b>2017</b> , 96, 1105-1112	9
2010	A single-tube flow cytometric procedure for enhancing the diagnosis and prognostic classification of patients with myelodysplastic syndromes. <b>2017</b> , 39, 577-584	6
2009	Stinging Insect Allergy. <b>2017</b> ,	0
2008	Turning the tide in myelodysplastic/myeloproliferative neoplasms. <b>2017</b> , 17, 425-440	91
2007	JAK2 V617F Mutation Testing in Patients Presenting With Hepatic and Portal Vein Thrombosis. <b>2017</b> , 317, 2228-2229	4

2006	Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. <b>2017</b> , 96, 1297-1302		22
2005	Myeloid neoplasms with germline DDX41 mutation. <b>2017</b> , 106, 163-174		44
2004	MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations. <b>2017</b> , 31, 1995-1997		3
2003	Eosinophil-rich tissue infiltrates in chronic myelomonocytic leukemia patients. <b>2017</b> , 58, 2875-2879		2
2002	The relationship between idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and autoimmunity. <b>2017</b> , 10, 649-657		10
2001	Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. <i>Blood</i> , <b>2017</b> , 130, 397-407	2.2	88
2000	Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. <b>2017</b> , 60, 18-23		17
1999	Targeting Aberrant Signaling in Myeloid Malignancies: Promise Versus Reality. <b>2017</b> , 31, 565-576		3
1998	Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes. <b>2017</b> , 8, 1573-1586		54
1997	Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era. <b>2017</b> , 31, 1845-1854		17
1996	Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis. <b>2017</b> , 10, 99		4
1995	Myeloid neoplasms with germ line RUNX1 mutation. <b>2017</b> , 106, 183-188		14
1994	Introduction: Genetic syndromes predisposing to myeloid neoplasia. <b>2017</b> , 54, 57-59		5
1993	Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. <b>2017</b> , 92, 885-891		29
1992	Révision de la classification des syndromes myéloprolifératifs selon lâMDS en 2016. <b>2017</b> , 2017, 25-28		
1991	Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. <b>2017</b> , 30, 1213-1222		36
1990	Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies. <b>2017</b> , 141, 759-775		21
1989	Genomic determinants of chronic myelomonocytic leukemia. <b>2017</b> , 31, 2815-2823		61

1988	A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. <b>2017</b> , 31, 2726-2731		146
1987	Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia. <b>2017</b> , 8, e2849		21
1986	How I treat chronic myelomonocytic leukemia. <i>Blood</i> , <b>2017</b> , 130, 126-136	2.2	62
1985	Mast Cell Diseases and Drug Hypersensitivity Reactions. <b>2017</b> , 4, 258-267		1
1984	Diagnosis and classification of hematologic malignancies on the basis of genetics. <i>Blood</i> , <b>2017</b> , 130, 410-423		113
1983	Morphologic and Molecular Characteristics of De Novo AML With V617F Mutation. <b>2017</b> , 15, 790-796		9
1982	Mutated and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia. <b>2017</b> , 102, e332-e335		0
1981	Bleeding is not the main clinical issue in many patients with inherited thrombocytopaenias. <b>2017</b> , 23, 673-681		15
1980	"Chronic myelogenous leukemia in primary blast crisis" rather than "de novo -positive acute myeloid leukemia". <b>2017</b> , 5, 757-760		1
1979	T- and NK-Cell Lymphomas and Systemic Lymphoproliferative Disorders and the Immunodeficiency Setting: 2015 SH/EAHP Workshop Report-Part 4. <b>2017</b> , 147, 188-203		16
1978	Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. <b>2017</b> , 148, 49-57		8
1977	Genetic predisposition to hematologic malignancies: management and surveillance. <i>Blood</i> , <b>2017</b> , 130, 424-432	2.2	104
1976	The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. <i>Blood</i> , <b>2017</b> , 130, 433-439	2.2	38
1975	High-throughput sequencing for noninvasive disease detection in hematologic malignancies. <i>Blood</i> , <b>2017</b> , 130, 440-452	2.2	40
1974	Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML. <i>Blood</i> , <b>2017</b> , 130, 832-835	2.2	39
1973	Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group. <b>2017</b> , 92, E534-E541		2
1972	Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. <b>2017</b> , 7, e550		14
1971	Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures. <b>2017</b> , 33, 336-348		43



1970	NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classification. <b>2017</b> , 92, E123-E124	8
1969	Monocytosis in polycythemia vera: Clinical and molecular correlates. <b>2017</b> , 92, 640-645	31
1968	Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy. <b>2017</b> , 24, 139-145	33
1967	Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. <b>2017</b> , 92, 599-606	32
1966	Preparing Viable Single Cells from Human Tissue and Tumors for Cytomic Analysis. <b>2017</b> , 118, 25C.1.1-25C.1.2329	
1965	Clinical and prognostic significance of eosinophilia and inv(16)/t(16;16) in pediatric acute myelomonocytic leukemia (AML-M4). <b>2017</b> , 64, e26512	2
1964	Is karyotyping still needed in the diagnosis and monitoring of chronic myeloid leukemia?. <b>2017</b> , 39, 281-282	
1963	Validation of cebpa mutation testing for use in a clinical setting. <b>2017</b> , 49, S109	
1962	Exposure to cryopreserved platelets mediates suppression of myeloid dendritic cell subset immune responses. <b>2017</b> , 49, S109	
1961	Calreticulin mutation detection in ffpe trephine biopsy specimens of known myeloproliferative neoplasm patients – is it possible?. <b>2017</b> , 49, S109	
1960	Modulation of immune responses in patients following cardiac surgery. <b>2017</b> , 49, S109-S110	
1959	Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis. <b>2017</b> , 92, 555-561	7
1958	Myelodysplastic disorders. <b>2017</b> , 45, 270-274	
1957	Acute leukaemia. <b>2017</b> , 45, 280-286	0
1956	Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm. <b>2017</b> , 31, 1629-1633	26
1955	Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. <b>2017</b> , 28, 1547-1553	36
1954	Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of F-FLT PET. <b>2017</b> , 58, 1603-1608	12
1953	Measurable residual disease testing in acute myeloid leukaemia. <b>2017</b> , 31, 1482-1490	132

1952	Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. <b>2017</b> , 123, 3050-3060		39
1951	Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. <b>2017</b> , 96, 887-894		3
1950	Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R). <b>2017</b> , 92, 614-621		8
1949	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. <i>Blood</i> , <b>2017</b> , 129, 3227-3236	2.2	86
1948	An abnormal bone marrow microenvironment contributes to hematopoietic dysfunction in Fanconi anemia. <b>2017</b> , 102, 1017-1027		18
1947	The classical nature of distinctive CMML monocytes. <i>Blood</i> , <b>2017</b> , 129, 1745-1746	2.2	8
1946	Myeloproliferative Neoplasms. <b>2017</b> , 816-829		
1945	A Lot to Learn about Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. <b>2017</b> , 23, 713-714		3
1944	Iron chelation therapy in low risk myelodysplastic syndrome. <b>2017</b> , 177, 375-387		8
1943	The bone marrow microenvironment - Home of the leukemic blasts. <b>2017</b> , 31, 277-286		80
1942	The only thing that is constant is change: The 2016 revision to the World Health Organisation classification of myelodysplastic syndrome. <b>2017</b> , 57, 102-103		
1941	WHO 2016 update on myeloid neoplasms. <b>2017</b> , 49, S39-S40		
1940	How good are we at predicting the fate of someone with acute myeloid leukaemia?. <b>2017</b> , 31, 1255-1258		21
1939	Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. <b>2017</b> , 92, 542-548		41
1938	Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera. <b>2017</b> , 58, 2768-2769		5
1937	The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. <b>2017</b> , 31, 2211-2218		51
1936	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , <b>2017</b> , 129, 424-447	2.2	2764
1935	Response to Harrison et al. 'Clinically relevant differences between BCSH and WHO diagnostic criteria for ET'. <b>2017</b> , 31, 768-769		

1934	Pure erythroid leukemia. <b>2017</b> , 92, 292-296		32
1933	Unusual extramedullary hematopoietic neoplasms in lymph nodes. <b>2017</b> , 62, 13-22		3
1932	Introduction to a review series on myeloproliferative neoplasms. <i>Blood</i> , <b>2017</b> , 129, 659	2.2	1
1931	Proliferative characteristics of Philadelphia-negative myeloproliferative neoplasms - clinical implications. <b>2017</b> , 39, 21-31		
1930	Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. <i>Blood</i> , <b>2017</b> , 129, 680-692	2.2	131
1929	Myeloid neoplasms with eosinophilia. <i>Blood</i> , <b>2017</b> , 129, 704-714	2.2	143
1928	Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. <i>Blood</i> , <b>2017</b> , 129, 1420-1427	2.2	346
1927	Clinical evolution of autoimmune cytopenias to idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and bone marrow failure syndromes. <b>2017</b> , 92, E26-E29		14
1926	Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. <i>Blood</i> , <b>2017</b> , 129, 667-679	2.2	275
1925	Genomics of chronic neutrophilic leukemia. <i>Blood</i> , <b>2017</b> , 129, 715-722	2.2	48
1924	The Microscope as a Tool for Disease Discovery-A Personal Voyage. <b>2017</b> , 12, 1-24		1
1923	Genomic analysis of myeloproliferative neoplasms in chronic and acute phases. <b>2017</b> , 102, e11-e14		29
1922	How I treat atypical chronic myeloid leukemia. <i>Blood</i> , <b>2017</b> , 129, 838-845	2.2	40
1921	From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. <b>2017</b> , 102, 18-29		8
1920	Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis. <b>2017</b> , 30, 382-392		26
1919	Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT. <b>2017</b> , 92, 344-350		9
1918	Conventional cytogenetics for myeloid neoplasms in the era of next-generation-sequencing. <b>2017</b> , 92, 227-229		2
1917	Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. <b>2017</b> , 92, 94-108		129

1916	Chromosome Preparation for Myeloid Malignancies. <b>2017</b> , 1541, 11-17		1
1915	How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes. <b>2017</b> , 10, 155-159		6
1914	[Mastocytosis : Clinical aspects, diagnostics, therapy]. <b>2017</b> , 68, 67-75		
1913	Splicing factor gene mutations in hematologic malignancies. <i>Blood</i> , <b>2017</b> , 129, 1260-1269	2.2	67
1912	Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement. <b>2017</b> , 129, 293-302		6
1911	Myeloid malignancies and the microenvironment. <i>Blood</i> , <b>2017</b> , 129, 811-822	2.2	94
1910	Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms. <b>2017</b> , 22, 354-360		1
1909	CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. <i>Blood</i> , <b>2017</b> , 129, 371-382	2.2	18
1908	Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?. <b>2017</b> , 176, 352-364		19
1907	Treatment of Myelofibrosis: Old and New Strategies. <b>2017</b> , 10, 1179545X17695233		14
1906	Models of Prognostication in Chronic Myelomonocytic Leukemia. <b>2017</b> , 12, 513-521		6
1905	Diagnostic and Prognostic Utility of Fluorescence In situ Hybridization (FISH) Analysis in Acute Myeloid Leukemia. <b>2017</b> , 12, 568-573		5
1904	Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population. <b>2017</b> , 7, 370-376		7
1903	Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article. <b>2017</b> , 96, e8337		4
1902	Mixed-Phenotype Acute Leukemia: Diagnostic Criteria and Pitfalls. <b>2017</b> , 141, 1462-1468		39
1901	Acute Myeloid Leukemia With a Rare t(7;14)(q21;q32) and Trisomy 4 With Poor Clinical Outcome: A Case Report. <b>2017</b> , 48, 376-380		
1900	Individual risk assessment in MDS in the era of genomic medicine. <b>2017</b> , 54, 133-140		2
1899	Philadelphia chromosome-like acute lymphoblastic leukemia. <i>Blood</i> , <b>2017</b> , 130, 2064-2072	2.2	125

1898	Clinical Correlates and Prognostic Significance of IL-8, sIL-2R, and Immunoglobulin-Free Light Chain Levels in Patients with Myelofibrosis. <b>2017</b> , 40, 574-578	7
1897	Diagnostic and therapeutic implications of genetic heterogeneity in myeloid neoplasms uncovered by comprehensive mutational analysis. <b>2017</b> , 8, 11-13	2
1896	Clonal Hematopoiesis and Atherosclerosis. <b>2017</b> , 377, 1401-1402	23
1895	The 2016 Revision to the World Health Organization Classification of Myelodysplastic Syndromes. <b>2017</b> , 5, 139-143	28
1894	Gene expression and risk of leukemic transformation in myelodysplasia. <i>Blood</i> , <b>2017</b> , 130, 2642-2653	2.2 40
1893	Indolent systemic mastocytosis associated with multiple myeloma: A rare coexistence. <b>2017</b> , 48, 364-368	
1892	The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes. <b>2017</b> , 30, 295-300	6
1891	Familial myelodysplastic syndrome/acute myeloid leukemia. <b>2017</b> , 30, 287-289	14
1890	Flow Cytometry of T cells and T-cell Neoplasms. <b>2017</b> , 37, 725-751	5
1889	Flow Cytometric Assessment of Chronic Myeloid Neoplasms. <b>2017</b> , 37, 803-819	1
1888	Mast Cell Disease Assessment by Flow Cytometric Analysis. <b>2017</b> , 37, 869-878	2
1887	Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of mutational status. <b>2017</b> , 102, 2030-2038	17
1886	Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia. <b>2017</b> , 102, 2039-2047	51
1885	Maintenance of cellular respiration indicates drug resistance in acute myeloid leukemia. <b>2017</b> , 62, 56-63	13
1884	Therapy for Chronic Myelomonocytic Leukemia in a New Era. <b>2017</b> , 12, 468-477	8
1883	NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. <b>2017</b> , 15, 1193-1207	77
1882	Clinical and laboratory assessment of a patient with thrombocytosis. <b>2017</b> , 78, 558-564	4
1881	A t(1;9) translocation involving as a novel mechanism in unclassifiable chronic myeloproliferative neoplasm. <b>2017</b> , 102, e510-e513	

1880	Gene in Childhood B-cell Precursor Acute Lymphoblastic Leukemia: Interplay between Genetic Susceptibility and Somatic Abnormalities. <b>2017</b> , 10, 738-744		7
1879	Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature. <b>2017</b> , 12, 397-405		5
1878	A segmentation method based on HMRF for the aided diagnosis of acute myeloid leukemia. <b>2017</b> , 152, 115-123		19
1877	Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. <b>2017</b> , 18, 1765-1780		57
1876	Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. <b>2017</b> , 102, 2021-2029		28
1875	Familial MPN Predisposition. <b>2017</b> , 12, 442-447		9
1874	Single-cell RNA-seq reveals a distinct transcriptome signature of aneuploid hematopoietic cells. <i>Blood</i> , <b>2017</b> , 130, 2762-2773	2.2	41
1873	Biologico-clinical significance of DNMT3A variants expression in acute myeloid leukemia. <b>2017</b> , 494, 270-277		11
1872	World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. <b>2017</b> , 92, 1243-1259		111
1871	[Not Available]. <b>2017</b> , 142, 1502-1507		
1870	Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. <i>Blood</i> , <b>2017</b> , 130, 2469-2474	2.2	94
1869	Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. <b>2017</b> , 102, 2134-2140		20
1868	Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes. <b>2017</b> , 62, 108-115		16
1867	Understanding lymphoma molecular complexity. <i>Blood</i> , <b>2017</b> , 130, 1780-1781	2.2	2
1866	State of the Art Update and Next Questions: Acute Myeloid Leukemia. <b>2017</b> , 17, 703-709		6
1865	Unravelling biology and shifting paradigms in cancer with single-cell sequencing. <b>2017</b> , 17, 557-569		157
1864	ICUS/CCUS/CHIP: basics & beyond. <b>2017</b> , 10, 915-920		12
1863	Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification. <b>2017</b> , 7, e594		6

1862	Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?. <b>2017</b> , 31, 2536-2537		10
1861	Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis. <b>2017</b> , 31, 2851-2852		16
1860	[Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the Polycythemia vera patients]. <b>2017</b> , 158, 901-909		1
1859	Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics. <b>2017</b> , 12, 448-454		3
1858	Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study. <b>2017</b> , 60, 135-144		7
1857	Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. <i>Blood</i> , <b>2017</b> , 130, 1768-1771	2.2	45
1856	Therapy-related acute myeloid leukemia with inv(16) after successful therapy for de novo acute myeloid leukemia with t(8;21). <b>2017</b> , 96, 2127-2129		0
1855	Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIPÂ) as epigenetic treatment for myelodysplastic syndrome (MDS). <b>2017</b> , 96, 1825-1832		11
1854	Myeloproliferative Neoplasms. <b>2017</b> , 377, 895-6		21
1853	Low CLL-1 Expression Is a Novel Adverse Predictor in 123 Patients with De Novo CD34 Acute Myeloid Leukemia. <b>2017</b> , 26, 1460-1467		9
1852	Chemogenomic Landscape of -mutated AML Reveals Importance of Allele Dosage in Genetics and Glucocorticoid Sensitivity. <b>2017</b> , 23, 6969-6981		26
1851	MDS classification is improving in an era of the WHO 2016 criteria of MDS: A population-based analysis among 9159 MDS patients diagnosed in the Netherlands. <b>2017</b> , 50, 137-140		2
1850	Mutations in myeloproliferative neoplasms - their significance and clinical use. <b>2017</b> , 10, 961-973		17
1849	An unusual type of myeloid sarcoma localization following myelofibrosis: A case report and literature review. <b>2017</b> , 8, 7-10		6
1848	Emerging Therapies and Clinical Challenges in Chronic Myelomonocytic Leukemia. <b>2017</b> , 17, S85-S87		
1847	Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib. <b>2017</b> , 99, 442-448		15
1846	Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome: A case report and literature review. <b>2017</b> , 96, e7975		10
1845	B-acute lymphoblastic leukemia/lymphoma (B-ALL) with precedent or concurrent myelodysplastic syndrome (MDS) with deletion 5q. <b>2017</b> , 10, 75-80		

1844	Smart applications of bionanosensors for BCR/ABL fusion gene detection in leukemia. <b>2017</b> , 29, 413-423	6
1843	Extramedullary hematopoiesis: a new feature of inherited thrombocytopenias?. <b>2017</b> , 15, 2226-2229	6
1842	Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies. <b>2017</b> , 143, 2511-2519	5
1841	Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype. <b>2017</b> , 99, 536-543	14
1840	Mutational profiling of acute myeloid leukemia with normal cytogenetics in Brazilian patients: the value of next-generation sequencing for genomic classification. <b>2017</b> , 65, 1155-1158	9
1839	Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. <b>2017</b> , 18, 1338-1347	176
1838	Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis. <b>2017</b> , 37, 753-769	24
1837	Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. <b>2017</b> , 102, e514-e517	8
1836	New Discoveries in Biology and Molecular Markers. <b>2017</b> , 17, S61-S64	
1835	The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval. <b>2017</b> , 17, e45-e53	12
1834	BCR-ABL Negative CML-Like Disorder. <b>2017</b> , 17, S107-S108	2
1833	Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification. <b>2017</b> , 61, 39-43	2
1832	Targeted next-generation sequencing using a multigene panel in myeloid neoplasms: Implementation in clinical diagnostics. <b>2017</b> , 39, 604-612	5
1831	Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. <b>2017</b> , 96, 1463-1470	31
1830	Immunoglobulin and B-cell disturbances in patients with chronic idiopathic neutropenia. <b>2017</b> , 183, 75-81	1
1829	Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia. <b>2017</b> , 142, 163-178	44
1828	Diagnostic anatomopathologique des n�oplasies my�oprolif�atives chroniques Ph-. <b>2017</b> , 2017, 54-58	
1827	DNA repair genes polymorphisms and genetic susceptibility to Philadelphia-negative myeloproliferative neoplasms in a Portuguese population: The role of base excision repair genes polymorphisms. <b>2017</b> , 13, 4641-4650	5



1826	European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. <b>2017</b> , 92, 1062-1067	23
1825	Response to Dr. Bain's comment on our review article: Pure Erythroid Leukemia. <b>2017</b> , 92, E622	2
1824	CD3 depleted haploidentical stem cell transplant in paediatric acute undifferentiated leukaemia. <b>2017</b> , 2, 12-13	
1823	Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. <b>2017</b> , 7, e584	49
1822	Molecular Malfeasance Mediating Myeloid Malignancies: The Genetics of Acute Myeloid Leukemia. <b>2017</b> , 1633, 1-17	3
1821	Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective. <b>2017</b> , 10, 809-819	4
1820	Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance. <b>2017</b> , 92, E614-E618	20
1819	Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia. <b>2017</b> , 23, 1879-1886	11
1818	A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. <b>2017</b> , 216-217, 10-15	10
1817	Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients. <b>2017</b> , 71, 897-908	9
1816	The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies. <b>2017</b> , 31, 370-388	13
1815	An African Man with Fever, Hepatomegaly and Pancytopenia. <b>2017</b> , 55, S179-S180	
1814	The biology of Philadelphia chromosome-like ALL. <b>2017</b> , 30, 212-221	23
1813	Validation of and proposals for refinements of the WHO 2016 classification for myelodysplastic syndromes. <b>2017</b> , 92, E631-E634	2
1812	Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice. <b>2017</b> , 96, 1591-1593	1
1811	The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms. <b>2017</b> , 17S, S37-S42	1
1810	Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints. <b>2017</b> , 17S, S16-S25	5
1809	Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia. <b>2017</b> , 31, 2271-2273	29

1808	Influence of IDH on FLT3-ITD status in newly diagnosed AML. <b>2017</b> , 31, 2526-2529		18
1807	mutation in blastic plasmacytoid dendritic cell neoplasm. <b>2017</b> , 102, e470-e472		4
1806	Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms. <b>2017</b> , 17S, S62-S74		14
1805	Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. <b>2017</b> , 7, e583		29
1804	Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond. <b>2017</b> , 54, 159-166		24
1803	Evidence-Based Advances in Ferret Medicine. <b>2017</b> , 20, 773-803		2
1802	New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , <b>2017</b> , 130, 1395-1401	2.2	43
1801	Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis. <b>2017</b> , 92, 1187-1192		17
1800	Neuroimaging evidence of brain abnormalities in mastocytosis. <b>2017</b> , 7, e1197		14
1799	Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , <b>2017</b> , 130, 1832-1844	2.2	44
1798	DNA of Erythroid Origin Is Present in Human Plasma and Informs the Types of Anemia. <b>2017</b> , 63, 1614-1623		44
1797	Pharmacotherapy of Myelofibrosis. <b>2017</b> , 77, 1549-1563		5
1796	The Complexities of Defining a Complex Karyotype in Hematological Malignancies: A Need for Standardization?. <b>2017</b> , 138, 65-66		4
1795	The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. <b>2017</b> , 96, 1595-1604		23
1794	Cell Surface Proteomics of N-Linked Glycoproteins for Typing of Human Lymphocytes. <b>2017</b> , 17, 1700156		8
1793	Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. <b>2017</b> , 92, 1193-1197		18
1792	Acute myeloid leukemia with e1a2 BCR-ABL1 fusion gene: two cases with peculiar molecular and clinical presentations. <b>2017</b> , 39, 379-384		1
1791	Myeloid Neoplasms. <b>2017</b> , 37, 575-585		1

1790	Clinicopathological analysis of 46 cases with CD4 and/or CD56 immature haematolymphoid malignancy: reappraisal of blastic plasmacytoid dendritic cell and related neoplasms. <b>2017</b> , 71, 972-984		9
1789	Survival for patients with rare haematologic malignancies: Changes in the early 21st century. <b>2017</b> , 84, 81-87		7
1788	Therapy-related myelodysplastic syndrome after successful treatment of acute promyelocytic leukemia: case report and literature review. <b>2017</b> , 25, 165-179		3
1787	Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence. <b>2017</b> , 60, 123-128		5
1786	A neoplasm with FIP1L1-PDGFR $\alpha$ fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia. <b>2017</b> , 216-217, 91-99		3
1785	Genetic Risk Assessment in Myeloproliferative Neoplasms. <b>2017</b> , 92, 1283-1290		34
1784	The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. <b>2017</b> , 96, 1653-1665		49
1783	Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms. <b>2017</b> , 106, 691-703		14
1782	Diagnostik lymphatischer Neoplasien. <b>2017</b> , 41,		0
1781	Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data. <b>2017</b> , 7, 643		5
1780	Myeloproliferative neoplasms: from origins to outcomes. <i>Blood</i> , <b>2017</b> , 130, 2475-2483	2.2	58
1779	A Novel PCM1-PDGFR $\beta$ Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5). <b>2017</b> , 138, 198-200		3
1778	Acute Myeloid Leukemia With Inv(16)(p13q22) Associated With Hidden Systemic Mastocytosis: Case Report and Review of Literature. <b>2017</b> , 10, 1179545X17700858		1
1777	The genomic landscape of pediatric myelodysplastic syndromes. <b>2017</b> , 8, 1557		77
1776	Does the mutational status affect the bone marrow morphological findings in patients with classical Philadelphia-negative myeloproliferative neoplasms?. <b>2017</b> , 10, 141-143		
1775	The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium. <b>2017</b> , 18, 1929-1938		12
1774	Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN. <b>2017</b> , 12, 592-597		10
1773	Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond. <b>2017</b> , 12, 510-512		22

1772	A scale of "bad" co-mutations in -driven AML. <i>Blood</i> , <b>2017</b> , 130, 1877-1879	2.2	5
1771	Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis. <b>2017</b> , 5, 1988-1991		2
1770	JAK2 detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis. <b>2017</b> , 63, 53-55		
1769	Heterogeneity of GATA2-related myeloid neoplasms. <b>2017</b> , 106, 175-182		29
1768	Upregulation of lysyl oxidase and adhesion to collagen of human megakaryocytes and platelets in primary myelofibrosis. <i>Blood</i> , <b>2017</b> , 130, 829-831	2.2	21
1767	Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms. <b>2017</b> , 135, 835-843		23
1766	Isolated erythrocytosis associated with a CALR mutation. <b>2017</b> , 66, 6-7		3
1765	Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome. <b>2017</b> , 92, 1118-1128		57
1764	Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML. <b>2017</b> , 31, 2247-2251		12
1763	Spontaneous loss of B lineage transcription factors leads to pre-B leukemia in Ebf1Bcl-x mice. <b>2017</b> , 6, e355		5
1762	Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2017</b> , 28, iv41-iv51		175
1761	Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. <b>2017</b> , 102, 1661-1670		40
1760	Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. <i>Blood</i> , <b>2017</b> , 130, 946-948	2.2	31
1759	High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. <i>Blood</i> , <b>2017</b> , 130, 1007-1013	2.2	69
1758	Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients. <b>2017</b> , 102, 1718-1726		24
1757	Dyserythropoiesis of myelodysplastic syndromes. <b>2017</b> , 24, 191-197		16
1756	Evaluation of Testing of Acute Leukemia Samples: Survey Result From the College of American Pathologists. <b>2017</b> , 141, 1101-1106		9
1755	Pathology of the Gastrointestinal Tract. <b>2017</b> , 443-446		

1754	Familial predisposition of myeloid malignancies: biological and clinical significance of recurrent germ line mutations. <b>2017</b> , 106, 160-162	
1753	Blastic Transformation in Mexican Population With Chronic Myelomonocytic Leukemia. <b>2017</b> , 17, 532-538	1
1752	[Transfusions in myelodysplastic syndromes]. <b>2017</b> , 24, 209-215	3
1751	American Society of Hematology 2016 annual meeting. <b>2017</b> , 10, 58-61	0
1750	Abstracts from the 3rd Conference on Aneuploidy and Cancer: Clinical and Experimental Aspects. <b>2017</b> , 10,	78
1749	Mastzellerkrankungen bei Patienten mit Insektengiftallergie: Konsequenzen für Diagnostik und Therapie. <b>2017</b> , 26, 41-52	
1748	Kinase Inhibitor Screening in Myeloid Malignancies. <b>2017</b> , 31, 693-704	3
1747	[Two cases of myeloid sarcomas with review of literature]. <b>2017</b> , 38, 774-777	
1746	Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity. <b>2017</b> , 54, 147-153	6
1745	Acute myeloid leukaemia genomics. <b>2017</b> , 179, 530-542	62
1744	Oral Manifestations of Hematologic Disease. <b>2017</b> , 25, 149-162	11
1743	Acute lymphoblastic leukemia: a comprehensive review and 2017 update. <b>2017</b> , 7, e577	436
1742	Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes. <b>2017</b> , 102, 1502-1510	19
1741	Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis. <b>2017</b> , 31, 643-661	15
1740	An exploration of the applicability of the refined disease risk index and its integration with other independent risk factors for individualized prognostication. <b>2017</b> , 52, 363-371	3
1739	A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. <b>2017</b> , 31, 318-324	18
1738	The importance of erythroblast enumeration in myeloid neoplasia. <b>2017</b> , 96, 329-330	7
1737	Evidence for a role of decitabine in the treatment of myeloid sarcoma. <b>2017</b> , 96, 505-506	15

1736	Emerging biological therapies to treat acute lymphoblastic leukemia. <b>2017</b> , 22, 107-121	13
1735	The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. <b>2017</b> , 17, 5-19	35 <sup>o</sup>
1734	The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations. <b>2017</b> , 30, 169-179	11
1733	DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. <b>2017</b> , 92, 56-61	48
1732	Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. <b>2017</b> , 58, 1488-1493	35
1731	Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia. <b>2017</b> , 31, 1278-1285	34
1730	Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL). <b>2017</b> , 58, 950-958	10
1729	After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera. <b>2017</b> , 31, 101-118	13
1728	How could patient reported outcomes improve patient management in chronic myeloid leukemia?. <b>2017</b> , 10, 9-14	8
1727	Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia. <b>2017</b> , 64, e26285	9
1726	Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS). <b>2017</b> , 58, 1686-1693	12
1725	Current Management of Childhood Acute Myeloid Leukemia. <b>2017</b> , 19, 1-10	43
1724	BCR-ABL-positive acute myeloid leukemia: About one case treated with ponatinib. <b>2017</b> , 96, 335-336	1
1723	MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report. <b>2017</b> , 40, 97-103	48
1722	A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?. <b>2017</b> , 31, 514-517	14
1721	Improved MPL mutation screening with multiplex PCR and capillary electrophoresis. <b>2017</b> , 179, 838-840	1
1720	Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. <b>2017</b> , 58, 872-881	18
1719	Primary myelofibrosis and its targeted therapy. <b>2017</b> , 96, 531-535	4

1718	Molecular biomarkers in acute myeloid leukemia. <b>2017</b> , 31, 63-76	126
1717	Detection of clonal heterogeneity and targetable mutations in myeloid sarcoma by high-throughput sequencing. <b>2017</b> , 58, 1008-1012	18
1716	Acute lymphoblastic leukemia presenting with hypereosinophilia: Case report and review of the literature. <b>2017</b> , 65, 97-100	5
1715	The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50. <b>2017</b> , 53, 35-38	3
1714	Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants. <b>2017</b> , 31, 759-762	33
1713	Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States. <b>2017</b> , 58, 1648-1654	23
1712	Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients. <b>2017</b> , 31, 970-973	27
1711	Das pathologische Blutbild. <b>2017</b> , 14, 46-58	
1710	Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates. <b>2017</b> , 7, 657	5
1709	Identification of cell-type-specific mutations in nodal T-cell lymphomas. <b>2017</b> , 7, e516	42
1708	Molecular predictors of post-transplant survival in acute myeloid leukemia. <b>2017</b> , 7, 641	6
1707	Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. <b>2017</b> , 7, 662	55
1706	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). <b>2017</b> ,	1
1705	Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts. <b>2017</b> , 7, 630	9
1704	RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. <b>2017</b> , 8, 2126	52
1703	Feasibility of iFISH patterns in hematologic malignancies among Congolese patients at Kinshasa University clinics. <b>2017</b> , 7, 1116-1119	1
1702	Therapy-associated myelodysplastic syndrome with monosomy 7 arising in a Muir-Torre Syndrome patient carrying mutation. <b>2018</b> , 8, 306-309	
1701	An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification. <b>2017</b> , 17, 534	4

1700	A Paediatric Acute Promyelocytic Leukaemia Patient Harboring a Cryptic PML-RARA Insertion due to a Complex Structural Chromosome 17 Rearrangement. <b>2017</b> , 153, 181-189	2
1699	Systemic mastocytosis associated with acute myeloid leukaemia. <b>2017</b> , 49, 652-654	
1698	Philadelphia Chromosome-like Mixed-Phenotype Acute Leukemia Demonstrating P2RY8-CRLF2 Fusion and JAK1 Mutation. <b>2017</b> , 148, 523-528	4
1697	Impending relapse of myelodysplastic syndrome after allogeneic transplant is difficult to diagnose and requires a multi-modal approach. <b>2017</b> , 17, 28	0
1696	Histomorphological responses after therapy with pegylated interferon $\alpha$ in patients with essential thrombocythemia (ET) and polycythemia vera (PV). <b>2017</b> , 6, 30	19
1695	Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing. <b>2017</b> , 8, 82475-82490	23
1694	Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond. <b>2017</b> , 2017, 489-497	17
1693	Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations. <b>2017</b> , 28, 2793-2798	13
1692	Diamond-Blackfan Anemia Predisposing to Myelodysplastic Syndrome in Early Adulthood.. <b>2017</b> , 1, 1-5	0
1691	New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes. <b>2017</b> , 37, 480-494	2
1690	PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features. <b>2017</b> , 8, 29887-29905	8
1689	Novel Therapeutics in Acute Myeloid Leukemia. <b>2017</b> , 37, 495-503	11
1688	Leukemia Clusters. <b>2017</b> , 1-12	
1687	25 Blutbildveränderungen (II). <b>2017</b> ,	
1686	Maternal iAMP21 acute lymphoblastic leukemia detected on prenatal cell-free DNA genetic screening. <b>2017</b> , 1, 1491-1494	3
1685	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. <b>2017</b> , 1, 1312-1323	55
1684	Myeloproliferative neoplasms: from origins to outcomes. <b>2017</b> , 2017, 470-479	10
1683	Clinical implications of somatic mutations in aplastic anemia and myelodysplastic syndrome in genomic age. <b>2017</b> , 2017, 66-72	10



1682	Activated kinases in ALL: time to act. <i>Blood</i> , <b>2017</b> , 129, 3280-3282	2.2	1
1681	Now I cuss less about ICUS. <i>Blood</i> , <b>2017</b> , 129, 3282-3283	2.2	
1680	Overexpression of short isoform has an important role in the development of myelodysplastic/myeloproliferative neoplasms. <b>2017</b> , 1, 1382-1386		8
1679	Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines. <b>2017</b> , 1, 972-979		19
1678	Therapy-related myelofibrosis does not appear to exist. <b>2017</b> , 1, 863-866		3
1677	Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. <b>2017</b> , 1, 2541-2552		19
1676	Myelodysplastic Syndrome Developing Presacral Extramedullary Hematopoiesis with Atypical MRI Findings. <b>2017</b> , 56, 1213-1217		4
1675	What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?. <b>2017</b> , 2017, 480-488		11
1674	Adult chronic myelomonocytic leukemia with trisomy 11: a case report. <b>2017</b> , 24, e547-e550		1
1673	From Erythroblasts to Mature Red Blood Cells: Organelle Clearance in Mammals. <b>2017</b> , 8, 1076		113
1672	Dogs with Acute Myeloid Leukemia Have Clonal Rearrangements in T and B Cell Receptors. <b>2017</b> , 4, 76		19
1671	NPM1 Mutant Mediated PML Delocalization and Stabilization Enhances Autophagy and Cell Survival in Leukemic Cells. <b>2017</b> , 7, 2289-2304		23
1670	Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor. <b>2017</b> , 13, 169-177		11
1669	CDC25 Inhibition in Acute Myeloid Leukemia-A Study of Patient Heterogeneity and the Effects of Different Inhibitors. <b>2017</b> , 22,		7
1668	Diagnostics and Prognostication of Myelodysplastic Syndromes. <b>2017</b> , 37, 465-474		13
1667	Mutations in Inherited and Sporadic Leukemia. <b>2017</b> , 5, 111		44
1666	Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells. <b>2017</b> , 8, 85085-85101		23
1665	A Rare Case of Pure Erythroid Sarcoma in a Pediatric Patient: Case Report and Literature Review. <b>2017</b> , 4,		3

1664	Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis. <b>2017</b> , 18,	9
1663	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. <b>2017</b> , 18,	16
1662	Hereditary thrombocytopenias: a growing list of disorders. <b>2017</b> , 2017, 385-399	65
1661	Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms. <b>2017</b> , 8, 106	43
1660	Insights in Anaphylaxis and Clonal Mast Cell Disorders. <b>2017</b> , 8, 792	14
1659	Targeted Treatment Options in Mastocytosis. <b>2017</b> , 4, 110	16
1658	(A Critical Appraisal of) Classification of Hypereosinophilic Disorders. <b>2017</b> , 4, 216	34
1657	Familial Myelodysplastic/Acute Leukemia Syndromes-Myeloid Neoplasms with Germline Predisposition. <b>2017</b> , 7, 206	4
1656	Inflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells. <b>2017</b> , 7, 265	52
1655	The Use of Flow Cytometry in Myelodysplastic Syndromes: A Review. <b>2017</b> , 7, 270	12
1654	MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. <b>2017</b> , 5, 4	202
1653	Clinical Assessment and Diagnosis of Germline Predisposition to Hematopoietic Malignancies: The University of Chicago Experience. <b>2017</b> , 5, 252	9
1652	Clinical Impact of Genomic Information in Pediatric Leukemia. <b>2017</b> , 5, 263	5
1651	Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience. <b>2017</b> , 5, 265	17
1650	Acquired Elliptocytosis as a Manifestation of Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia. <b>2017</b> , 2017, 3625946	4
1649	Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. <b>2017</b> , 2017, 9876819	5
1648	Immune Thrombocytopenia and JAK2V617F Positive Essential Thrombocythemia: Literature Review and Case Report. <b>2017</b> , 2017, 3725089	3
1647	Myelodysplastic Syndrome Clinically Presenting with the "Classic TTP Pentad". <b>2017</b> , 2017, 4619406	3

1646	A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Extensively Studied by Flow Cytometry and Immunohistochemistry. <b>2017</b> , 2017, 4984951	4
1645	Preclinical Antileukemia Activity of Tramesan: A Newly Identified Bioactive Fungal Metabolite. <b>2017</b> , 2017, 5061639	9
1644	Myelodysplasia and Mast Cell Leukemia with t(9;22). <b>2017</b> , 2017, 9249302	2
1643	Acute Myeloid Leukemia with Basophilic Differentiation Transformed from Myelodysplastic Syndrome. <b>2017</b> , 2017, 4695491	1
1642	A Rare Case of Paraneoplastic Aortitis Associated with Chronic Myelomonocytic Leukemia. <b>2017</b> , 2017, 3091973	5
1641	Uncovering Clinical Features of De Novo Philadelphia Positive Myelodysplasia. <b>2017</b> , 2017, 5404131	3
1640	Emerging therapies for acute myeloid leukemia: translating biology into the clinic. <b>2017</b> , 2,	21
1639	Signal Pathway in Precursor B-Cell Lymphoblastic Leukemia/Lymphoma. <b>2017</b> ,	
1638	Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy. <b>2018</b> , 11, 131-155	32
1637	Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects. <b>2017</b> , 7, 85-93	7
1636	Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. <b>2017</b> , 10, 1585-1601	48
1635	Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients. <b>2017</b> , 12, e0170160	18
1634	The uniqueness of morphological features of pure erythroid leukemia in myeloid neoplasm with erythroid predominance: A reassessment using criteria revised in the 2016 World Health Organization classification. <b>2017</b> , 12, e0172029	2
1633	Evaluation of Opportunities to Improve Hematopathology Diagnosis for Vietnam Pathologists. <b>2017</b> , 148, 529-537	3
1632	Dilemmas in a pregnant woman with myelofibrosis secondary to signet ring adenocarcinoma: a case report. <b>2017</b> , 17, 679	0
1631	Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. <b>2017</b> , 17, 852	29
1630	A unique set of complex chromosomal abnormalities in an infant with myeloid leukemia associated with Down syndrome. <b>2017</b> , 10, 35	2
1629	Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. <b>2017</b> , 10, 156	137

1628	Pyrosequencing quantified methylation level of miR-124 predicts shorter survival for patients with myelodysplastic syndrome. <b>2017</b> , 9, 91	8
1627	mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome. <b>2017</b> , 5, 33	10
1626	Blastic plasmacytoid dendritic cell neoplasm following acquired erythropoietic protoporphyria. <b>2017</b> , 30, 450-451	1
1625	A RARE CASE OF MIXED PHENOTYPE ACUTE LEUKEMIA- B/T CELL TYPE. <b>2017</b> , 57, 82-83	1
1624	Differences of basic and induced autophagic activity between K562 and K562/ADM cells. <b>2017</b> , 6, 281-290	6
1623	Myelodysplasia. 156-166	
1622	Study of clinical, haematological and cytogenetic profile of patients with acute erythroid leukaemia. <b>2017</b> , 11, 712	2
1621	Adult acute megakaryoblastic leukemia: rare association with cytopenias of undetermined significance and p210 and p190 - transcripts. <b>2017</b> , 10, 5047-5051	7
1620	Is it really the Transplant Renaissance in CML Acceleration Phase?. <b>2017</b> , 05,	
1619	Classification and risk assessment in AML: integrating cytogenetics and molecular profiling. <b>2017</b> , 2017, 37-44	30
1618	B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy. <b>2017</b> , 8, 66728-66741	19
1617	Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. <b>2017</b> , 8, 101735-101744	26
1616	genetic variants in leukemias: current insights into treatment outcomes. <b>2017</b> , 10, 169-181	12
1615	Thrombocytosis in a patient with upper gastrointestinal bleeding. <b>2017</b> , 6, 69-71	1
1614	Juvenile myelomonocytic leukemia. <b>2017</b> , 23, 144-153	1
1613	Single-cell dissection of monosomy 7 syndromes. <i>Blood</i> , <b>2017</b> , 130, 2693-2695	2.2
1612	Therapy-related myeloid neoplasms as a concerning complication in acute promyelocytic leukemia. <b>2017</b> , 9, 7204	3
1611	Allogeneic Hematopoietic Stem Cell Transplantation In Therapy-Related Myeloid Neoplasms (t-MN) of the Adult: Monocentric Observational Study and Review of the Literature. <b>2018</b> , 10, e2018005	7

1610	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. <b>2017</b> , 8, 73483-73500	99
1609	Spotlight on anagrelide hydrochloride for the treatment of essential thrombocythemia. <b>2017</b> , Volume 7, 11-23	3
1608	Monosomal karyotype in myeloid neoplasias: a literature review. <b>2017</b> , 10, 2163-2171	10
1607	Intensive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives. <b>2017</b> , 11, 110-114	4
1606	Clonal Cytopenias and Oligoblastic Myelogenous Leukemia (myelodysplasia) Have Neoplastic, not Hyperplastic, Erythropoiesis. <b>2017</b> , 35, 1376	1
1605	Introduction to Genomics in Hematologic Malignancy. <b>2017</b> , 35, 927-928	2
1604	Reply to M.A. Lichtman. <b>2017</b> , 35, 1376-1377	
1603	Genomics of Myeloproliferative Neoplasms. <b>2017</b> , 35, 947-954	43
1602	In Response to "BCR- ABL Testing by Polymerase Chain Reaction in Patients With Neutrophilia: The William Beaumont Hospital Experience and the Case for Rational Laboratory Test Requests". <b>2017</b> , 13, 283-284	1
1601	Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. <b>2017</b> , 35, 968-974	72
1600	Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia. <b>2017</b> , 35, 2708-2715	42
1599	T-cell lymphoma. <b>2017</b> , 23, 22-26	
1598	miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6. <b>2017</b> , 8, 21380-21397	9
1597	HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?. <b>2017</b> , 8, 28187-28202	7
1596	Altered follicular helper T cell impaired antibody production in a murine model of myelodysplastic syndromes. <b>2017</b> , 8, 98270-98279	4
1595	Uncoding the genetic heterogeneity of myelodysplastic syndrome. <b>2017</b> , 2017, 447-452	17
1594	The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study. <b>2017</b> , 8, 37239-37249 <sup>11</sup>	
1593	Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents. <b>2018</b> , 97, 563-572	12

1592	Incidence, Survival, and Risk Factors for Adults with Acute Myeloid Leukemia Not Otherwise Specified and Acute Myeloid Leukemia with Recurrent Genetic Abnormalities: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database, 2001-2013. <b>2018</b> , 139, 115-127	40
1591	Mutational analysis aids the diagnosis of primary myelofibrosis with atypical morphology. <b>2018</b> , 97, 1101-1102	
1590	Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. <b>2018</b> , 107, 673-680	21
1589	Reactive Conditions and Other Diseases Where Flow Cytometric Findings May Mimic Haematological Malignancies. 61-74	
1588	Examples of Immunophenotypic Features in Various Categories of Acute Leukaemia. 75-88	
1587	Ambiguous Lineage and Mixed Phenotype Acute Leukaemia. 191-198	
1586	Flow Cytometry in Myelodysplastic Syndromes. 199-214	0
1585	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). <b>2018</b> , 32, 1370-1379	25
1584	Loss of Full-Length GATA1 Expression in Megakaryocytes Is a Sensitive and Specific Immunohistochemical Marker for the Diagnosis of Myeloid Proliferative Disorder Related to Down Syndrome. <b>2018</b> , 149, 300-309	5
1583	Associations between fatigue, physical activity, and QoL in patients with myeloproliferative neoplasms. <b>2018</b> , 100, 550-559	11
1582	Therapiestrategien bei Erwachsenen mit akuter lymphatischer Leukämie. <b>2018</b> , 21, 38-48	
1581	Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. <b>2018</b> , 40, 366-371	9
1580	Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management. <b>2018</b> , 93, 578-587	19
1579	Atypical chronic myeloid leukaemia: A case of an orphan disease-A multicenter report by the Polish Adult Leukemia Group. <b>2018</b> , 36, 570	5
1578	Polycythemia Vera. <b>2018</b> , 19, 12	33
1577	False-negative mutation in a suspected myeloproliferative neoplasm: identification, resolution and corrective action. <b>2018</b> , 71, 473-474	1
1576	Acute myeloid leukemia with translocation: A case report and review of the literature. <b>2018</b> , 6, 2050313X17750334	334
1575	Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. <b>2018</b> , 32, 1338-1348	56

1574	Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia. <b>2018</b> , 55, 202-208	4
1573	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. <b>2018</b> , 32, 1609-1620	50
1572	Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?. <b>2018</b> , 32, 1482-1492	33
1571	Octasomy 21 in a patient with secondary AML after CMML: the role of acquired NRAS mutations in triggering aneuploidy. <b>2018</b> , 59, 2478-2481	0
1570	Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis. <b>2018</b> , 32, 1515-1528	40
1569	Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. <b>2018</b> , 59, 2737-2739	8
1568	Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia. <b>2018</b> , 23, 51-62	4
1567	Emerging drugs for the treatment of Myelofibrosis. <b>2018</b> , 23, 37-49	9
1566	Beyond JAK-2: potential targets for myeloproliferative neoplasm therapy. <b>2018</b> , 11, 315-324	4
1565	Do athletes have a right to access data in their Athlete Biological Passport?. <b>2018</b> , 10, 802-806	6
1564	Calreticulin mutation analysis in non-mutated Janus kinase 2 essential thrombocythemia patients in Chiang Mai University: analysis of three methods and clinical correlations. <b>2018</b> , 23, 613-619	0
1563	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <b>2018</b> , 32, 1057-1069	263
1562	Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan. <b>2018</b> , 107, 681-688	10
1561	Cytogenetic features in primary myelodysplastic syndrome Egyptian patients. <b>2018</b> , 10, 77-83	6
1560	Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study. <b>2018</b> , 181, 205-214	12
1559	AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. <b>2018</b> , 53, 683-691	10
1558	Chronic neutrophilic leukemia, an extremely rare cause of neutrophilia in childhood: Cure with hematopoietic stem cell transplantation. <b>2018</b> , 22, e13199	
1557	Circulating exosomal microRNAs in acquired aplastic anemia and myelodysplastic syndromes. <b>2018</b> , 103, 1150-1159	19

1556	Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. <b>2018</b> , 55, 215-222	7
1555	Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. <b>2018</b> , 124, 2704-2713	29
1554	Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making. <b>2018</b> , 13, 202-211	19
1553	A typical atypical chronic myeloid leukemia. <b>2018</b> , 6, 915-916	2
1552	Monocyte function in patients with myelodysplastic syndrome. <b>2018</b> , 104, 641-647	8
1551	Inter-observer variance and the need for standardization in the morphological classification of myelodysplastic syndrome. <b>2018</b> , 69, 54-59	13
1550	A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone. <b>2018</b> , 181, 476-485	5
1549	Renovascular hypertension associated with JAK2 V617F positive myeloproliferative neoplasms treated with angioplasty: 2 cases and literature review. <b>2018</b> , 20, 798-804	5
1548	Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. <b>2018</b> , 124, 2758-2765	41
1547	Acute myeloid leukemia (AML) with t(7;12)(q36;p13) is associated with infancy and trisomy 19: Data from Nordic Society for Pediatric Hematology and Oncology (NOPHO-AML) and review of the literature. <b>2018</b> , 57, 359-365	9
1546	Posttransplant Lymphoproliferative Disorder in Kidney and Liver Transplant Recipients: A Single-Center Experience. <b>2018</b> , 50, 2154-2158	3
1545	Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia. <b>2018</b> , 27, 377-387	17
1544	Outcome of patients with acute undifferentiated leukemia after allogeneic hematopoietic stem cell transplantation. <b>2018</b> , 59, 3006-3009	5
1543	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <b>2018</b> , 36, 561	38
1542	An increase in diagnostic JAK2 V617F mutation testing: Is masked polycythaemia vera the explanation?. <b>2018</b> , 52, e37-e38	2
1541	Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. <b>2018</b> , 8, 39	43
1540	Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients. <b>2018</b> , 101, 86-94	19
1539	How I investigate Clonal cytogenetic abnormalities of undetermined significance. <b>2018</b> , 40, 385-391	7



1538	Efficacy and safety of decitabine against cutaneous granuloblastic sarcoma: a case report. <b>2018</b> , 97, 1485-14863	
1537	"Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL. <b>2018</b> , 18, 301-310	4
1536	Evaluation of the Utility of Bone Marrow Morphology and Ancillary Studies in Pediatric Patients Under Surveillance for Myelodysplastic Syndrome. <b>2018</b> , 149, 499-513	2
1535	Germline alterations in a consecutive series of acute myeloid leukemia. <b>2018</b> , 32, 2282-2285	14
1534	PAS positivity of erythroid precursor cells is associated with a poor prognosis in newly diagnosed myelodysplastic syndrome patients. <b>2018</b> , 108, 30-38	
1533	A Rare Case of Pediatric Bone Precursor B-Cell Lymphoma Presenting With Multiple Fractures. <b>2018</b> , 40, 489-490	
1532	[Diagnostic workup in front of an atypical non hemolytic anemia]. <b>2018</b> , 39, 855-862	0
1531	regulates quiescence and differentiation of adult hematopoietic stem cells by restricting RNA polymerase II elongation. <b>2018</b> , 103, 1110-1123	18
1530	IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies. <b>2018</b> , 32, 1249-1253	10
1529	Acute myeloid/T-lymphoblastic leukaemia (AMTL): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy. <b>2018</b> , 180, 919-924	20
1528	Myeloid Malignancies. <b>2018</b> , 397-421	1
1527	Chronic neutrophilic leukemia. <b>2018</b> , 31, 88-89	1
1526	Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. <b>2018</b> , 22, 157-170	225
1525	A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34). <b>2018</b> , 59, 2506-2508	2
1524	Rare BCR-ABL1 transcript in a RUNX1-RUNX1T1-positive de novo acute myeloid leukemia: The chicken and egg tale. <b>2018</b> , 40, e24-e27	1
1523	A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. <b>2018</b> , 31, 873-880	3
1522	GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy. <b>2018</b> , 11, 169-184	17
1521	Refining remission evaluation in MDS with isolated del(5q). <b>2018</b> , 180, 469-470	

1520	8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms. <b>2018</b> , 66, 73-78		20
1519	Prognostic implications of low transferrin saturation in patients with primary myelofibrosis. <b>2018</b> , 66, 89-95		4
1518	How I treat myelodysplastic syndromes of childhood. <i>Blood</i> , <b>2018</b> , 131, 1406-1414	2.2	37
1517	Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. <b>2018</b> , 67, 67-74		7
1516	Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. <b>2018</b> , 31, 1141-1154		15
1515	Chronic neutrophilic leukemia: new science and new diagnostic criteria. <b>2018</b> , 8, 19		11
1514	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. <b>2018</b> , 8, 18		13
1513	Introducing whole-genome sequencing into routine cancer care: the Genomics England 100'000 Genomes Project. <b>2018</b> , 29, 784-787		25
1512	Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia. <b>2018</b> , 59, 2503-2505		2
1511	Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis. <b>2018</b> , 130, 126-133		13
1510	Myeloid Neoplasms Following Solid Organ Transplantation: Clinicopathologic Studies of 23 Cases. <b>2017</b> , 149, 55-66		8
1509	Mastocytosis - pathogenesis, clinical manifestation and treatment. <b>2018</b> , 16, 42-57		4
1508	Rare aggressive natural killer cell leukemia presented with leukopenia and disseminated intravascular coagulation—diagnostic challenge. <b>2018</b> , 11, 5-7		
1507	FGFR1 rearranged hematological neoplasms - molecularly defined and clinically heterogeneous. <b>2018</b> , 59, 1520-1522		5
1506	Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?. <b>2018</b> , 11, 185-194		38
1505	Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response. <b>2018</b> , 7, e1433521		19
1504	Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia. <b>2018</b> , 130, 115-125		
1503	Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools. <b>2018</b> , 100, 444-454		12

1502	Harmonization of interpretative comments in laboratory hematology reporting: the recommendations of the Working Group on Diagnostic Hematology of the Italian Society of Clinical Chemistry and Clinical Molecular Biology (WGDH-SIBioC). <b>2018</b> , 57, 66-77	7
1501	A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XN analyzers in routine laboratory practice. <b>2018</b> , 78, 159-164	5
1500	Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients. <b>2018</b> , 59, 2242-2245	7
1499	Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response. <b>2018</b> , 8, 9	13
1498	Clinical challenges in de novo pediatric acute myeloid leukemia. <b>2018</b> , 18, 277-293	16
1497	The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort. <b>2018</b> , 100, 544-549	4
1496	Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms. <b>2018</b> , 45, 516-528	12
1495	ASXL1 mutations in AML are associated with specific clinical and cytogenetic characteristics. <b>2018</b> , 59, 2439-2446	14
1494	A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. <b>2018</b> , 32, 1493-1499	25
1493	A case of B-cell precursor acute lymphoblastic leukemia with IL3-IGH rearrangement revealed by thromboembolism and marked eosinophilia. <b>2018</b> , 59, 2489-2492	3
1492	Pruritic arthropod bite-like papules in T-cell large granular lymphocytic leukaemia and chronic myelomonocytic leukaemia. <b>2018</b> , 43, 449-453	2
1491	The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. <b>2018</b> , 8, 15	221
1490	Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry. <b>2018</b> , 40, 320-325	1
1489	Rapidly Growing Lesion on the Chest. <b>2018</b> , 109, 821-822	
1488	Deletion of RUNX1 exons 1 and 2 associated with familial platelet disorder with propensity to acute myeloid leukemia. <b>2018</b> , 222-223, 32-37	14
1487	Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?. <b>2018</b> , 8, 8	0
1486	Mast Cell Activation Syndromes and Environmental Exposures. <b>2018</b> , 5, 41-51	
1485	Partial tandem duplication of may predict a subset of myelodysplastic syndrome with unique characteristics and poor outcome. <b>2018</b> , 103, e131-e134	5

1484 Acute Myeloid Leukemia. **2018**, 173-191

1483 Myeloid Proliferations of Down Syndrome. **2018**, 193-198

1482 Acute Leukemias of Ambiguous Lineage. **2018**, 199-209

1481 Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). **2018**, 267-276

1480 Myelodysplastic Syndrome. **2018**, 159-171

1479 EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. **2018**, 8, 12 30

1478 Feline primary erythrocytosis: a multicentre case series of 18 cats. **2018**, 20, 1192-1198 5

1477 Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia. **2018**, 93, E88-E91 13

1476 Atypical chronic myeloid leukemia: a rare entity with management challenges. **2018**, 14, 177-185 12

1475 Complete monocular vision loss due to optic nerve involvement of blastic plasmacytoid dendritic cell neoplasm. **2018**, 57, 989-991 1

1474 Emergence and evolution of mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. **2018**, 103, e143-e146 24

1473 Myeloid neoplasms with t(12;22)(p13;q12)/MN1-EVT6: a systematic review of 12 cases. **2018**, 97, 417-424 7

1472 Molecular approaches identify a cryptic MECOM rearrangement in a child with a rapidly progressive myeloid neoplasm. **2018**, 221, 25-30 5

1471 Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected. **2018**, 6, 1368-1372 34

1470 Hematoma intraparenquimatoso del sistema nervioso central asociado con dasatinib en el tratamiento de leucemia mieloide crónica en fase acelerada. Presentación de dos casos y revisión de la literatura. **2018**, 22, 151-156 0

1469 TNF-related apoptosis-inducing ligand (TRAIL) as the potential therapeutic target in hematological malignancies. **2018**, 98, 566-576 23

1468 Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia. **2018**, 11, 129-143 12

1467 Neuropilin-1/CD304 Expression by Flow Cytometry in Pediatric Precursor B-Acute Lymphoblastic Leukemia: A Minimal Residual Disease and Potential Prognostic Marker. **2018**, 40, 200-207 5

1466	Disease and treatment characteristics of polycythemia vera patients in Belgium: Results from a scientific survey. <b>2018</b> , 100, 361-366	2
1465	Flow cytometric false myeloperoxidase-positive childhood B-lineage acute lymphoblastic leukemia. <b>2018</b> , 94, 477-483	6
1464	Changes in the World Health Organization 2016 classification of myeloid neoplasms everyone should know. <b>2018</b> , 25, 120-128	1
1463	Driver mutations in primary myelofibrosis and their implications. <b>2018</b> , 25, 129-135	8
1462	Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. <b>2018</b> , 183, 835-838	23
1461	Non-neoplastic histiocytic and dendritic cell disorders in lymph nodes. <b>2018</b> , 35, 20-33	8
1460	De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity. <b>2018</b> , 31, 705-717	17
1459	Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. <b>2018</b> , 31, 690-704	22
1458	Essential thrombocythemia treatment algorithm 2018. <b>2018</b> , 8, 2	60
1457	Chronic myelomonocytic leukemia with central nervous system involvement. <b>2018</b> , 59, 2267-2268	0
1456	Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations. <b>2018</b> , 21, 556-563	20
1455	Polycythemia vera treatment algorithm 2018. <b>2018</b> , 8, 3	43
1454	Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms. <b>2018</b> , 22, 98-103	4
1453	Association of mutations with morphological dysplasia in acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. <b>2018</b> , 103, 626-633	12
1452	Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia. <b>2018</b> , 65, 34-41	1
1451	Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1/PDGFRΑ rearrangement. <b>2018</b> , 220, 13-18	3
1450	Imatinib for the treatment of hypereosinophilic syndromes. <b>2018</b> , 14, 163-170	11
1449	Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia. <b>2018</b> , 65, 67-73	9

1448	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. <b>2018</b> , 8, 4		21
1447	Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia. <b>2018</b> , 11, 247-252		1
1446	Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT. <i>Blood</i> , <b>2018</b> , 131, 1846-1857	2.2	21
1445	Management of older adults with myelodysplastic syndromes (MDS). <b>2018</b> , 9, 302-307		5
1444	Intravascular neoplastic cells in canine cutaneous plasmacytomas. <b>2018</b> , 30, 329-332		6
1443	Is bone marrow examination always necessary to establish the diagnosis of myelodysplastic syndromes? A proposed non-invasive diagnostic model. <b>2018</b> , 59, 2227-2232		2
1442	Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform. <b>2018</b> , 11, 109-116		3
1441	Delayed diagnosis of congenital sideroblastic anemia. <b>2018</b> , 55, 177-178		1
1440	Coincidence of 5q deletion and the JAK2V617F mutation: report of two patients with overlapping myelodysplastic and myeloproliferative features and review of the literature. <b>2018</b> , 59, 2233-2237		
1439	Loss of RKIP is a frequent event in myeloid sarcoma and promotes leukemic tissue infiltration. <i>Blood</i> , <b>2018</b> , 131, 826-830	2.2	9
1438	Incidence, racial disparities and survival outcomes of mast cell malignancies: analysis from a national database. <b>2018</b> , 59, 2254-2257		1
1437	Allelic Polymorphisms of s and s Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML. <b>2018</b> , 6, 745-754		21
1436	International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. <i>Blood</i> , <b>2018</b> , 132, 264-276	2.2	53
1435	Disseminated Cutaneous Lesions in a Patient With a Medical History of Myelodysplastic Syndrome. <b>2018</b> , 4, 1281-1282		0
1434	The WHO diagnostic criteria for polycythemia vera-role of red cell mass versus hemoglobin/hematocrit level and morphology. <b>2018</b> , 97, 1581-1590		7
1433	Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis. <b>2018</b> , 13, 173-182		11
1432	BCR/ABL1-negative, triple-negative, myeloproliferative neoplasm with a hitherto undescribed, isolated, SH2B3 (LNK) gene mutation: A case report. <b>2018</b> , 13, 4-8		
1431	Significance of Clonal Mutations in Bone Marrow Failure and Inherited Myelodysplastic Syndrome/Acute Myeloid Leukemia Predisposition Syndromes. <b>2018</b> , 32, 643-655		11

1430	Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey. <b>2018</b> , 18, 420	11
1429	Down syndrome associated childhood myeloid leukemia with yet unreported acquired chromosomal abnormalities and a new potential adverse marker: dup(1)(q25q44). <b>2018</b> , 11, 22	2
1428	Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. <b>2018</b> , 11, 42	45
1427	Dynamics of mutation and prognostic relevance in patients with primary myelodysplastic syndrome. <b>2018</b> , 10, 42	22
1426	Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review. <b>2018</b> , 18, 343	2
1425	De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child. <b>2018</b> , 13, 14	3
1424	A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. <b>2018</b> , 32, 1850-1856	19
1423	Chronic subdural collection overlying an intra-axial hemorrhagic lesion in chronic myelomonocytic leukemia: special report and review of the literature. <b>2018</b> , 18, 371-377	1
1422	Mixed phenotypic acute leukemia. <b>2018</b> , 31, 90-91	1
1421	Myeloproliferative Neoplasms in Danish Twins. <b>2018</b> , 139, 195-198	4
1420	Whole-exome sequencing and microRNA profiling reveal PI3K/AKT pathway involvement in juvenile myelomonocytic leukemia. <b>2018</b> , 6, 85-97	1
1419	Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. <b>2018</b> , 32, 2352-2362	21
1418	Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group. <b>2018</b> , 2, e31	21
1417	Mastozytose - Pathogenese, Klinik und Therapie. <b>2018</b> , 16, 42-59	1
1416	Therapeutic effect of Northern Labrador tea extracts for acute myeloid leukemia. <b>2018</b> , 32, 1636-1641	3
1415	Myeloid sarcoma with megakaryoblastic differentiation presenting as a breast mass. <b>2018</b> , 11, 178-182	3
1414	Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Adults. <b>2018</b> , 24, 1621-1628	2
1413	H2AFY is a novel fusion partner of MECOM in acute myeloid leukemia. <b>2018</b> , 222-223, 9-12	3

1412	Detección de mutaciones en el dominio tirosina quinasa de BCR-ABL1 en pacientes colombianos con leucemia mieloide crónica LMC, resistentes al imatinib. <b>2018</b> , 22, 8-17	
1411	Current status and trends in the diagnostics of AML and MDS. <b>2018</b> , 32, 508-519	23
1410	Predictive factors of fatal bleeding in acute promyelocytic leukemia. <b>2018</b> , 164 Suppl 1, S98-S102	9
1409	Therapy-Related Acute Promyelocytic Leukemia. <b>2018</b> , 231-242	
1408	The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms. <b>2018</b> , 103, e192-e195	26
1407	Hematopoietic cell transplantation for myeloid/NK cell precursor acute leukemia in second remission. <b>2018</b> , 6, 1023-1028	
1406	Assessment of Endothelial Dysfunction With Flow-Mediated Dilatation in Myeloproliferative Disorders. <b>2018</b> , 24, 1102-1108	5
1405	Improving combination cancer therapy: the CombiPlex development platform. <b>2018</b> , 14, 1317-1332	39
1404	MicroRNA-155 expression and function in AML: An evolving paradigm. <b>2018</b> , 62, 1-6	19
1403	Prevalence of oral lesions in and dental needs of patients with newly diagnosed acute leukemia. <b>2018</b> , 149, 470-480	7
1402	Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation. <b>2018</b> , 40, 120-131	16
1401	Active Smoking and Hematocrit and Fasting Circulating Erythropoietin Concentrations in the General Population. <b>2018</b> , 93, 337-343	7
1400	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. <b>2018</b> , 8, 25	18
1399	Clinicopathological characteristics of de novo and secondary myeloid sarcoma: A monocentric retrospective study. <b>2018</b> , 100, 603-612	19
1398	Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. <b>2018</b> , 97, 1349-1356	24
1397	Current approaches to challenging scenarios in myeloproliferative neoplasms. <b>2018</b> , 18, 567-578	3
1396	Cutaneous T-Cell Lymphoma, a Novel Manifestation of PDGFRA-Rearranged Neoplasm. <b>2018</b> , 40, 610-613	2
1395	Time to repeal and replace response criteria for acute myeloid leukemia?. <b>2018</b> , 32, 416-425	33



1394	Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. <b>2018</b> , 59, 2998-3001	5
1393	Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of or. <b>2018</b> , 103, e348-e350	27
1392	Diagnosis and Treatment of Chronic Myeloid Leukemia. <b>2018</b> , 49-68	
1391	Diagnostic biologique dans l'HTA, formes secondaires. <b>2018</b> , 29, 20-21	
1390	JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. <b>2018</b> , 19, 664-668	1
1389	Bleeding and Thrombosis in Hematologic Neoplasia. <b>2018</b> , 1263-1289	1
1388	Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy. <b>2018</b> , 31, 1318-1331	8
1387	Diagnosis and Treatment of Adult Acute Lymphoblastic Leukemia. <b>2018</b> , 337-357	
1386	Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease. <b>2018</b> , 18, e211-e218	2
1385	The -2518 A/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic predisposition factor for secondary myelofibrosis and biomarker of disease severity. <b>2018</b> , 32, 2266-2270	9
1384	An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL). <b>2018</b> , 97, 945-953	24
1383	Immunobiology of Acute Leukemia. <b>2018</b> , 237-279	2
1382	Diagnosis and Treatment of Adult Acute Myeloid Leukemia Other than Acute Promyelocytic Leukemia. <b>2018</b> , 375-407	
1381	ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial. <b>2018</b> , 14, 1995-2004	18
1380	Higher Sclerostin/SOST expression is associated with lower percentage of circulatory blasts and better prognosis in patients with myelofibrosis. <b>2018</b> , 97, 1293-1294	
1379	Mutation analysis of therapy-related myeloid neoplasms. <b>2018</b> , 222-223, 38-45	8
1378	Prognostic Prediction Model for Second Allogeneic Stem-Cell Transplantation in Patients With Relapsed Acute Myeloid Leukemia: Single-Center Report. <b>2018</b> , 18, e167-e182	1
1377	Age and cytogenetic abnormalities. <b>2018</b> , 40, 199	

1376	Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms. <b>2018</b> , 8, 32	9
1375	Limited Utility of Fluorescence In Situ Hybridization for Recurrent Abnormalities in Acute Myeloid Leukemia at Diagnosis and Follow-up. <b>2018</b> , 149, 418-424	4
1374	ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival. <b>2018</b> , 34, 757-763	14
1373	Calreticulin Mutations in Bulgarian MPN Patients. <b>2018</b> , 24, 171-174	1
1372	Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. <b>2018</b> , 182, 141-145	2
1371	AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia. <b>2018</b> , 94, 82-93	61
1370	Familial Acute Myeloid Leukemia and Myelodysplasia in Hungary. <b>2018</b> , 24, 83-88	6
1369	A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. <b>2018</b> , 32, 413-418	42
1368	Mastocytosis: a case series of 107 consecutive patients. <b>2018</b> , 178, e28-e29	2
1367	Expression of Coagulation Factor XIII Subunit A Correlates with Outcome in Childhood Acute Lymphoblastic Leukemia. <b>2018</b> , 24, 345-352	4
1366	Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation. <b>2018</b> , 182, 148-152	3
1365	Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia. <b>2018</b> , 59, 146-154	10
1364	A pattern-based approach to reactive lymphadenopathies. <b>2018</b> , 35, 4-19	14
1363	SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. <b>2018</b> , 32, 139-148	17
1362	Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations. <b>2018</b> , 73, 230-238	59
1361	Characteristics of bone marrow cell dysplasia and its effectiveness in diagnosing myelodysplastic syndrome. <b>2018</b> , 23, 65-76	
1360	Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing. <b>2018</b> , 59, 501-504	29
1359	Differential effects on gene transcription and hematopoietic differentiation correlate with GATA2 mutant disease phenotypes. <b>2018</b> , 32, 194-202	32

1358	Acute leukemic transformation of myelodysplastic syndrome: Is cytochemistry still relevant?. <b>2018</b> , 93, 148-149	
1357	Alternative splicing of hTERT: a further mechanism for the control of active hTERT in acute myeloid leukemia. <b>2018</b> , 59, 702-709	4
1356	Beneficial role of increased FOXP3 regulatory T-cells in acute myeloid leukaemia therapy response. <b>2018</b> , 182, 581-583	6
1355	Diagnostic Dilemma in Ambiguous Lineage Acute Leukemia: A Case Report. <b>2018</b> , 34, 178-180	
1354	Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML. <b>2018</b> , 32, 295-302	25
1353	The diverse expression of the WT1 gene in patients with acquired bone marrow failure syndromes. <b>2018</b> , 59, 950-957	0
1352	Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. <b>2018</b> , 182, 594-597	18
1351	MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients. <b>2018</b> , 93, 100-106	23
1350	How we diagnose and treat systemic mastocytosis in adults. <b>2018</b> , 180, 11-23	37
1349	Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS. <b>2018</b> , 69, 90-100	16
1348	Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes. <b>2018</b> , 57, 80-88	21
1347	Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). <b>2018</b> , 93, E27-E30	14
1346	Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis. <b>2018</b> , 32, 837-839	20
1345	Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cyto reduction in myeloproliferative neoplasms. <b>2018</b> , 29, 723-728	5
1344	JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib. <b>2018</b> , 73, 171-175	4
1343	The MOSAICC study: Assessing feasibility for biological sample collection in epidemiology studies and comparison of DNA yields from saliva and whole blood samples. <b>2018</b> , 82, 114-118	4
1342	The role of bone marrow morphology in the diagnosis of relapsed acute myeloid leukemia. <b>2018</b> , 32, 1053	1
1341	Erythroleukemia-historical perspectives and recent advances in diagnosis and management. <b>2018</b> , 32, 96-105	22

1340	Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT). <b>2018</b> , 93, 31-39	10
1339	Splenic Rupture Secondary to Blastic Plasmacytoid Dendritic Cell Neoplasm. <b>2018</b> , 22, 544-545	
1338	Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. <b>2018</b> , 93, 65-73	37
1337	Recommendations on the use of ruxolitinib for the treatment of myelofibrosis. <b>2018</b> , 23, 194-200	1
1336	Atypical haematological presentation in a case of polycythaemia vera with a new variant mutation detected in exon 12: c.1605G>T (p.Met535Ile). <b>2018</b> , 71, 180-184	1
1335	A ten-color tube with dried antibody reagents for the screening of hematological malignancies. <b>2018</b> , 40, 136-143	8
1334	Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis. <b>2018</b> , 107, 166-172	6
1333	Analysis of Clinical Profile and Outcome of Tuberculosis in Patients with Acute Leukemia. <b>2018</b> , 34, 430-442	7
1332	A novel cryptic CFBF-MYH11 gene fusion present at birth leading to acute myeloid leukemia and allowing molecular monitoring for minimal residual disease. <b>2018</b> , 11, 34-38	3
1331	Incidence of second solid cancers in mastocytosis patients: a SEER database analysis. <b>2018</b> , 59, 1474-1477	4
1330	Consumption of fruits, vegetables, and risk of hematological malignancies: a systematic review and meta-analysis of prospective studies. <b>2018</b> , 59, 434-447	16
1329	A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1. <b>2018</b> , 59, 1121-1126	1
1328	Impact of clinical utility of MRD assessment with different techniques on survival in acute B lymphoblastic leukemia. <b>2018</b> , 59, 1073-1083	5
1327	Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). <b>2018</b> , 59, 1113-1120	12
1326	MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients. <b>2018</b> , 59, 844-854	4
1325	Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2. <b>2018</b> , 32, 556-558	12
1324	Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. <b>2018</b> , 59, 1143-1152	37
1323	Genomic characterization of chromosome translocations in patients with T/myeloid mixed-phenotype acute leukemia. <b>2018</b> , 59, 1231-1238	7

1322	High absolute basophil count is a powerful independent predictor of inferior overall survival in patients with primary myelofibrosis. <b>2018</b> , 23, 201-207		4
1321	Initial flow cytometric evaluation of the Clearlab lymphoid screen. <b>2018</b> , 94, 707-713		6
1320	The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes. <b>2018</b> , 97, 247-254		6
1319	Multifocal occurrence of intraoral isolated MS in a patient without leukemic presentation: A case report and literature review. <b>2018</b> , 125, e42-e48		4
1318	DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML. <b>2018</b> , 59, 1938-1948		7
1317	Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia. <b>2018</b> , 11, 13-24		6
1316	Mechanisms underlying the heterogeneity of myelodysplastic syndromes. <b>2018</b> , 58, 17-26		10
1315	Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis. <b>2018</b> , 183, 678-681		10
1314	mutational analysis in acute myeloid leukaemia by a laboratory-developed next-generation sequencing assay. <b>2018</b> , 71, 522-531		10
1313	Between a rock and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. <b>2018</b> , 97, 435-441		69
1312	Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. <b>2018</b> , 93, 129-147		108
1311	Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML. <b>2018</b> , 65, 1-4		13
1310	Isolated myeloperoxidase expression in pediatric B/myeloid mixed phenotype acute leukemia is linked with better survival. <i>Blood</i> , <b>2018</b> , 131, 573-577	2.2	13
1309	Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. <b>2018</b> , 100, 257-263		23
1308	A retrospective review of acute myeloid leukaemia in 35 dogs diagnosed by a combination of morphologic findings, flow cytometric immunophenotyping and cytochemical staining results (2007-2015). <b>2018</b> , 16, 268-275		4
1307	Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. <b>2018</b> , 31, 569-580		6
1306	Shanghai Health Study (2001-2009): What was learned about benzene health effects?. <b>2018</b> , 48, 217-251		20
1305	Hematolymphoid Disorders. <b>2018</b> , 527-572.e5		

1304	Identification of Germline Variants in Tumor Genomic Sequencing Analysis. <b>2018</b> , 20, 123-125		11
1303	Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. <b>2018</b> , 173, 32-41		8
1302	Therapy-related acute myeloid leukaemia and myelodysplastic syndrome in Victoria, Australia 2003-2014. <b>2018</b> , 48, 822-829		5
1301	Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. <b>2018</b> , 31, 429-441		11
1300	A spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician's perspective. <b>2018</b> , 11, 25-35		
1299	Prognostic Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Adults with Chronic Myelomonocytic Leukemia: A Nationwide Retrospective Analysis in Japan. <b>2018</b> , 24, 840-848		10
1298	Polycythemia vera and essential thrombocythemia: algorithmic approach. <b>2018</b> , 25, 112-119		8
1297	Isolated myelosarcoma is characterized by recurrent mutations and concurrent preleukemic clones in the bone marrow. <i>Blood</i> , <b>2018</b> , 131, 577-581	2.2	11
1296	SOHO State-of-the-Art Update and Next Questions: MPN. <b>2018</b> , 18, 1-12		4
1295	The usefulness of mutational data on prognosis of myelodysplastic syndromes: alone or incorporated into the IPSS-R?. <b>2018</b> , 183, 815-819		5
1294	TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia. <b>2018</b> , 233, 5838-5846		16
1293	Therapy-related Acute Myeloid Leukemia After the Treatment of Primary Solid Cancer in Children: A Single-center Experience. <b>2018</b> , 40, e23-e28		2
1292	Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy. <b>2018</b> , 97, 225-232		23
1291	Megakaryocyte and polyploidization. <b>2018</b> , 57, 1-13		42
1290	Age-related clonal hematopoiesis. <i>Blood</i> , <b>2018</b> , 131, 496-504	2.2	145
1289	A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. <b>2018</b> , 93, 277-285		35
1288	Transformation of MDS/MPN-RS-T to AML: Trisomy 13, resistant thrombocytosis and transient disease control with oral busulfan therapy. <b>2018</b> , 93, E16-E17		
1287	A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. <i>Blood</i> , <b>2018</b> , 131, 717-732	2.2	142

1286	Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. <b>2018</b> , 97, 109-121	18
1285	JAK2 V617F mutation can be reliably detected in serum using droplet digital PCR. <b>2018</b> , 40, 181-186	4
1284	,, and mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms. <b>2018</b> , 103, e63-e68	9
1283	Definition of a SNOMED CT pathology subset and microglossary, based on 1.17 million biological samples from the Catalan Pathology Registry. <b>2018</b> , 78, 167-176	6
1282	Myeloid/lymphoid neoplasms with FGFR1 rearrangement. <b>2018</b> , 59, 1672-1676	29
1281	Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis. <b>2018</b> , 59, 1742-1745	6
1280	Simultaneous occurrence of two distinct leukemic clones with PML-RAR $\alpha$ and RUNX1-RUNX1T1 in a case of acute myeloid leukemia. <b>2018</b> , 97, 529-531	
1279	DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia. <b>2018</b> , 51, 68-79	22
1278	Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis. <b>2018</b> , 20, 420-423	10
1277	Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia. <b>2018</b> , 11, 47-53	1
1276	Acute Leukemia in Horses. <b>2018</b> , 55, 159-172	20
1275	Novel epigenetic therapies in hematological malignancies: Current status and beyond. <b>2018</b> , 51, 198-210	18
1274	Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes. <b>2018</b> , 59, 803-812	10
1273	Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors. <b>2018</b> , 59, 452-458	65
1272	Diagnostic challenges in T-lymphoblastic lymphoma, early T-cell precursor acute lymphoblastic leukemia or mixed phenotype acute leukemia: A case report. <b>2018</b> , 97, e12743	6
1271	Acute Undifferentiated Leukemia and Mixed-Phenotype Acute Leukemias. <b>2018</b> , 481-487.e1	
1270	Recent advances in the diagnosis and management of primary myelofibrosis. <b>2018</b> , 33, 679-690	8
1269	Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature. <b>2018</b> , 4, 1-4	0

1268	Hematopoietic Neoplasia. <b>2018</b> , 363-395	
1267	The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. <b>2018</b> , 2, 1765-1772	63
1266	Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy. <b>2018</b> , 128, 5383-5398	16
1265	Polymorphisms of the CYR61 gene in patients with acute myeloid leukemia in a Han Chinese population. <b>2018</b> , 97, e11963	2
1264	Therapeutic Approach to Young Patients With Low-Risk Essential Thrombocythemia: Primum Non Nocere. <b>2018</b> , JCO2018793497	1
1263	The role of cytogenetics and molecular biology in the diagnosis, treatment and monitoring of patients with chronic myeloid leukemia. <b>2018</b> , 54,	1
1262	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. <b>2018</b> , 36, 310-318	224
1261	Acute Myeloid Leukemia: The Good, the Bad, and the Ugly. <b>2018</b> , 38, 555-573	44
1260	Molecular Hematopathology. <b>2018</b> , 712-760.e18	0
1259	Morphologic and immunophenotypic features of a case of acute monoblastic leukemia with unusual positivity for Glycophorin-A. <b>2018</b> , 10, 7823	1
1258	Acute myeloid leukemia with myelodysplasia related changes. <b>2018</b> ,	3
1257	Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. <b>2018</b> , 36, 1831-1839	67
1256	Monografia Giovani FADOI: dalle evidenze alla pratica clinica. <b>2018</b> , 6, 1	
1255	Co-Occurrence of Myeloid Sarcoma of the Lymph Node and Acute Monocytic Myeloid Leukemia: A Case Report and Literature Review. <b>2018</b> , 11, 791-799	1
1254	Are Enterocolic Mucosal Mast Cell Aggregates Clinically Relevant in Patients Without Suspected or Established Systemic Mastocytosis?. <b>2018</b> , 42, 1390-1395	6
1253	The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells. <b>2018</b> , 10, 162	13
1252	Overexpression of TEL-MN1 Fusion Enhances Resistance of HL-60 Cells to Idarubicin. <b>2018</b> , 63, 308-314	1
1251	Precursor Lymphoid Neoplasms. <b>2018</b> , 467-480.e1	



1250	Breast cancer resistance protein (BCRP) gene expression in a cohort of adult Egyptian patients with acute myeloid leukemia. <b>2018</b> , 18, 958-964	0
1249	Acute myeloid leukemia with new complex t(8;21;22) induced hemophagocytic lymphohistiocytosis: A case report. <b>2018</b> , 97, e12762	
1248	Incidental abnormal bone marrow signal on magnetic resonance imaging and reflexive testing for the V617F mutation. <b>2018</b> , 8, 881-882	1
1247	Septic Shock Predisposed by an Underlying Chronic Neutrophilic Leukemia with an Atypical Presentation; A Case Report. <b>2018</b> , 11, 871-879	2
1246	Primary Philadelphia chromosome positive acute myeloid leukemia: A case report. <b>2018</b> , 97, e12949	6
1245	The Use of Natural Health Products Especially Papaya Leaf Extract and Dandelion Root Extract in Previously Untreated Chronic Myelomonocytic Leukemia. <b>2018</b> , 2018, 7267920	5
1244	A Case of Myeloproliferative Neoplasm with BCR-FGFR1 Rearrangement: Favorable Outcome after Haploidentical Allogeneic Transplantation. <b>2018</b> , 2018, 5724960	4
1243	A novel PAX5 rearrangement in TCF3-PBX1 acute lymphoblastic leukemia: a case report. <b>2018</b> , 11, 122	1
1242	Mixed phenotype acute leukemia (MPAL). <b>2018</b> ,	1
1241	Small Non-Coding RNAs in Regulation of Course and Therapeutic Efficacy in Acute Myeloid Leukemia. <b>2018</b> ,	
1240	Myeloproliferative and $\hat{a}$ Overlap $\hat{a}$ Myelodysplastic/Myeloproliferative Neoplasms. <b>2018</b> , 488-538.e4	3
1239	Concomitant presence of JAK2V617F mutation and BCR-ABL translocation in two patients: A new entity or a variant of myeloproliferative neoplasms (Case report). <b>2018</b> , 18, 1001-1006	1
1238	Therapy-Related Erythroleukemia in a Man With Metastatic Ewing Sarcoma: A Clinical Role for Advanced Molecular Diagnostics.. <b>2018</b> , 2, 1-6	
1237	in Plasma is a Potential Prognostic Biomarker in Acute Myeloid Leukemia. <b>2018</b> , 13, 236-241	1
1236	Successful Platelet Apheresis for Drug-Resistant Essential Thrombocytosis in the Preoperative Management of Rectal Cancer. <b>2018</b> , 51, 380-386	
1235	Characterizing the Molecular Abnormalities in Rare Ph Acute Myeloid Leukemia. <b>2018</b> , 131, 1246-1248	
1234	Ruxolitinib for the Treatment of Essential Thrombocythemia. <b>2018</b> , 2, e56	5
1233	Chronic Myeloproliferative Neoplasms: Some Remaining Challenges. <b>2018</b> , 2, e147	

1232	Complex and monosomal karyotype are distinct cytogenetic entities with an adverse prognostic impact in paediatric acute myeloid leukaemia. A NOPHO-DBH-AML study. <b>2018</b> , 183, 618-628	4
1231	Minimal/Measurable Residual Disease Monitoring in -Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives. <b>2018</b> , 19,	35
1230	M3/M3v acute myeloid leukemia (AML M3/M3v)::Acute promyelocytic leukemia (APL)::Acute promyelocytic leukemia (APL) PML/RARA. <b>2018</b> ,	1
1229	Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis. <b>2018</b> , 8, 114	11
1228	Comprehensive Monitoring of Patients with Chronic Myeloid Leukemia. <b>2018</b> , 1, 43-50	
1227	Evaluating measurable residual disease in acute myeloid leukemia. <b>2018</b> , 2, 1356-1366	87
1226	MPL-mutated essential thrombocythemia: a morphologic reappraisal. <b>2018</b> , 8, 121	13
1225	The prognostic impact of loss of chromosome 7 material detected by fluorescence in situ hybridization (FISH) in myeloid malignancies. <b>2018</b> , 30, 133-138	1
1224	Molecular landscape and targeted therapy of acute myeloid leukemia. <b>2018</b> , 6, 32	20
1223	Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission. <b>2019</b> , 94, 231-239	7
1222	Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan. <b>2018</b> , 75, 50-57	13
1221	Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. <b>2018</b> , 8, 118	3
1220	Increasing therapy-related myeloid neoplasms in multiple myeloma. <b>2019</b> , 49, e13050	8
1219	Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use. <b>2018</b> , 8, 113	66
1218	Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience. <b>2018</b> , 75, 29-35	10
1217	Venous thromboembolic events during warm autoimmune hemolytic anemia. <b>2018</b> , 13, e0207218	29
1216	A unique case of mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2);BCR-ABL1 sarcoma with epitheliotropism mimicking intestinal T cell lymphoma. <b>2018</b> , 11, 93-98	
1215	Clinical use of FLT3 inhibitors in acute myeloid leukemia. <b>2018</b> , 11, 7041-7052	21

1214	[Acute Promyelocytic Leukemia: New treatment strategies with ATRA and ATO - AML-BFM-Recommendations]. <b>2018</b> , 230, 299-304	5
1213	Prefibrotic myelofibrosis: treatment algorithm 2018. <b>2018</b> , 8, 104	18
1212	Bone mesenchymal stromal cells exhibit functional inhibition but no chromosomal aberrations in chronic myelogenous leukemia. <b>2019</b> , 17, 999-1007	0
1211	Myelodysplastic syndrome from theoretical review to clinical application view. <b>2018</b> , 12, 397	14
1210	Utilization of CMA in myeloid, lymphoid and plasma cell disorders. <b>2018</b> , 228-229, 181-183	
1209	Plasmablastic Lymphoma in an Immunocompetent Patient with MDS/MPN with Ring Sideroblasts and Thrombocytosis-A Case Report. <b>2018</b> , 2018, 2525070	2
1208	Large-Scale Data Sharing Initiatives in Genomic Oncology. <b>2018</b> , 1, 135-148	1
1207	A Rare Case of Triple-Negative Essential Thrombocythemia in a Young Postsplenectomy Patient: A Diagnostic Challenge. <b>2018</b> , 2018, 9079462	3
1206	Two-way detection of image features and immunolabeling of lymphoma cells with one-step microarray analysis. <b>2018</b> , 12, 064106	2
1205	Cytotoxic and pro-apoptotic action of MjTX-I, a phospholipase A2 isolated from snake venom, towards leukemic cells. <b>2018</b> , 24, 40	9
1204	Determination of acceptable limits of precision parameters for lymphocyte count by flow cytometry. <b>2018</b> , 76, 687-693	
1203	The Clinical and Laboratory Features of Clonal Hematopoiesis of Indeterminate Potential. <b>2018</b> , 1, 37-42	1
1202	Gastric carcinoma subsequent to myelodysplastic syndrome with t (1; 19) chromosome translocation: A rare case report and its potential mechanisms. <b>2018</b> , 97, e11535	
1201	[62/m with bee venom allergy and reddish-brown disseminated small macules and papules mainly localized on the trunk : Preparation for the specialist examination: part 5]. <b>2018</b> , 69, 96-99	
1200	The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia. <b>2018</b> , 7, 31	5
1199	Cohort Profile: The Haematological Malignancy Research Network (HMRN): a UK population-based patient cohort. <b>2018</b> , 47, 700-700g	26
1198	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet. <b>2018</b> , 2, e150	48
1197	The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. <b>2018</b> , 16, 360	36

1196	Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias. <b>2018</b> , 9, 5280	22
1195	Better treatment outcomes in patients with actively treated therapy-related myeloid neoplasms harboring a normal karyotype. <b>2018</b> , 13, e0209800	1
1194	Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark. <b>2019</b> , 11, 23-33	10
1193	A complex translocation (1;17;15) with spliced short-type PML-RARA fusion transcripts in acute promyelocytic leukemia: A case report. <b>2019</b> , 17, 1360-1366	4
1192	A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset. <b>2018</b> , 9, 5455	22
1191	Identification of Deregulated Signaling Pathways in Jurkat Cells in Response to a Novel Acylspermidine Analogue-N-Erucoyl Spermidine. <b>2018</b> , 11, 2516865718814543	3
1190	Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease. <b>2018</b> , 19,	18
1189	Early T-cell precursor acute lymphoblastic leukemia. <b>2018</b> ,	
1188	Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. <b>2019</b> , 94, 363-377	71
1187	Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature. <b>2018</b> , 9, 27882-27894	41
1186	Successful alternative treatment for relapsed adult acute lymphoblastic leukemia with dendritic cells-cytokine-induced killer cells combined with a rituximab-based regimen. <b>2018</b> , 11, 7555-7558	3
1185	Detection of Exon 12 and 14 Mutations in Janus Kinase 2 Gene Including a Novel Mutant in V617F Negative Polycythemia Vera Patients from Pakistan. <b>2018</b> , 9, 4341-4345	0
1184	Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis. <b>2018</b> , 6, 33	3
1183	Genetic predictors of response to specific drugs in primary myelofibrosis. <b>2018</b> , 8, 120	0
1182	Mutational spectrum of acute myeloid leukemia patients with double mutations based on next-generation sequencing and its prognostic significance. <b>2018</b> , 9, 24970-24979	24
1181	Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. <b>2018</b> , 124, 4601-4609	6
1180	: guardian of the epigenetic galaxy. <i>Blood</i> , <b>2018</b> , 132, 1468-1469	2.2 1
1179	Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report. <b>2018</b> , 12, 105	2

1178	Molecular alterations in acute myeloid leukemia and their clinical and therapeutical implications. <b>2018</b> , 151, 362-367		2
1177	A Flushed Face and Dilated Retinal Veins. <b>2018</b> , 136, 1414-1415		1
1176	Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies. <b>2018</b> , 13, 426-434		13
1175	Role of TGF- $\beta$ /miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis. <b>2018</b> , 12, 2102-2123		13
1174	Chronic Myelomonocytic Leukemia Mimicking Invasive Fungal Rhinosinusitis. <b>2018</b> , 45, 596-598		1
1173	Significance of Cytogenetics in Leukemia Diagnostics. <b>2018</b> , 6, 165-175		1
1172	Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycythemia vera and essential thrombocythemia. <b>2018</b> , 73, 45-46		1
1171	Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. <i>Blood</i> , <b>2018</b> , 132, 2100-2103	2.2	26
1170	Why and how to treat Ph-like ALL?. <b>2018</b> , 31, 351-356		22
1169	Fanconi Anemia: A Pathway of Hematopoiesis and Cancer Predisposition. <b>2018</b> , 81-97		1
1168	Myelodysplastic Syndrome and Subsequent Diagnosis of Primary Solid Tumors: Evidence from the National Cancer Institute 2001-2011. <b>2018</b> , 38, 5819-5823		0
1167	Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS. <b>2018</b> , 74, 21-41		13
1166	Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. <b>2018</b> , 32, 2546-2557		62
1165	Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML. <b>2018</b> , 8, 13883		6
1164	[Acute Lymphoblastic Leukemia - Diagnostics, Subgroups and Therapies]. <b>2018</b> , 143, 1311-1317		2
1163	Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera. <b>2018</b> , 24, 47-55		2
1162	Therapy-related myeloid neoplasms: clinical perspectives. <b>2018</b> , 11, 5909-5915		9
1161	. <b>2018</b> , 13, 1249-1255		3

1160	A novel dual-cytokine-antibody fusion protein for the treatment of CD38-positive malignancies. <b>2018</b> , 31, 173-179		6
1159	TET2 deficiency leads to stem cell factor-dependent clonal expansion of dysfunctional erythroid progenitors. <i>Blood</i> , <b>2018</b> , 132, 2406-2417	2.2	29
1158	Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia. <b>2018</b> , 8, 47-61		12
1157	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. <b>2018</b> , 379, 1416-1430		256
1156	[Change in paradigm in the treatment of pediatric acquired bone marrow failure syndromes in Hungary]. <b>2018</b> , 159, 1710-1719		
1155	S100 Proteins in Acute Myeloid Leukemia. <b>2018</b> , 20, 1175-1186		15
1154	Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia. <b>2018</b> , 19, 67		20
1153	Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate. <b>2018</b> , 8, 15855		15
1152	Rare gene fusion rearrangement SPTNB1-PDGFRB in an atypical myeloproliferative neoplasm. <b>2018</b> , 11, 56		0
1151	The predictive value of morphological findings in early diagnosis of acute myeloid leukemia with recurrent cytogenetic abnormalities. <b>2018</b> , 75, 23-28		4
1150	Successful Decitabine Treatment in Unfit, Elderly Patients with Acute Myeloid Leukemia following Chronic Myeloproliferative Neoplasm. <b>2018</b> , 140, 231-233		4
1149	Myeloid Sarcoma of the Paranasal Sinuses in a Patient with Acute Myeloid Leukemia. <b>2018</b> , 246, 141-146		8
1148	Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion. <b>2018</b> , 19,		3
1147	A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia. <b>2018</b> , 78, 6762-6770		11
1146	Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors. <b>2018</b> , 19,		21
1145	Myelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: concomitant occurrence of two molecularly distinct diseases. <b>2018</b> , 10, 7658		2
1144	Current management of patients with chronic myelomonocytic leukemia. <b>2018</b> , 30, 409-417		5
1143	Emergence of chronic myeloid leukemia following autologous stem cell transplantation in a young woman with multiple myeloma. <b>2018</b> , 53, 254-256		2

1142	Genital ulcers as diagnostic clue for acute myeloid leukaemia. <b>2018</b> , 15, 845-848	1
1141	Massive splenomegaly: flow cytometry as a diagnostic tool for systemic mastocytosis. <b>2018</b> , 53, 251-254	
1140	Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value. <b>2018</b> , 124, 3849-3855	8
1139	del (5q) solely in Myelodysplastic syndrome. <b>2018</b> ,	
1138	Acute myeloid leukemia: 2019 update on risk-stratification and management. <b>2018</b> , 93, 1267-1291	171
1137	Germline loss-of-function and alterations in adult myelodysplastic syndromes. <i>Blood</i> , <b>2018</b> , 132, 2309-2313	23
1136	Rapidly Growing Lesion on the Chest. <b>2018</b> , 109, 821-822	
1135	Functional genomic landscape of acute myeloid leukaemia. <b>2018</b> , 562, 526-531	391
1134	Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene. <b>2018</b> , 115, E10437-E10446	38
1133	What is pre-fibrotic myelofibrosis and how should it be managed in 2018?. <b>2018</b> , 183, 23-34	9
1132	Application of immunophenotypic analysis in distinguishing chronic myelomonocytic leukemia from reactive monocytosis. <b>2018</b> , 94, 901-909	5
1131	The prognostic impact of lymphocyte subsets in newly diagnosed acute myeloid leukemia. <b>2018</b> , 53, 198-204	5
1130	Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group. <b>2018</b> , 228-229, 218-235	12
1129	Médecine génomique en oncologie : état de l'art et défis à relever. <b>2018</b> , 2018, 28-33	
1128	SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms. <b>2018</b> , 6, 29	5
1127	[WHO classification of myeloid neoplasms]. <b>2018</b> , 39, 315-318	
1126	Identifying patients with genetic predisposition to acute myeloid leukemia. <b>2018</b> , 31, 373-378	15
1125	Cooccurring V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms. <i>Blood</i> , <b>2018</b> , 132, 2695-2699	2.2 1

1124	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community. <b>2018</b> , 13, 581-587		9
1123	Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms. <b>2018</b> , 228-229, 197-217		11
1122	Incidence of Myelodysplastic Syndromes in a Major Canadian Metropolitan Area. <b>2018</b> , 3, 378-383		1
1121	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. <b>2018</b> , 73, 51-57		13
1120	[AML in Adults - An Update on Diagnosis, Risk Classification and Therapy]. <b>2018</b> , 143, 1297-1303		1
1119	Leveraging JAK-STAT regulation in myelofibrosis to improve outcomes with allogeneic hematopoietic stem-cell transplant. <b>2018</b> , 9, 251-259		2
1118	Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. <i>Blood</i> , <b>2018</b> , 132, 1584-1592	2.2	24
1117	How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes. <i>Blood</i> , <b>2018</b> , 132, 1657-1663	2.2	28
1116	Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. <b>2018</b> , 73, 21-23		33
1115	Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. <b>2018</b> , 9, 3649		76
1114	A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. <i>Blood</i> , <b>2018</b> , 132, 1664-1674	2.2	51
1113	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. <b>2018</b> , 93, E401-E404		2
1112	Lenalidomide induced durable remission in a patient with MDS/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome. <b>2018</b> , 10, 37-40		4
1111	GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia. <b>2018</b> , 8, 87		20
1110	Emerging therapies for the treatment of essential thrombocythemia. <b>2018</b> , 6, 567-575		
1109	A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome. <b>2018</b> , 7, 144		10
1108	Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of and. <b>2018</b> , 9, 10987-10994		4
1107	Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis. <b>2018</b> , 10,		13



1106	The genetic basis and cell of origin of mixed phenotype acute leukaemia. <b>2018</b> , 562, 373-379	140
1105	Recently approved therapies in acute myeloid leukemia: A complex treatment landscape. <b>2018</b> , 73, 58-66	38
1104	Myelodysplastic Syndromes. <b>2018</b> , 539-563.e2	1
1103	Usefulness of presepsin for early detection of infections in patients with hematologic disorders. <b>2018</b> , 486, 374-380	3
1102	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. <b>2018</b> , 8, 82	14
1101	Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial. <b>2018</b> , 109, 3209-3215	9
1100	High-Risk Acute Promyelocytic Leukemia with Unusual T/Myeloid Immunophenotype Successfully Treated with ATRA and Arsenic Trioxide-Based Regimen. <b>2018</b> , 11, 67-74	3
1099	Developing DNA methylation-based prognostic biomarkers of acute myeloid leukemia. <b>2018</b> , 119, 10041-10050	
1098	Novel Agents in the Treatment of Polycythemia Vera Beyond Hydroxyurea. <b>2018</b> , 18, S14-S16	
1097	The cytokine network in acute myeloid leukemia (AML): A focus on pro- and anti-inflammatory mediators. <b>2018</b> , 43, 8-15	56
1096	Usability of femoral head bone marrow to verify reference ranges for the assessment of myelodysplasia by flow cytometry. <b>2018</b> , 40, 726-733	0
1095	Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. <b>2018</b> , 18, e529-e535	
1094	Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges. <b>2018</b> , 2018, 2080185	1
1093	Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. <b>2018</b> , 93, E383-E386	2
1092	Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. <b>2018</b> , 93, 1474-1484	31
1091	Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis. <b>2018</b> , 13, 407-416	11
1090	KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia. <b>2018</b> , 108, 665-669	6
1089	Molecular Genetics of MDS. <b>2018</b> , 18, S45-S47	

1088	Clinical significance of hyaluronan levels and its pro-osteogenic effect on mesenchymal stromal cells in myelodysplastic syndromes. <b>2018</b> , 16, 234	3
1087	Significant common environmental effects on leukocyte subpopulations. <b>2018</b> , 13, e0196193	
1086	Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. <b>2018</b> , 2, 3581-3589	26
1085	Myeloproliferative Neoplasien (MPN). <b>2018</b> , 47, 398-402	2
1084	Cerebral Venous Sinus Thrombosis as the First Manifestation of JAK2-positive Essential Thrombocythemia. <b>2018</b> , 131, 748-750	8
1083	deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm. <b>2018</b> , 2, 534-548	21
1082	JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy. <b>2018</b> , 2018, 110-117	5
1081	Genetics and prognosis of ALL in children vs adults. <b>2018</b> , 2018, 137-145	34
1080	Clinical consequences of clonal hematopoiesis of indeterminate potential. <b>2018</b> , 2018, 264-269	23
1079	Genetic heterogeneity of cytogenetically normal AML with mutations of. <b>2018</b> , 2, 2724-2731	30
1078	[Auer rod-like inclusions in non blast cells]. <b>2018</b> , 76, 114-117	
1077	New drugs for acute myeloid leukemia inspired by genomics and when to use them. <b>2018</b> , 2018, 45-50	16
1076	Cell-lineage level-targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes. <b>2018</b> , 2, 2513-2521	7
1075	161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS. <b>2018</b> , 2, 1459-1469	61
1074	Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. <b>2018</b> , 2, 370-380	55
1073	Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. <b>2018</b> , 2, 1807-1816	21
1072	Clinical consequences of clonal hematopoiesis of indeterminate potential. <b>2018</b> , 2, 3404-3410	87
1071	Impact of somatic and germline mutations on the outcome of systemic mastocytosis. <b>2018</b> , 2, 2814-2828	28

1070	mutated AML can relapse with wild-type : persistent clonal hematopoiesis can drive relapse. <b>2018</b> , 2, 3118-3125	47
1069	and mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation. <b>2018</b> , 2, 3526-3539	18
1068	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. <b>2018</b> , 2, 2964-2972	40
1067	[Investigation and treatment of prefibrotic/early primary myelofibrosis. A case study]. <b>2018</b> , 159, 603-609	
1066	Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000-2014. <b>2018</b> , 32, 2580-2589	11
1065	Quantitation of acute monocytic leukemia cells spiked in control monocytes using surface-enhanced Raman spectroscopy. <b>2018</b> , 10, 2785-2791	5
1064	Management of Myelofibrosis-Related Cytopenias. <b>2018</b> , 13, 164-172	11
1063	Evaluation and comparison of automated hematology analyzer, flow cytometry, and digital morphology analyzer for monocyte counting. <b>2018</b> , 40, 577-585	8
1062	[New and traditional directions in the biology and management of childhood acute lymphoblastic leukemia]. <b>2018</b> , 159, 786-797	1
1061	Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. <b>2018</b> , 93, 824-840	73
1060	Acute Promyelocytic Leukemia. <b>2018</b> ,	2
1059	Cutaneous Mastocytosis in Adults and Children: New Classification and Prognostic Factors. <b>2018</b> , 38, 351-363	25
1058	Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms. <b>2018</b> , 116, 1064-1073	12
1057	Antiproliferative and toxicological properties of drimanes obtained from <i>Drimys brasiliensis</i> stem barks. <b>2018</b> , 103, 1498-1506	1
1056	Rare labial ulcer related to the use of all-trans retinoic acid in a patient with acute promyelocytic leukemia. <b>2018</b> , 38, 234-238	3
1055	Distinctive CD8 T cell and MHC class I signatures in polycythemia vera patients. <b>2018</b> , 97, 1563-1575	6
1054	Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes. <b>2018</b> , 18, 495-500	1
1053	Chronic myeloproliferative neoplasms in the elderly. <b>2018</b> , 58, 33-42	0

1052	Molecular Diagnosis of Hematopoietic Neoplasms: 2018 Update. <b>2018</b> , 38, 293-310	3
1051	Shifting of erythroleukemia to myelodysplastic syndrome according to the revised WHO classification: Biologic and cytogenetic features of shifted erythroleukemia. <b>2018</b> , 70, 13-19	2
1050	How I treat older patients with acute myeloid leukemia. <b>2018</b> , 124, 2472-2483	5
1049	Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single-Institution Experience. <b>2018</b> , 18, e287-e294	4
1048	Evolving Understanding of Chronic Myelomonocytic Leukemia: Implications for Future Treatment Paradigms. <b>2018</b> , 18, 519-527	
1047	Outcomes and predictors of survival in blast phase myeloproliferative neoplasms. <b>2018</b> , 70, 49-55	18
1046	Hotspot mutations in cancer genes may be missed in routine diagnostics due to neighbouring sequence variants. <b>2018</b> , 105, 37-40	
1045	EV11 expression predicts outcome in higher-risk myelodysplastic syndrome patients. <b>2018</b> , 59, 2929-2940	3
1044	Molecular patterns in cytopenia patients with or without evidence of myeloid neoplasm—a comparison of 756 cases. <b>2018</b> , 32, 2295-2298	9
1043	Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after azacitidine treatment. <b>2018</b> , 59, 3010-3012	2
1042	[Multiplex ligation-dependent probe amplification in oncohematological diagnostics and research]. <b>2018</b> , 159, 583-592	1
1041	Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor. <b>2018</b> , 29, 1880-1882	16
1040	Simultaneous Presentation of Giant Cell Arteritis and Myelodysplastic Syndrome in an Elderly Japanese Man. <b>2018</b> , 57, 2889-2893	1
1039	Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia. <b>2018</b> , 182, 373-383	4
1038	Lymphoblastic Neoplasms: B-Lymphoblastic Leukemia/Lymphoma. <b>2018</b> , 385-406	
1037	Lymphoblastic Neoplasms—Lymphoblastic Leukemia/Lymphoma. <b>2018</b> , 407-416	
1036	Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States. <b>2018</b> , 18, 590-596	11
1035	Study of DNA methyl transferase 3A mutation in acute myeloid leukemic patients. <b>2018</b> , 19, 315-319	3

1034	A new baby in the c-Myc-directed transcriptional machinery: Che-1/AATF. <b>2018</b> , 17, 1286-1290	2
1033	Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment. <b>2018</b> , 182, 830-842	12
1032	Myeloproliferative Neoplasms—An Overview. <b>2018</b> , 193-202	
1031	Myelodysplastic/Myeloproliferative Neoplasms. <b>2018</b> , 261-277	
1030	Acute Myeloid Leukemia, Not Otherwise Specified. <b>2018</b> , 345-374	1
1029	FLT3 receptor/CD135 expression by flow cytometry in acute myeloid leukemia: Relation to FLT3 gene mutations and mRNA transcripts. <b>2018</b> , 19, 345-351	2
1028	Myelodysplastic Syndrome/Acute Myeloid Leukemia Arising in Idiopathic Erythrocytosis. <b>2018</b> , 2018, 4378310	
1027	Gaucher Disease and Myelofibrosis: A Combined Disease or a Misdiagnosis?. <b>2018</b> , 139, 240-242	1
1026	Genetic Predisposition to Myeloproliferative Neoplasms: Another Piece of the Puzzle. <b>2018</b> , 139, 238-239	
1025	Diagnostic algorithm for lower-risk myelodysplastic syndromes. <b>2018</b> , 32, 1679-1696	3
1024	Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms. <b>2018</b> , 8, 65	24
1023	Eosinophils from Physiology to Disease: A Comprehensive Review. <b>2018</b> , 2018, 9095275	95
1022	Disparate effects of Shb gene deficiency on disease characteristics in murine models of myeloid, B-cell, and T-cell leukemia. <b>2018</b> , 40, 1010428318771472	4
1021	Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes. <b>2018</b> , 13, 244-255	16
1020	Essential thrombocythaemia with mutation in : clinicopathological correlation and comparison with 2V617F-mutated and mutated genotypes. <b>2018</b> , 71, 975-980	9
1019	Myelodysplastic syndrome in an infant with constitutional pure duplication 1q41-qter. <b>2018</b> , 5, 6	
1018	Atypical chronic myeloid leukaemia - a rare subtype of myelodysplastic/myeloproliferative neoplasm. <b>2018</b> , 22, 14-19	2
1017	Myeloproliferative Neoplasms Associated With JAK2, MPL, and CALR Mutations. <b>2018</b> , 217-238	

1016	Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series. <b>2018</b> , 18, e463-e468	18
1015	Germ line predisposition to myeloid malignancies appearing in adulthood. <b>2018</b> , 11, 625-636	3
1014	Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?. <b>2018</b> , 101, 502-507	4
1013	Monitoring minimal residual disease by ddPCR in acute lymphoblastic leukemia associated with the FGFR1 gene rearrangement. <b>2018</b> , 40, e117-e120	3
1012	A Very Rare Case of Hypereosinophilic Syndrome Secondary to Natural Killer/T-Cell Lymphoma. <b>2018</b> , 2018, 5965029	
1011	CSF3R Mutations are frequently associated with abnormalities of RUNX1, CFBF, CEBPA, and NPM1 genes in acute myeloid leukemia. <b>2018</b> , 124, 3329-3338	31
1010	Exploring the effect of chidamide on blastic plasmacytoid dendritic cell neoplasm: a case report and literature review. <b>2018</b> , 14, 47-51	3
1009	Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia. <b>2018</b> , 13, 341-347	3
1008	Recommendations for the diagnosis and treatment of patients with polycythaemia vera. <b>2018</b> , 101, 654	11
1007	The 2016 WHO versus 2008 WHO Criteria for the Diagnosis of Chronic Myelomonocytic Leukemia. <b>2018</b> , 38, 481-483	6
1006	Myeloid Sarcoma: The Other Side of Acute Leukemia. <b>2018</b> ,	2
1005	Acute myeloid leukaemia. <b>2018</b> , 392, 593-606	280
1004	Philadelphia-like acute lymphoblastic leukemia: diagnostic dilemma and management perspectives. <b>2018</b> , 67, 1-9	12
1003	Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. <b>2018</b> , 103, 1593-1603	30
1002	Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy. <b>2018</b> , 97, 2325-2332	7
1001	Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors. <b>2018</b> , 35, 119	10
1000	Allogeneic Hematopoietic Cell Transplantation Is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: Systematic Review and Meta-analysis. <b>2018</b> , 18, 703-709.e1	17
999	Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy. <b>2018</b> , 11, 697-706	27

998	Impact of Bone Marrow Aspirate Tregs on the Response Rate of Younger Newly Diagnosed Acute Myeloid Leukemia Patients. <b>2018</b> , 2018, 9325261	2
997	Essential Thrombocythemia and Cardiac Surgery: A Case Series and Review of the Literature. <b>2018</b> , 106, 482-490	5
996	PI3K inhibitors and the search for the Holy Grail. <i>Blood</i> , <b>2018</b> , 132, 240-241	2.2 2
995	Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts. <b>2018</b> , 101, 711-720	37
994	Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms. <b>2018</b> , 38, 147-154	4
993	A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs. <b>2018</b> , 97, 2299-2308	31
992	Cytogenetic Profiles of 472 Indian Children with Acute Myeloid Leukemia. <b>2018</b> , 55, 469-473	1
991	Dysregulation of miR-200s clusters as potential prognostic biomarkers in acute myeloid leukemia. <b>2018</b> , 16, 135	6
990	Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. <b>2018</b> , 93, 1551-1560	85
989	New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update. <b>2018</b> , 10,	27
988	Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management. <b>2018</b> , 130, 495-504	4
987	Are clonal cells circulating in the peripheral blood of myelodysplastic syndrome?: Quantitative comparison between bone marrow and peripheral blood by targeted gene sequencing and fluorescence in situ hybridization. <b>2018</b> , 71, 92-94	4
986	Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. <b>2018</b> , 93, 1245-1253	18
985	Myelodysplastic Syndromes and Myeloproliferative Neoplasms in Children. <b>2018</b> , 994-1004.e7	
984	The Polycythemias. <b>2018</b> , 1071-1105	2
983	Expression of aberrant antigens in hematological malignancies: A single center experience. <b>2018</b> , 34, 457-462	2
982	A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia. <b>2018</b> , 9, 45-47	0
981	Aggressive Systemic Mastocytosis in Association with Pure Red Cell Aplasia. <b>2018</b> , 2018, 6928571	1

980	Associations Between XPD Lys751Gln Polymorphism and Leukemia: A Meta-Analysis. <b>2018</b> , 9, 218	6
979	Evaluation by Flow Cytometry of Mature Monocyte Subpopulations for the Diagnosis and Follow-Up of Chronic Myelomonocytic Leukemia. <b>2018</b> , 8, 109	17
978	Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions. <b>2018</b> , 8, 152	22
977	Identification and validation of SRY-box containing gene family member methylation as a prognostic and predictive biomarker in myeloid malignancies. <b>2018</b> , 10, 92	18
976	Allele Specific PCR: A Cost Effective Screening Method for MPL Mutations in Myeloproliferative Neoplasms. <b>2018</b> , 34, 765-767	1
975	Acute Myeloid Leukemia. <b>2018</b> , 429-466.e5	4
974	Bone Marrow Expression of Mast Cell Disorders. <b>2018</b> , 38, 379-395	1
973	Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data. <b>2018</b> , 7, 16	3
972	Monosomy 7 in Pediatric Myelodysplastic Syndromes. <b>2018</b> , 32, 729-743	17
971	Thalidomide in Combination with Chemotherapy in Treating Elderly Patients with Acute Myeloid Leukemia. <b>2018</b> , 41, 461-465	2
970	Pregnancy associated acute leukemia: Single center experience. <b>2018</b> , 16, 53-58	6
969	Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia. <b>2018</b> , 101, 508-513	7
968	Increased Dkk-1 plasma levels may discriminate disease subtypes in myeloproliferative neoplasms. <b>2018</b> , 22, 4005	7
967	Diagnosis and Prognosis: Molecular. <b>2018</b> , 15-37	
966	Prediction of acute myeloid leukaemia risk in healthy individuals. <b>2018</b> , 559, 400-404	368
965	Chronic Myeloid Leukemia Following Treatment for Primary Neoplasms or Other Medical Conditions. <b>2018</b> , 150, 246-258	5
964	The Possible Importance of $\beta$ Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia. <b>2018</b> , 19,	26
963	Targeting General Transcriptional Machinery as a Therapeutic Strategy for Adult T-Cell Leukemia. <b>2018</b> , 23,	7



962	Histological evaluation of myeloproliferative neoplasms. <b>2018</b> , 58, 45-50		2
961	Chronic Neutrophilic Leukemia and Chronic Eosinophilic Leukemia, NOS. <b>2018</b> , 239-243		
960	Acute Myeloid LeukemiaâOverview. <b>2018</b> , 293-302		
959	Acute Leukemias of Ambiguous Lineage. <b>2018</b> , 417-428		
958	PCM1-JAK2 Fusion in a Patient With Acute Myeloid Leukemia. <b>2018</b> , 38, 492-494		9
957	Mixed-phenotype acute leukemia characteristics: first report from Iran. <b>2018</b> , 18, 513-521		4
956	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <b>2018</b> , 183, 35-46		6
955	Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways. <b>2018</b> , 11, 73		17
954	Myelodysplastic Syndromes/NeoplasmsâClassification. <b>2018</b> , 165-192		
953	Acute Myeloid Leukemias With Recurrent Genetic Abnormalities. <b>2018</b> , 303-325		
952	Systematic reviews of economic burden and health-related quality of life in patients with acute myeloid leukemia. <b>2018</b> , 69, 224-232		18
951	Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. <b>2018</b> , 71, 60-62		11
950	Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. <b>2018</b> , 9, 2670		47
949	Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. <b>2018</b> , 183, 110-118		30
948	Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. <i>Blood</i> , <b>2018</b> , 132, 973-976	2.2	19
947	Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia. <b>2018</b> , 108, 411-415		7
946	Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. <b>2018</b> , 559, 350-355		144
945	Serum chitotriosidase: a circulating biomarker in polycythemia vera. <b>2018</b> , 23, 793-802		2

944	Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. <b>2018</b> , 23, 785-792		15
943	Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myelodysplasies. <b>2018</b> , 182, 843-850		7
942	Myelodysplastic Syndromes: Mechanisms, Diagnosis, and Treatment. <b>2018</b> , 563-563		
941	CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. <i>Blood</i> , <b>2018</b> , 132, 1936-1950	2.2	13
940	The cells are ambiguous, not the message. <i>Blood</i> , <b>2018</b> , 132, 239-240	2.2	
939	Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens. <b>2018</b> , 16, 197		11
938	Preservation Method and Phosphate Buffered Saline Washing Affect the Acute Myeloid Leukemia Proteome. <b>2018</b> , 19,		2
937	Austrian recommendations for the management of polycythemia vera. <b>2018</b> , 130, 535-542		3
936	Safety of ultra-rush protocols for hymenoptera venom immunotherapy in systemic mastocytosis. <b>2018</b> , 73, 2260-2263		9
935	Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia. <b>2018</b> , 17, 40		15
934	Survival analysis of adult patients with ALL in Mexico City: first report from the Acute Leukemia Workgroup (ALWG) (GTLA). <b>2018</b> , 7, 2423-2433		7
933	The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice. <b>2018</b> , 144, 1239-1251		5
932	The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS. <b>2018</b> , 70, 34-36		7
931	CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. <b>2018</b> , 8, 21		17
930	INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia. <b>2018</b> , 37, 8		15
929	A pilot study on the usefulness of peripheral blood flow cytometry for the diagnosis of lower risk myelodysplastic syndromes: the "MDS thermometer". <b>2018</b> , 18, 6		5
928	First case of AML with rare chromosome translocations: a case report of twins. <b>2018</b> , 18, 458		7
927	Cytoreductive treatment patterns among US veterans with polycythemia vera. <b>2018</b> , 18, 528		6

926	Chronische myeloische Leukämie. <b>2018</b> , 24, 427-442	2
925	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. <b>2018</b> , 24, 1406-1414	28
924	Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. <b>2018</b> , 32, 1621-1630	53
923	Expression of the transcription factor ZBTB46 distinguishes human histiocytic disorders of classical dendritic cell origin. <b>2018</b> , 31, 1479-1486	7
922	Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience. <b>2018</b> , 2, e44	8
921	Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia. <b>2018</b> , 32, 1860-1865	13
920	mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents. <b>2018</b> , 103, e455-e457	15
919	GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML. <b>2018</b> , 32, 2502-2507	33
918	Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. <b>2018</b> , 32, 2512-2518	19
917	Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. <b>2018</b> , 103, 1278-1287	74
916	Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report. <b>2018</b> , 15, 7132-7138	1
915	Acute myeloid leukaemia: How to combine multiple tools. <b>2018</b> , 40 Suppl 1, 109-119	8
914	Easy discrimination of hematogones from lymphoblasts in B-cell progenitor acute lymphoblastic leukemia patients using CD81/CD58 expression ratio. <b>2018</b> , 40, 734-739	7
913	The advances in therapy of blastic plasmacytoid dendritic cell neoplasm. <b>2018</b> , 27, 733-739	11
912	Polycythemia vera: diagnosis, clinical course, and current management. <b>2018</b> , 48, 698-710	5
911	New and emerging therapies for acute myeloid leukaemia. <b>2018</b> , 66, 1088-1095	16
910	SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q. <b>2018</b> , 18, 629-635	3
909	Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation. <b>2018</b> , 7, e1468957	11

908	NPM1 alternative transcripts are upregulated in acute myeloid and lymphoblastic leukemia and their expression level affects patient outcome. <b>2018</b> , 16, 232		12
907	Epidemiological and cytogenetic profiles of patients with hematological malignancies and their relationship with aging. <b>2018</b> , 40, 200-206		3
906	Guidelines on myelodysplastic syndromes: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. <b>2018</b> , 40, 255-261		
905	Part 2: Myelodysplastic syndromes - classification systems. <b>2018</b> , 40, 262-266		0
904	Part 4: Myelodysplastic syndromes-Treatment of low-risk patients with the 5q deletion. <b>2018</b> , 40, 274-277		1
903	Applicability of the AML knowledge bank approach. <i>Blood</i> , <b>2018</b> , 132, 775-776	2.2	1
902	Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases. <b>2018</b> , 93, 1461-1466		17
901	Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients. <b>2018</b> , 93, 1347-1357		7
900	The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome. <b>2018</b> , 8, 78		15
899	P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. <b>2018</b> , 93, 1376-1383		8
898	Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations. <b>2018</b> , 93, 1358-1367		22
897	Keeping PACE with Ph Positive to Ph-Like Detection in B-Lineage Acute Lymphoblastic Leukemia: A Practical and Cost Effective (PACE) Approach in a Resource Constrained Setting. <b>2018</b> , 34, 595-601		7
896	Impacts of demographic and laboratory parameters on key hematological indices in an adult population of southern Taiwan: A cohort study. <b>2018</b> , 13, e0201708		2
895	Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia. <b>2018</b> , 38, 495-502		2
894	Improved Survival of Elderly-fit Patients With Acute Myeloid Leukemia Requiring Intensive Therapy: 3-Year Multicenter Analysis From TALWG. <b>2018</b> , 18, e509-e514		4
893	Blast-phase chronic myelomonocytic leukemia: more than just semantics. <b>2018</b> , 32, 2093-2094		1
892	Investigational CHK1 inhibitors in early stage clinical trials for acute myeloid leukemia. <b>2018</b> , 27, 661-666		4
891	MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia. <b>2018</b> , 19,		48

890	Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology. <b>2018</b> , 20, 717-737		28
889	Cytokine Measurements for Diagnosing and Characterizing Leukemoid Reactions and Immunohistochemical Validation of a Granulocyte Colony-Stimulating Factor and CXCL8-Producing Renal Cell Carcinoma. <b>2018</b> , 13, 1177271918792246		4
888	Clinical and biological implications of in acute myeloid leukemia with. <b>2018</b> , 10, 2457-2466		3
887	Retrospective analysis of 36 fusion genes in 2479 Chinese patients of de novo acute lymphoblastic leukemia. <b>2018</b> , 72, 99-104		12
886	FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis. <b>2018</b> , 23, 1511-1519		20
885	GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms. <b>2018</b> , 38, 296-305		1
884	Identifying Blood and Bone Marrow Abnormalities in the Laboratory. <b>2018</b> , 1-15		1
883	Cytopenias: Reactive and Neoplastic. <b>2018</b> , 17-79		1
882	Rapid diagnosis of mixed phenotype acute leukemia after identifying a blood histogram abnormality. <b>2018</b> , 12, e00101		1
881	Advances in treatment formulations for acute myeloid leukemia. <b>2018</b> , 23, 1936-1949		32
880	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <b>2018</b> , 55, 248-255		13
879	Diagnosis and management of prefibrotic myelofibrosis. <b>2018</b> , 11, 537-545		5
878	Myelodysplastic Syndromes. <b>2018</b> ,		
877	Chronic Myelomonocytic Leukemia (CMML). <b>2018</b> , 65-79		
876	Monocytosis. <b>2018</b> , 195-224		0
875	Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea. <b>2018</b> , 8, 56		3
874	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. <i>Blood</i> , <b>2018</b> , 132, 694-706	2.2	104
873	Iron overload in patients with myelodysplastic syndromes: An updated overview. <b>2018</b> , 124, 3979-3989		16

872	A novel type of mutation characterized by multiple internal tandem repeats in a case of cytogenetically normal acute myeloid leukemia. <b>2018</b> , 103, e575-e577	7
871	Mean platelet component and mean platelet volume as useful screening markers for myelodysplastic syndrome. <b>2018</b> , 1, e50	4
870	Mixed Cytoses and Cytopenias. <b>2018</b> , 257-279	
869	B-Cell Lymphocytosis. <b>2018</b> , 329-381	
868	Leukocytosis: Neutrophilia, Basophilia, and Blasts. <b>2018</b> , 135-170	1
867	Thrombocytosis. <b>2018</b> , 225-242	
866	Erythrocytosis. <b>2018</b> , 243-256	
865	The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. <b>2018</b> , 8, 49	21
864	New Insights into Clonal Mast Cell Disorders Including Mastocytosis. <b>2018</b> , 38, 341-350	7
863	Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. <b>2018</b> , 40, 831-835	
862	Molecular alterations in acute myeloid leukemia and their clinical and therapeutical implications. <b>2018</b> , 151, 362-367	10
861	SH2B3 aberrations enriched in iAMP21 B lymphoblastic leukemia. <b>2018</b> , 226-227, 30-35	9
860	Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. <b>2018</b> , 4, 1413-1420	47
859	Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. <b>2018</b> , 103, 1662-1668	26
858	Shining a light on cell signaling in leukemia through proteomics: relevance for the clinic. <b>2018</b> , 15, 613-622	2
857	Cytogenetics of MDS. <b>2018</b> , 43-64	
856	Cytoplasmic CD3 expression in infant acute megakaryoblastic leukemia: A new ambiguous lineage subtype?. <b>2018</b> , 71, 6-12	1
855	Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia. <b>2018</b> , 13, 265-274	30

854	Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. <b>2019</b> , 33, 181-190	28
853	ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications. <b>2019</b> , 86, 30-38	33
852	Current and evolving understanding of atypical chronic myeloid leukemia. <b>2019</b> , 33, 74-81	15
851	Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis. <b>2019</b> , 185, 382-386	2
850	(1-3)- $\beta$ -D-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations. <b>2019</b> , 98, 527-531	3
849	Myelodysplastic Syndrome Updated. <b>2019</b> , 86, 7-13	20
848	Endoglin is Highly Expressed in Human Mast Cells. <b>2019</b> , 27, 613-617	8
847	The Molecular Pathology of Myelodysplastic Syndrome. <b>2019</b> , 86, 24-29	16
846	Next generation sequencing in hematolymphoid neoplasia. <b>2019</b> , 56, 2-6	4
845	Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms. <b>2019</b> , 185, 136-139	7
844	Mutation profiling of 16 candidate genes in de novo acute myeloid leukemia patients. <b>2019</b> , 13, 229-237	12
843	Lymphoid Leukemias. <b>2019</b> , 1049-1063.e1	0
842	The Diagnostic Work-Up of Hypereosinophilia. <b>2019</b> , 86, 39-52	15
841	The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know. <b>2019</b> , 56, 90-95	34
840	Gemtuzumab ozogamicin for acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. <b>2019</b> , 104, 113-119	132
839	Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome. <b>2019</b> , 25, 63-72	11
838	Allogeneic hematopoietic stem cell transplantation for 8p11 myeloproliferative syndrome with BCR-FGFR1 gene rearrangement: a case report and literature review. <b>2019</b> , 54, 326-329	7
837	Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. <b>2019</b> , 33, 205-216	30

- 836 Cryptic ETV6-PDGFRB fusion in a highly complex rearrangement of chromosomes 1, 5, and 12 due to a chromothripsis-like event in a myelodysplastic syndrome/myeloproliferative neoplasm. **2019**, 60, 1304-1307 4
- 835 Chromosomal Abnormalities and Prognosis in -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. **2019**, 37, 2632-2642 40
- 834 Zusammenarbeit und multidisziplinäre Diagnostik in der Hämatologie in der Praxis. **2019**, 22, 64-65
- 833 Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms. **2019**, 45, 604-611 25
- 832 Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. *Blood*, **2019**, 134, 867-879 2.2 29
- 831 Genetic and Epigenetic Profiling in Personalized Medicine: Advances in Treatment of Acute Myeloid Leukemia. **2019**, 341-374
- 830 Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3. **2019**, 181, 111590 5
- 829 Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk. *Blood*, **2019**, 134, 960-969 2.2 29
- 828 Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. **2019**, 98, 2319-2328 3
- 827 BCR-ABL1- and CBFβ-MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis. **2019**, 98, 2461-2462 1
- 826 Identification of significant geographic clustering of polycythemia vera cases in Montreal, Canada. **2019**, 125, 3953-3959 12
- 825 Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia. **2019**, 9, 65 12
- 824 Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient. **2019**, 20, 1389-1397 3
- 823 Myelodysplastic syndromes and idiopathic pulmonary fibrosis: a dangerous liaison. **2019**, 20, 182 1
- 822 Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients. **2019**, 68, 71-75 8
- 821 Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity. **2019**, 14, e0220189 2
- 820 Diagnosis of Myeloproliferative Neoplasms: Current Perspectives from Recent Research. **2019**, 211-230
- 819 A Critical Review of Animal Models Used in Acute Myeloid Leukemia Pathophysiology. **2019**, 10, 11



818	World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. <b>2019</b> , 94, 1149-1167	86
817	Systemic mastocytosis with renal light chain amyloidosis: associated non-mast cell disorder or concurrent disease. <b>2019</b> , 12, 157-162	
816	Clinical use of SNP-microarrays for the detection of genome-wide changes in haematological malignancies. <b>2019</b> , 142, 58-67	11
815	Molecular landscape in adult acute myeloid leukemia: where we are where we going?. <b>2019</b> , 4, 17-17	1
814	Pocket Guide to Diagnostic Hematopathology. <b>2019</b> ,	
813	Personalized Medicine in Healthcare Systems. <b>2019</b> ,	1
812	Cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 SNPs in relation with prognostic factors in acute myeloid leukemia. <b>2019</b> , 8, 5492-5506	8
811	Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors. <b>2019</b> , 14, 460-468	12
810	Metabolic Plasticity of Acute Myeloid Leukemia. <b>2019</b> , 8,	56
809	Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing. <b>2019</b> ,	5
808	Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation. <b>2019</b> , 25, 2431-2437	28
807	Transfer Learning with Joint Distribution Adaptation and Maximum Margin Criterion. <b>2019</b> , 1169, 012028	2
806	An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. <b>2019</b> , 9, 12070	32
805	Diagnose der AML und Bedeutung der MRD. <b>2019</b> , 22, 8-14	
804	Functional Toll-Like Receptors (TLRs) Are Expressed by a Majority of Primary Human Acute Myeloid Leukemia Cells and Inducibility of the TLR Signaling Pathway Is Associated with a More Favorable Phenotype. <b>2019</b> , 11,	13
803	Enhanced polo-like kinase 1 expression in myelodysplastic syndromes. <b>2019</b> , 54, 102-107	
802	Incidence and spatial distribution of Chronic Myeloid Leukemia by regions of economic development in the state of Pernambuco, Brazil. <b>2019</b> , 41, 212-215	2
801	A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in . <b>2019</b> , 8, 5108-5115	5

800	The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical research. <b>2019</b> , 131, 410-418	9
799	Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). <b>2019</b> , 84, 106194	13
798	BAFF/APRIL System Is Functional in B-Cell Acute Lymphoblastic Leukemia in a Disease Subtype Manner. <b>2019</b> , 9, 594	2
797	AML-derived mesenchymal stem cells upregulate CTGF expression through the BMP pathway and induce K562-ADM fusiform transformation and chemoresistance. <b>2019</b> , 42, 1035-1046	4
796	Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. <b>2019</b> , 25, 2366-2374	0
795	A case of acute promyelocytic leukemia variant with derivative chromosome 3 der(3)t(3;8) associated with 8q partial gain. <b>2019</b> , 12, 32	1
794	Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation. <b>2019</b> , 79, 1305-1319	21
793	Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia. <b>2019</b> , 84, 106190	6
792	Concurrent chromothripsis events in a case of TP53 depleted acute myeloid leukemia with myelodysplasia-related changes. <b>2019</b> , 237, 63-68	2
791	From big flow cytometry datasets to smart diagnostic strategies: The EuroFlow approach. <b>2019</b> , 475, 112631	11
790	Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study. <b>2019</b> , 19, 579-584.e1	6
789	Current Aspects of Clonal Hematopoiesis: Implications for Clinical Diagnosis. <b>2019</b> , 39, 509-514	5
788	Korean Society for Genetic Diagnostics Guidelines for Validation of Next-Generation Sequencing-Based Somatic Variant Detection in Hematologic Malignancies. <b>2019</b> , 39, 515-523	5
787	High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype. <b>2019</b> , 8,	16
786	Natural Killer Cells Offer Differential Protection From Leukemia in Chinese Southern Han. <b>2019</b> , 10, 1646	10
785	Implications of intrachromosomal amplification of chromosome 21 on outcome in pediatric acute lymphoblastic leukemia: Does it affect our patients too?. <b>2019</b> , 11, 7826	1
784	Patient-based prediction algorithm of relapse after allo-HSCT for acute Leukemia and its usefulness in the decision-making process using a machine learning approach. <b>2019</b> , 8, 5058-5067	15
783	Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies. <b>2019</b> , 58, 889-902	23

782	Determining the frequency of iron overload at diagnosis in de novo acute myeloid leukemia patients with multilineage dysplasia or myelodysplasia-related changes: a case control study. <b>2019</b> , 12, 135-141	
781	The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia. <b>2019</b> , 94, 1141-1148	17
780	Detection of / Fusion Using Dual Colour Dual Fusion / Probe: An Illustrative Report. <b>2019</b> , 35, 570-574	0
779	TP53 abnormalities and chromosomal aneuploidy in acute panmyelosis with myelofibrosis. <b>2019</b> , 33, 2956-2962	1
778	Eosinophilic disorders: evaluation of current classification and diagnostic criteria, proposal of a practical diagnostic algorithm. <b>2019</b> , 9, 36	27
777	Update on mutations in the HIF: EPO pathway and their role in erythrocytosis. <b>2019</b> , 37, 100590	30
776	Acute promyelocytic leukemia with a cryptic insertion of RARA into TBL1XR1. <b>2019</b> , 58, 820-823	11
775	Novel approaches to treating advanced systemic mastocytosis. <b>2019</b> , 11, 77-92	13
774	t(15; 17) associated with primary myelofibrosis: a case report of an unusual clinical presentation and diagnostic dilemma. <b>2019</b> , 12, 5449-5455	2
773	Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene. <b>2019</b> , 58, 3449-3453	2
772	Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach. <b>2019</b> , 37, 424-433	1
771	Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS. <b>2019</b> , 7, 2387-2395.e3	21
770	The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies. <b>2019</b> , 84, 106196	4
769	MRD in AML: The Role of New Techniques. <b>2019</b> , 9, 655	57
768	Myelodysplastic Syndromes: An Update on Pathophysiology and Management. <b>2019</b> ,	
767	Azacitidine as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. <b>2019</b> , 2, e58	0
766	Transcriptional networks in acute myeloid leukemia. <b>2019</b> , 58, 859-874	8
765	SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation. <b>2019</b> , 187, 49-64	18

764	Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA. <b>2019</b> , 90, 80-96		3
763	CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients. <b>2019</b> , 98, 2339-2346		3
762	Intracranial acute promyelocytic leukemia at presentation-A case-based discussion. <b>2019</b> , 11, 41-45		1
761	Blastic Plasmacytoid Dendritic Cell Neoplasm: First Case Report From Rwanda and Review of the Literature. <b>2019</b> , 5, 1-6		0
760	Pitfalls in molecular diagnostics. <b>2019</b> , 36, 342-354		7
759	Investigating thrombocytosis. <b>2019</b> , 366, l4183		6
758	ETV6-related thrombocytopenia and leukemia predisposition. <i>Blood</i> , <b>2019</b> , 134, 663-667	2.2	25
757	From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?. <b>2019</b> , 37, 100587		13
756	Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias). <b>2019</b> , 152, 302-321		3
755	Automatic recognition of different types of acute leukaemia in peripheral blood by image analysis. <b>2019</b> , 72, 755-761		22
754	Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. <b>2019</b> , 94, 1753-1768		13
753	Increased SLAMF7 monocytes in myelofibrosis patients harboring V617F provide a therapeutic target of elotuzumab. <i>Blood</i> , <b>2019</b> , 134, 814-825	2.2	16
752	Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. <i>Blood</i> , <b>2019</b> , 134, 678-687	2.2	34
751	"Somatic" and "pathogenic" - is the classification strategy applicable in times of large-scale sequencing?. <b>2019</b> , 104, 1515-1520		7
750	How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. <b>2019</b> , 33, 2795-2804		67
749	Comprehensive clinical, molecular and histopathological analysis of bone marrow in chronic myeloproliferative neoplasia. <b>2019</b> , 219, 440-444		
748	Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases. <b>2019</b> , 37, 628-633		2
747	Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice. <b>2019</b> , 110, 699-708		16

746	6-Sulfo LacNAc (Slan) as a Marker for Non-classical Monocytes. <b>2019</b> , 10, 2052	10
745	Pruritus as a sign of systemic disease. <b>2019</b> , 37, 644-656	7
744	A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia. <b>2019</b> , 86, 106223	2
743	Hyper eosinophilic syndromes in the precision medicine era: clinical, molecular aspects and therapeutic approaches (targeted therapies). <b>2019</b> , 12, 1077-1088	4
742	Acute promyelocytic leukemia during pregnancy: A case report and 10-year institutional review of hematologic malignancies during pregnancy. <b>2019</b> , 215, 152672	5
741	Effect of nanofluidic electrolyte on the electrochemically enhanced long-term efficiency of vanadium redox flow battery. <b>2019</b> , 1, e90	4
740	Clonal dominance of a donor-derived del(20q) clone after allogeneic hematopoietic stem cell transplantation in an acute myeloid leukemia patient with del(20q). <b>2019</b> , 33, e22951	4
739	The differences of hemogram, myelogram, and driver gene mutations in classic myeloproliferative neoplasms. <b>2022</b> , 102698	
738	Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia. <b>2022</b> , 12,	0
737	SOHO State of the Art & Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes. <b>2022</b> ,	0
736	ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.	0
735	Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia.	0
734	Aktueller diagnostischer Standard und Risikostratifizierung der AML. <b>2022</b> , 25, 10-15	0
733	Abnormal B-Cell Maturation and Increased Transitional B Cells in CBL Syndrome. 10,	0
732	In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia—A Narrative Review of Current Knowledge. <b>2022</b> , 11, 4283	
731	Site-specific venous thrombosis in essential thrombocythemia: impact on subsequent vascular events and survival.	
730	Antibiotic and glucocorticoid-induced recapitulated hematological remission in acute myeloid leukemia: A case report and review of literature. <b>2022</b> , 10, 7890-7898	
729	Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells. <b>2022</b> , 81-109	0

- 728 Application of Rotational Thromboelastometry in Patients with Acute Promyelocytic Leukemia. **2022**, 28, 107602962211198
- 727 One Case of Myelodysplastic Syndrome Treated with Herbal Medicine. **2022**, 43, 444-450
- 726 The characteristics and prognostic significance of the SET-CAN/NUP214 fusion gene in hematological malignancies: A systematic review. **2022**, 101, e29294
- 725 De novo acute myeloid leukemia harboring concomitant t(8;21)(q22;q22);RUNX1::RUNX1T1 and BCR::ABL1 (p190 minor transcript).
- 724 Commonly Assessed Markers in Childhood BCP-ALL Diagnostic Panels and Their Association with Genetic Aberrations and Outcome Prediction. **2022**, 13, 1374 1
- 723 Patients with myeloproliferative neoplasms and COVID -19 have increased rates of arterial thrombosis. **2022**, 6, 0
- 722 Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model. **2022**, 12,
- 721 Hematocrit Self-Testing in Patients with Polycythemia Vera and Other Hematological Conditions: Assessing the Accuracy of the StatStrip Xpress<sup>®</sup> 2 LAC/Hb/Hct Device and User Opinion about the Device in Real-World Clinical Practice. **2022**, 11, 4234
- 720 SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma. **2022**, 1
- 719 A case of chronic neutrophilic leukaemia and multiple myeloma showing the benefits of lenalidomide and cyclophosphamide therapy in treating both conditions.
- 718 Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia. **2022**, 14, 265-269
- 717 Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management.
- 716 Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper.
- 715 Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia.
- 714 Clonal hematopoiesis of indeterminate potential: clinical relevance of an incidental finding in liquid profiling. **2022**, 0
- 713 DDX41: the poster child for familial AML. **2022**, 140, 667-669 1
- 712 The effect of haploidentical hematopoietic stem cell transplantation on comutations based on next-generation sequencing in adult acute myeloid leukemia patients with the FLT3-ITD mutation.
- 711 JAK2 rs10974944 is associated with both V617F-positive and negative myeloproliferative neoplasms in a Vietnamese population: A potential genetic marker.

710	Enhancer deregulation in TET2 Mutant Clonal Hematopoiesis is associated with increased COVID-19 related inflammation severity and mortality.	
709	Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern.	1
708	Outcome of adolescents and young adults with acute lymphoblastic leukemia in a single center in Brazil. <b>2022</b> ,	
707	Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome. <b>2022</b> , 12,	0
706	Unified classification and risk-stratification in Acute Myeloid Leukemia. <b>2022</b> , 13,	4
705	Clinical challenge for gastroenterologists—Gastrointestinal manifestations of systemic mastocytosis: A comprehensive review. <b>2022</b> , 28, 3767-3779	0
704	Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates.	
703	Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases.	0
702	Clinical manifestations of clonal hematopoiesis: what has SF3B1-mutant MDS taught us?. <b>2022</b> ,	0
701	Single cell genomics in AML: extending the frontiers of AML research.	1
700	Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders. 12,	0
699	The risk and prognostic influence of caspase 9 promotor polymorphisms in Egyptian patients with acute myeloid leukemia.	
698	Augmented Expression of the IL3RA/CD123 Gene in MLL/KMT2A-Rearranged Pediatric AML and Infant ALL. <b>2022</b> , 2, 245-263	
697	Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate. 12,	0
696	Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia.	0
695	Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS.	3
694	Extracellular Vesicles in Myeloid Neoplasms. <b>2022</b> , 23, 8827	0
693	The Need for Rapid Cytogenetics in the Era of Unique Therapies for Acute Myeloid Leukemia.	

- 692 Immunophenotypic changes of monocytes in myelodysplastic syndrome and clinical significance.
- 691 Netrin-1 induces the anti-apoptotic and pro-survival effects of B-ALL cells through the Unc5b-MAPK axis. **2022**, 20, 1
- 690 Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment. 13,
- 689 Update on VEXAS and role of allogeneic bone marrow transplant: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT. 0
- 688 Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. 3
- 687 Challenges of diagnosing and managing pre-fibrotic myelofibrosis: A case-based and practical approach. **2022**, 101378 0
- 686 Perceptions of patient disease burden and management approaches in systemic mastocytosis: Results of the TouchStone Healthcare Provider Survey. 1
- 685 Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study.
- 684 Prognostic Factors Contributing to the Survival of Hematopoietic Stem Cell Transplantation in the General Population with Leukemia: a Systematic Review.
- 683 Pharmacogenomic profiling of pediatric acute myeloid leukemia to identify therapeutic vulnerabilities and inform functional precision medicine. 1
- 682 Advances in molecular characterization of myeloid proliferations associated with Down syndrome. 13,
- 681 Tracking fibrosis in myeloproliferative neoplasms by CCR2 expression on CD34+ cells. 12,
- 680 JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander?. **2022**, 27, 842-846 0
- 679 A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies. **2022**, 23, 8600 2
- 678 Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.
- 677 Spectrum of stable and unstable rearrangements in lymphocytic chromosomes investigated in Bhopal population 30 years post MIC disaster amid co-exposure to lifestyle, living, and occupational hazards. 1
- 676 Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review. **2022**, 0
- 675 KMT2A-CBL fusion in rapidly progressive myeloid disorder. **2022**, 266-267, 90-92



- 674 Expression profiles analysis identifies specific interferon-stimulated signatures as potential diagnostic and predictive indicators of JAK2V617F+ myelofibrosis. 13,
- 673 Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the TouchStone SM Patient Survey. 0
- 672 Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults.
- 671 Zinc finger protein 384 (ZNF384) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia. 1-9
- 670 Higher RUNX1 expression levels are associated with worse overall and leukaemia-free survival in myelodysplastic syndrome patients.
- 669 Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia. 0
- 668 Functional imaging with dual-energy computed tomography for supplementary non-invasive assessment of mast cell burden in systemic mastocytosis. 2022, 12,
- 667 Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms. 0
- 666 Cytogenetics and Molecular Genetics in Pediatric Acute Lymphoblastic Leukemia (ALL) and Its Correlation with Induction Outcomes.
- 665 High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. 2022, 36, 2306-2316 5
- 664 Prevalence of elevated hemoglobin and hematocrit levels in patients with obstructive sleep apnea and the impact of treatment with continuous positive airway pressure: a meta-analysis. 2022, 27, 889-901 1
- 663 Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications. 1
- 662 Characteristics and outcomes of secondary acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: Multicenter study from the Thai Acute Leukemia Study Group. 2022,
- 661 Correlation Analysis and Prognostic Impacts of Biological Characteristics in Elderly Patients with Acute Myeloid Leukemia. Volume 17, 1187-1197 1
- 660 Myeloid/Lymphoid Neoplasms with Platelet Derived Growth Factor Receptor Alpha (PDGFRA) Rearrangement.
- 659 Identification of Leukemia-Associated Immunophenotypes by Database-guided Flow Cytometry Provides a Highly Sensitive and Reproducible Strategy for the Study of Measurable Residual Disease in Acute Myeloblastic Leukemia. 2022, 14, 4010 0
- 658 Chasing leukemia differentiation through induction therapy, relapse and transplantation. 2022, 101000
- 657 Expression level and prognostic potential of beta-catenin-interacting protein in acute myeloid leukemia. 2022, 101, e30022

- 656 Clinicopathological characteristics, genetics and prognosis of patients with myeloid sarcoma: a single-center study. *jclinpath-2021-208000*
- 655 Germline predisposition variants occur in myelodysplastic syndrome patients of all ages. 1
- 654 Performance evaluation and clinical impact of the OncoPrint Myeloid Research Assay for gene expression analysis in myeloid haematologic malignancies. *jclinpath-2022-208425*
- 653 Characterization of Philadelphia-like Pre-B Acute Lymphoblastic Leukemia: Experiences in Mexican Pediatric Patients. **2022**, 23, 9587 0
- 652 Incidence, clinical characteristics, and prognostic nomograms for patients with myeloid sarcoma: A SEER-based study. 12, 0
- 651 Hedgehog/GLI signaling in hematopoietic development and acute myeloid leukemia—from bench to bedside. 10, 1
- 650 Single-cell analysis of acute lymphoblastic and lineage ambiguous leukemia - approaches and molecular insights. 0
- 649 Regression of leukemia cutis with gilteritinib in a case of FLT3-positive acute myeloid leukemia. **2022**, 7, 100184
- 648 PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120. **2022**, 83, 104224
- 647 Evaluation of different diagnostic tools for detection of acquired von Willebrand syndrome in patients with polycythemia vera or essential thrombocythemia. **2022**, 218, 35-43 0
- 646 CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. **2022**, 121, 106928 0
- 645 Acquired somatic variants confirm the independent development of AML in monozygotic twins with germline CEBPA variant. **2022**, 121, 106933
- 644 Splanchnic vein thrombosis associated with myeloproliferative neoplasms. **2022**, 218, 8-16 3
- 643 Leukemias, Lymphomas, and Plasma Cell Disorders. **2023**, 237-300
- 642 Association between germline pathogenic variants in cancer-predisposing genes and lymphoma risk. 0
- 641 Genome-Based Medicine for Acute Myeloid Leukemia: Study and Targeting of Molecular Alterations and Use of Minimal Residual Disease as a Biomarker. **2022**, 3, 543-568 0
- 640 Persistently high incidence rates of childhood acute leukemias from 2010 to 2017 in Mexico City: A population study from the MIGICCL. 10, 0
- 639 Clinical and mechanistic insights into the roles of DDX41 in haematological malignancies. 0

- 638 Myeloproliferative neoplasms complicated with Ethalassemia: Two case report. 10, 10655-10662 ○
- 637 EXABS-161-MPN Management of Pre-Fibrotic Primary Myelofibrosis. **2022**, 22, S65-S66 ○
- 636 RANKL down-regulates the mast cell proliferation through inducing senescence. **2022**, 159, 156018 1
- 635 The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?. **2022**, 13, 204062072211128 1
- 634 Characteristics of myeloproliferative neoplasm-associated portal hypertension and endoscopic management of variceal bleeding. **2022**, 13, 204062232211256 ○
- 633 Diffuse Large B-cell Lymphoma Involving an Abundant Infiltration of T Follicular Helper Cells: A Case Report. **2022**, ○
- 632 Acute Myeloid Leukemias After the Treatment of Classical Hodgkinâs Lymphoma: A Literature Review. **2022**, 15, 414-423 ○
- 631 Profile of polycythaemia vera in South Western Nigeria. **2022**, 31, 462 ○
- 630 Myeloproliferative Neoplasms. **2022**, ○
- 629 Diagnostic Applications of Nuclear Medicine: Leukemias. **2022**, 529-567 ○
- 628 hyperlipidemia-post-initiation-of-nilotinib-among-chronic-myeloid-leukemia-patients-in-a-tertiary-hospital-of-malaysia. **2022**, 8, 32-37 ○
- 627 Plasminogen Activator Inhibitor-1 in Acute Myeloid Leukemia: Is It Useful in Predicting Response to Induction Remission Therapy?. **2022**, 10, 1894-1898 ○
- 626 Effect of pediatric- versus adult-type chemotherapy regimens on outcomes of allogeneic hematopoietic stem cell transplants for adult T-cell acute lymphoblastic leukemia in first complete remission. 1
- 625 Should the Panic Values in Clinical Biochemistry Laboratories be Revised According to Criteria in the Diagnosis of Chronic Myeloproliferative Neoplasms?. ○
- 624 Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis. **2022**, 101, 2497-2506 ○
- 623 Reprogramming lipid metabolism as potential strategy for hematological malignancy therapy. 12, ○
- 622 GSK3 inhibitor suppresses cell growth and metabolic process in FLT3-ITD leukemia cells. ○
- 621 Digital system augmented by artificial intelligence to interpret bone marrow samples for hematological disease diagnosis. ○

620	Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients. <b>2022</b> , 36, 2453-2460	1
619	Neratinib inhibits proliferation and promotes apoptosis of acute myeloid leukemia cells by activating autophagy-dependent ferroptosis.	1
618	Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations.	0
617	Accelerated and blast phase myeloproliferative neoplasms. <b>2022</b> , 101379	1
616	Clinical parameter-based prediction of DNA methylation classification generates a prediction model of prognosis in patients with juvenile myelomonocytic leukemia. <b>2022</b> , 12,	0
615	Simultaneous detection of JAK2 , CALR , and MPL mutations and quantitation of JAK2 V617F allele burden in myeloproliferative neoplasms using the quenching probe-Tm method in i-densy.	0
614	The genomic analysis brings a new piece to the molecular jigsaw of idiopathic erythrocytosis. <b>2022</b> , 11,	0
613	Activating Mutation in the Receptor Tyrosine Kinase FLT3 with Clinicopathological Relevance in Canine Mast Cell Tumors. <b>2022</b> , 2022, 1-10	0
612	La nòplasia mioïde associèe à un ràrrangement de PDGFRB : une pathologie rare de diagnostic difficile. <b>2022</b> ,	0
611	SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome. <b>2022</b> ,	1
610	A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges. <b>2022</b> , 14, 4166	0
609	Clinical Application of Biomarkers for Hematologic Malignancies. <b>2022</b> , 150-212	0
608	Response to àthe WHO classification of haematolymphoid tumoursâ(Editorial).	0
607	Towards personalized medicine with iPS cell technology: a case report of advanced systemic mastocytosis with associated eosinophilia. <b>2022</b> , 101, 2533-2536	1
606	The ABNL-MARRO 001 study: a phase 1â2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes. <b>2022</b> , 22,	0
605	Clinical implementation of genetic testing in adults for hereditary hematologic malignancy syndromes. <b>2022</b> ,	0
604	Meta-Analytic Comparison of Global RNA Transcriptomes of Acute and Chronic Myeloid Leukemia Cells Reveals Novel Gene Candidates Governing Myeloid Malignancies. <b>2022</b> , 14, 4681	1
603	Frequency and clinical impact of WT1 mutations in the context of CEBPA-mutated acute myeloid leukemia. <b>2022</b> , 27, 994-1002	0

602	Extracellular Vesicles in Haematological Disorders: A Friend or a Foe?. <b>2022</b> , 23, 10118	0
601	Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection. <b>2022</b> , 14, 4504	0
600	Targeting Ca <sup>2+</sup> and Mitochondrial Homeostasis by Antipsychotic Thioridazine in Leukemia Cells. <b>2022</b> , 12, 1477	0
599	Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms. <b>2022</b> , 17, 127-139	1
598	Acute myeloid leukemia with myelodysplasia-related changes and blasts of the mixed T/myeloid phenotype: a case report. <b>2022</b> , 50, 030006052211227	0
597	Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia.	5
596	Effect of Mutation Allele Frequency on the Risk Stratification of Myelodysplastic Syndrome Patients.	0
595	Development of E-ice-COLD-PCR assay combined with HRM analysis for Nucleophosmin1 gene mutation detection in acute myelogenous leukemia. <b>2022</b> , 17, e0274034	1
594	The role of next-generation sequencing in acute myeloid leukemia. Publish Ahead of Print,	1
593	Oncogenic lesions and molecular subtypes in adults with B-cell acute lymphoblastic leukemia.	0
592	Inhibition of interleukin-1 $\beta$ reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm. <b>2022</b> , 13,	2
591	Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse Outcomes. OF1-OF18	1
590	Splenic artery embolization for treatment of portal hypertension due to essential thrombocythemia. <b>2022</b> , 1, 149-152	0
589	Deep morphology learning enhances ex vivo drug profiling-based precision medicine.	1
588	Comparative Characteristics of Cytogenetic Abnormalities in Different Types of Myelodysplastic Syndromes. <b>2022</b> , 56, 423-430	0
587	Molecular Diagnostic Testing for Hematopoietic Neoplasms. <b>2022</b> , 42, 325-347	0
586	Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion. 28,	0
585	Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?. <b>2022</b> , 101014	0

- 584 von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well-controlled platelet counts. 0
- 583 Updates on eosinophilic disorders. 1
- 582 Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study. 1-8 0
- 581 Epidemiologic outlook of therapy-related myeloid neoplasms and selection of high-risk patients: A Korean nationwide study. 0
- 580 Diagnosis and Treatment of Myelodysplastic Syndromes. **2022**, 328, 872 2
- 579 Genomic Landscape of Mixed-Phenotype Acute Leukemia. **2022**, 23, 11259 0
- 578 Case report: Leukemia cutis as the first manifestation of chronic neutrophilic leukemia in a 6-year-old girl. 10, 0
- 577 Long-standing thrombocytosis often precedes thromboembolic complications heralding the diagnosis of essential thrombocythemia. **2022**, 0
- 576 Histiocytoid giant cellulitis-like Sweet syndrome at the site of sternal aspiration: A case report and review of literature. **2022**, 10, 9768-9775 0
- 575 Adult-onset hereditary myeloid malignancy and allogeneic stem cell transplantation. 12, 0
- 574 Combining metaphase cytogenetics with single nucleotide polymorphism arrays can improve the diagnostic yield and identify prognosis more precisely in myelodysplastic syndromes. **2022**, 54, 2627-2636 0
- 573 Association of Toll-like receptors polymorphisms with the risk of acute lymphoblastic leukemia in the Brazilian Amazon. **2022**, 12, 0
- 572 Overview of Molecular Quantification of the BCR-ABL Oncogene in CML Patients. **2022**, 19, 693-698 0
- 571 Can we use platelet-to-lymphocyte ratio (PLR) to differentiate JAK2-unmutated erythrocytosis from polycythemia vera?. **2022**, 0
- 570 Philadelphia-negative myeloproliferative neoplasms display alterations in monocyte subpopulations frequency and immunophenotype. **2022**, 39, 0
- 569 A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry. 1-10 0
- 568 Novel translocation of POGZ/STK11 in de novo mast cell leukemia with KIT D816H mutation. 1-5 0
- 567 Treatment of myeloid neoplasia with doxorubicin and cytarabine in 11 dogs. 0

566	Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia Across Therapy Subtypes.	1
565	The impact of pretransplant use of tyrosine kinase inhibitors on allogeneic stem cell transplantation in patients with chronic myeloid leukemia - A single-institution retrospective study.	0
564	Role of Sirtuins in the Pathobiology of Onco-Hematological Diseases: A PROSPERO-Registered Study and In Silico Analysis. <b>2022</b> , 14, 4611	0
563	Relationship Between Pre-Transplant Nutritional Status and Outcomes of Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <b>2022</b> ,	0
562	Patients with blastic plasmacytoid dendritic cell neoplasm in pregnancy: A rare case report. <b>2022</b> , 101, e30622	0
561	Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms âresults of the EUROPE trial by EMSCO.	0
560	ASXL1/2 mutations and myeloid malignancies. <b>2022</b> , 15,	0
559	Histone methylation modification patterns and relevant M-RiskScore in acute myeloid leukemia. <b>2022</b> , 8, e10610	0
558	Thrombosis Risk Assessment in Myeloproliferative Neoplasmâ There a Role for Viscoelastic Testing?.	0
557	The recognition of oral manifestations of haematological disease saves lives: a case report. <b>2022</b> , 46,	0
556	Extramedullary Hematopoiesis in Myelodysplastic Syndromes: A Systematic Literature Review. <b>2022</b> , 3, 569-573	0
555	Pediatric Germline Predisposition to Myeloid Neoplasms.	0
554	Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival.	0
553	Allogeneic haematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukaemia: A single-centre experience. <b>2022</b> ,	0
552	Wiskott Aldrich Syndrome-2 Caused by Novel Wiskott Aldrich Syndrome ProteinâInteracting Protein (WIP) Deficiency Is Associated with Juvenile Myelomonocytic Leukaemia â Case Report.	0
551	PHF6 mutation is associated with poor outcome in acute myeloid leukaemia.	0
550	Papel da equipa de enfermagem na consulta multidisciplinar a doentes com neoplasias mieloproliferativas. <b>2019</b> , 24-28	0
549	NPM1 mutations are associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype.. <b>2022</b> , 106965	0

548	Myeloid neoplasms on poly (ADP-ribose) polymerase inhibitor therapy. 1-4	0
547	Proceedings of the 2022 National Toxicology Program Satellite Symposium. 019262332211248	0
546	The Down-Regulation of Circ_0059707 in Acute Myeloid Leukemia Promotes Cell Growth and Inhibits Apoptosis by Regulating miR-1287-5p. <b>2022</b> , 29, 6688-6699	0
545	Broad genomic workup including optical genome mapping uncovers a DDX3X: MLLT10 gene fusion in acute myeloid leukemia. 12,	1
544	High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant.	0
543	A case of lung cancer with essential thrombocythemia treated by thoracoscopic right lower lobectomy. <b>2022</b> , 36, 671-676	0
542	Unique role of DDX41, a DEAD-box type RNA helicase, in hematopoiesis and leukemogenesis. 12,	0
541	TET2 deficiency promotes MDS-associated leukemogenesis. <b>2022</b> , 12,	0
540	Limited activity of luspatercept in myelofibrosis and myeloid neoplasms other than myelodysplastic syndromes with ring sideroblasts.	1
539	Pediatric non-Down syndrome acute megakaryoblastic leukemia patients in China: A single center's real-world analysis. 12,	0
538	Hematologic Malignancies Patients Face High Symptom Burden and Are Lately Referred to Palliative Consultation: Analysis of a Single Center Experience. 104990912211322	0
537	Short-term efficacy of decitabine-based therapy in JMML: a retrospective study from a single center in China.	0
536	Comparative analysis of extracellular vesicle isolation methods from human AML bone marrow cells and AML cell lines. 12,	1
535	Prognostic and Predictive Biomarkers in Precursor B-cell Acute Lymphoblastic Leukemia.	0
534	Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes.	0
533	The International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Myeloproliferative Neoplasms.	2
532	Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing.	1
531	A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older.	1



- 530 Therapy related myeloid neoplasms following PARP inhibitors: real-life experience. ○
- 529 Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing. ○
- 528 Synchronous in situ follicular neoplasia with MALT lymphoma and intramucosal adenocarcinoma in stomach: A case report. ○
- 527 Prognostic impact of the controlling nutritional status score in patients with hematologic malignancies: A systematic review and meta-analysis. 13, ○
- 526 Clinical view versus guideline adherence in ferritin monitoring and initiating iron chelation therapy in patients with myelodysplastic syndromes. ○
- 525 Significance of bone marrow fibrosis in acute myeloid leukemia for survival in the real-world. 12, ○
- 524 Iron Chelation Improves Ineffective Erythropoiesis and Iron Overload in Myelodysplastic Syndrome Mice. ○
- 523 Significance of abnormal blood coagulation in patients with chronic myelomonocytic leukemia. ○
- 522 Ligand-based discovery of a novel GATA2 inhibitor targeting acute myeloid leukemia cells. 2, ○
- 521 Contemporary evaluation of acute myeloid leukemia patients with long-term survival exceeding 5 years. ○
- 520 Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency. ○
- 519 Professional Case Management in Outpatient Settings for Patients With Myeloproliferative Neoplasms. **2022**, 27, 271-276 ○
- 518 Anagrelide in essential thrombocythemia: Efficacy and long-term consequences in young patient population. **2022**, 123, 106962 ○
- 517 Acute Myeloid Leukemia Secondary to Chemotherapy Drug for Double Solid Tumors: A Case Report and Literature Review. **2022**, 12, 9151-9154 ○
- 516 Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis. **2022**, 613-619 ○
- 515 Serum proteomics screening intercellular adhesion molecule-2 improves intermediate-risk stratification in acute myeloid leukemia. **2022**, 13, 204062072211323 ○
- 514 Hypereosinophilic syndrome - diagnostic and treatment approach. **2022**, 75, 127-131 ○
- 513 Face masks and polycythemia is the standard hemoglobin cutoff valid in the pandemic?. **2022**, 0 ○

- 512 Cytogenetics. **2022**, ○
- 511 Treatment of eosinophilic and hypereosinophilic disorders. **2022**, 1281-1308 ○
- 510 Chromosomal Aberrations in Cancer. 1-19 ○
- 509 Allogeneic stem cell transplantation for patients with myelodysplastic syndromes. ○
- 508 Prognostic Role of Cell Blood Count in Chronic Myeloid Neoplasm and Acute Myeloid Leukemia and Its Possible Implications in Hematopoietic Stem Cell Transplantation. **2022**, 12, 2493 ○
- 507 A glimpse into translocation (8;21) in acute myeloid leukemia: Profile and therapeutic outcomes from a tertiary care hematology center from East India. 2, 85-90 ○
- 506 Cytogenetics analysis as the central point of genetic testing in acute myeloid leukemia (AML): a laboratory perspective for clinical applications. ○
- 505 International Consensus Classification for Myeloid Neoplasms At-A-Glance. ○
- 504 Treatment Outcomes and Prognostic Factors in 66 Patients with Chronic Myelomonocytic Leukemia (CMML) in a Single Center. Volume 15, 7843-7854 ○
- 503 Improving Diagnosis and Clinical Management of Acquired Systemic Autoinflammatory Diseases. Volume 15, 5739-5755 ○
- 502 Isolated myeloid sarcoma with pericardial and pleural effusions as first manifestation: A case report. **2022**, 101, e31026 ○
- 501 Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome. **2022**, 12, ○
- 500 Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms. ○
- 499 Clinical Validation and Diagnostic Utility of Optical Genome Mapping for Enhanced Cytogenomic Analysis of Hematological Neoplasms. **2022**, 2 ○
- 498 Safety, outcomes and T cell characteristics in patients with relapsed or refractory MDS or CMML treated with atezolizumab in combination with guadecitabine. ○
- 497 Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms. ○
- 496 Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels. ○
- 495 Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms. **2022**, 12, 2570 ○

494	The International Consensus Classification of acute myeloid leukemia.	1
493	Non-driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia.	1
492	Recent progress of JAK inhibitors for hematological disorders. 1-12	0
491	Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.	0
490	One novel ACOT7&NIPHP4 fusion gene identified in one patient with acute lymphoblastic leukemia: a case report. <b>2022</b> , 15,	0
489	Subtype-specific 3D genome alteration in acute myeloid leukaemia.	1
488	JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.	0
487	Integrative genomic and transcriptomic profiling reveals distinct molecular subsets in adult mixed phenotype acute leukemia.	0
486	Conduite à tenir devant une prédisposition génétique aux hémopathies malignes chez un patient candidat à la greffe de cellules souches hématopoïétiques (CSH) : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). <b>2022</b> ,	0
485	Identification of the immunosuppressive effect of T <sub>H</sub> cells correlated to bone morphogenetic protein 2 in acute myeloid leukemia. 13,	0
484	SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis.	0
483	Lenalidomide and Eltrombopag for Treatment of Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Clinical Trial.	0
482	Development and validation of a novel prognosis prediction model for patients with myelodysplastic syndrome. 12,	0
481	The inflammasomes: crosstalk between innate immunity and hematology.	0
480	Correlation of Thrombosis and Clinicohematological Parameters with JAK2V617F Mutation in Philadelphia-Negative CMPNs: A Study from India.	0
479	Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies.	0
478	Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies. <b>2022</b> , 6, e787	0
477	Oncogenes. 1-25	1

- 476 Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes. **2022**, 14, 4941 ○
- 475 Patient-reported outcomes of patients with myelofibrosis or essential thrombocythemia enrolled in the MOST study. 1-16 ○
- 474 The new diagnostic criteria for myelodysplasia-related acute myeloid leukemia is useful for predicting clinical outcome: comparison of the 4th and 5th World Health Organization classifications. ○
- 473 Inherited heterozygous Fanconi anemia gene mutations in a therapy-related CMML patient with a rare NUP98-HOXC11 fusion: A case report. 12, ○
- 472 Predictors of Increased Risk of Adverse Cardiovascular Outcomes Among Patients with Myeloproliferative Neoplasms and Atrial Fibrillation. **2022**, ○
- 471 Disease correlates and clinical relevance of Hereditary Alpha-Tryptasemia in patients with Systemic Mastocytosis. **2022**, 1
- 470 The fundamental role of synergy between laboratory professionals and clinicians to minimize pseudohypokalemia cases in subjects affected by hyperleukocytosis. 1-4 ○
- 469 Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis. **2022**, 14, 5239 1
- 468 Autophagy in Hematological Malignancies. **2022**, 14, 5072 1
- 467 SF3B1 Mutations in Hematological Malignancies. **2022**, 14, 4927 2
- 466 High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia. ○
- 465 Metabolic Biomarkers Affecting Cell Proliferation and Prognosis in Polycythemia Vera. **2022**, 14, 4913 ○
- 464 Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation. **2022**, 18, e1010463 ○
- 463 LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence. **2022**, 14, 5236 ○
- 462 Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia. ○
- 461 Significance of reduced renal function in patients with chronic myelomonocytic leukemia. ○
- 460 Acute Myeloid Leukemia in Adults: Mast Cell Leukemia and Other Mast Cell Neoplasms. 1-21 ○
- 459 Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. ○

458	Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options. 030089162211331	0
457	A British Society for Haematology good practice paper: Recommendations for laboratory testing of UK patients with acute myeloid leukaemia.	1
456	Multi-hit TET2 mutations as a differential molecular signature of oligomonocytic and overt chronic myelomonocytic leukemia.	0
455	Trend of circulating CD34 + cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment.	0
454	Effects of age on polycythemia, cardiometabolic risk and their associations in middle-aged men.	0
453	Mitochondrial Electron Transport Chain Complex II Dysfunction Causes Premature Aging of Hematopoietic Stem Cells.	0
452	Diagnostic Approach for Acute Myeloid Leukemia Based on the World Health Organization Classification of Hematologic Neoplasms. <b>2022</b> , 97, 308-318	0
451	Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia. 12,	0
450	Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia.	0
449	Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.	0
448	An Exceptional Case of Light Chain Only Variant of Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits Secondary to Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature. <b>2022</b> , 2022, 1-7	0
447	Targeting BET Proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML.	0
446	Single-cell methods in myeloproliferative neoplasms - old questions, new technologies.	0
445	Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.	0
444	Germline DDX41 mutations define a unique subtype of myeloid neoplasms.	1
443	Adult mixed phenotype acute leukemia ( MPAL ): B/myeloid MPAL isoMPO is distinct from other MPAL subtypes.	0
442	Management of polycythemia vera: a survey of treatment patterns in Italy.	0
441	Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.	0

- 440 Association between serum albumin and 60-day mortality in Chinese Hakka patients with non-APL acute myeloid leukemia: a retrospective cohort study. **2022**, 22, 0
- 439 A Bioinformatics View on Acute Myeloid Leukemia Surface Molecules by Combined Bayesian and ABC Analysis. **2022**, 9, 642 0
- 438 TP53-altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs. 1-11 1
- 437 Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases. **2022**, 12, 1
- 436 Diagnostic and Therapeutic Implications of Long Non-Coding RNAs in Leukemia. **2022**, 12, 1770 0
- 435 The 8p11 myeloproliferative syndrome: Genotypic and phenotypic classification and targeted therapy. 12, 0
- 434 Molecular patterns identify distinct subclasses of myeloid neoplasia. 0
- 433 Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasms. **2022**, 156, 113884 0
- 432 Myelodysplastic neoplasms: An overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment. **2022**, 156, 113905 0
- 431 Mapping the genetic features of T-ALL cases through simplified NGS approach. **2022**, 245, 109151 0
- 430 Modeling leukemia with zebrafish (*Danio rerio*): Towards precision medicine. **2022**, 421, 113401 0
- 429 A Case of Focal Segmental Glomerulosclerosis Associated With Essential Thrombocythemia. **2023**, 0
- 428 The First Case of Acute Myeloid Leukemia With Underlying Fanconi Anemia due to FANCF Variants in Korea. **2023**, 43, 204-207 0
- 427 The Manifestation of a Patient With Myelofibrosis in 68Ga-DOTA-FAPI-04 PET/CT Mimicking "Super Bone Imaging" **2022**, 47, 1056-1058 0
- 426 Secondary causes of elevated hemoglobin in patients undergoing molecular testing for suspected polycythemia vera in southwestern Ontario: a chart review. **2022**, 10, E988-E992 0
- 425 Risks of therapy-related hematologic neoplasms beyond myelodysplastic syndromes and acute myeloid leukemia. 0
- 424 Inherited bone marrow failure syndromes: a review of current practices and potential future research directions. Publish Ahead of Print, 0
- 423 A neonatal case of congenital blastic plasmacytoid dendritic cell neoplasm with KMT2C gene duplication. 0

422	Diagnosis of acute myelomonocytic leukemia in a patient with extramedullary testicular lesion. <b>2022</b> , 17, 81-87	0
421	Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival.	1
420	Possibilities of targeted therapy for myelofibrosis: Moscow experience. <b>2022</b> , 17, 94-105	0
419	Successful Treatment of Pediatric Acute Myeloid Leukemia Presenting with Hyperbilirubinemia Secondary to Myeloid Sarcoma: A Case Report. <b>2022</b> , 9, 1699	0
418	Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms.	0
417	Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age. <b>2022</b> , 101033	1
416	The adverse impact of ecotropic viral integration site-1 ( EVI1 ) overexpression on the prognosis of acute myeloid leukemia with KMT2A gene rearrangement in different risk stratification subtypes.	0
415	Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment. <b>2022</b> , 14, 5531	0
414	Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.	0
413	Improved myeloablative conditioning regimen for allogeneic stem cell transplantation in adult patients with chronic myelomonocytic leukaemia.	0
412	Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.	0
411	Evaluation of Diagnostic Efficacy of NRP-1/CD304 in Hematological Diseases.	0
410	A 72-Year-Old Woman With Dyspnea, Multiple Pulmonary Nodules, and Mediastinal Lymphadenopathy. <b>2022</b> , 162, e253-e257	0
409	TET2 Mutation May Be More Valuable in Predicting Thrombosis in ET Patients Compared to PV Patients: A Preliminary Report. <b>2022</b> , 11, 6615	0
408	Juvenile Myelomonocytic Leukemia in a Child: A Case Report of Palliative Chemotherapy and Literature Review Applied to Limited Resources Centers. <b>2022</b> , 2022, 1-7	0
407	Proposed new prognostic model using the systemic immune-inflammation index for primary central nervous system lymphoma: A prospective-retrospective multicohort analysis. 13,	0
406	Myelodysplastic syndromes. <b>2022</b> , 8,	0
405	Evaluation of the WBC -differential flagging performances and accuracy of the HORIBA Yumizen H2500 cell counter in oncology patients from a single institution.	0

404	Outcomes after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with der(1;7)(q10;p10).	0
403	Resolution of the Expert Council on the issues of diagnosis and treatment of myeloproliferative neoplasms, existing standards and the possibility of their implementation in real clinical practice in Russia. <b>2022</b> , 17, 60-66	0
402	Real-life challenges using personalized prognostic scoring systems in acute myeloid leukemia.	0
401	Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profiles. 13,	0
400	Pancytopenia/Aplastic Anemia/Bone Marrow Failure. <b>2023</b> , 927-941.e2	0
399	Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable â retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.	0
398	Discovery of oxindole-based FLT3 inhibitors as a promising therapeutic lead for acute myeloid leukemia carrying the oncogenic ITD mutation.	2
397	Germinal Center-Derived Diffuse Large B-cell Lymphomas with Aberrant Co-expression of MUM1 in Adults and Children. <b>2022</b> , 11, 1-6	0
396	Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients. <b>2023</b> , 124, 106999	0
395	Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. <b>2023</b> , 10, e59-e70	1
394	Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemia. <b>2023</b> , 124, 107002	0
393	Transfusion dependence is a risk factor for severe infections in myelodysplastic syndromes. <b>2023</b> , 124, 107000	0
392	Germline Predisposition in the Field of Myeloproliferative Neoplasms. <b>2022</b> ,	0
391	Isolated cerebellar infarction in a case of JAK 2 mutation-negative polycythemia vera: A case report. <b>2022</b> , 8, 225	0
390	Hematopoietic and Lymphoid Tumors. <b>2021</b> , 377-521	0
389	Diagnosing Czech Patients with Inherited Platelet Disorders. <b>2022</b> , 23, 14386	0
388	A genomic DNA-based NGS method for the simultaneous detection of multiple fusion genes in pediatric leukemia. <b>2022</b> , 25,	0
387	The clinical and biological characterization of acute myeloid leukemia patients with S100A4 overexpression. <b>2022</b> ,	0



- 386 A Rational Approach to JAK2 Mutation Testing in Patients with Elevated Hemoglobin: Results from the JAK2 Prediction Cohort (JAKPOT) Study. 0
- 385 BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis. 0
- 384 International Consensus Classification of acute lymphoblastic leukemia/lymphoma. 2
- 383 Outcomes of Allogeneic Stem Cell Transplant in Chronic Myeloid Leukemia - Blast Phase: A Single-center Experience from South India. 0
- 382 The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia of unknown significance. 0
- 381 Abnormal platelet immunophenotypes and percentage of giant platelets in myelodysplastic syndrome: A pilot study. **2022**, 17, e0278040 0
- 380 A Case of Chronic Myeloid Leukemia Presenting as Bilateral Retinopathy. **2022**, 0
- 379 CLINICAL FEATURES OF FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA CASES AND THE ROLE OF FLT3 INHIBITORS IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA: A SINGLE CENTER EXPERIENCE. 0
- 378 A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment. 12, 0
- 377 Case Report: Spontaneous remission of early T-cell precursor acute lymphoblastic leukemia. 11, 1407 0
- 376 Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia. 0
- 375 Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group. 1
- 374 Identification of Myelodysplastic Syndrome Risk-related Genes and their Association with Immune Infiltration. 0
- 373 The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective. 0
- 372 Significance of C-reactive protein in patients with chronic myelomonocytic leukemia. 0
- 371 Significance of hypergammaglobulinemia in patients with chronic myelomonocytic leukemia. 0
- 370 Establishment of isogenic induced pluripotent stem cells with or without pathogenic mutation for understanding the pathogenesis of myeloproliferative neoplasms. **2022**, 0
- 369 The use of carbon monoxide breath test to detect the effect of iron overload on erythrocyte lifespan in MDS. 12, 0

- 368 Role of Biomarkers in the Management of Acute Myeloid Leukemia. **2022**, 23, 14543 ○
- 367 A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study. **2022**, ○
- 366 Role of Bcl-2 inhibition in myelodysplastic syndromes. ○
- 365 A treatment-refractory and aggressive MDS-MLD with multiple highly complex chromosome 5 intrachromosomal rearrangements: a case report. ○
- 364 A case of AORPA in an adult presenting as secondary polycythemia. **2022**, 34, ○
- 363 Molecular prognostication in Ph-negative MPNs in 2022. **2022**, 2022, 225-234 3
- 362 Efficacy and safety of blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia: a systemic review and meta-analysis. **2022**, ○
- 361 Leucemie mieloidi acute. **2022**, 24, 1-11 ○
- 360 Rapid and Automated Semiconductor-Based Next-Generation Sequencing for Simultaneous Detection of Somatic DNA and RNA Aberrations in Myeloid Neoplasms. **2022**, ○
- 359 Optimizing outcomes in secondary AML. **2022**, 2022, 23-29 ○
- 358 Die akute Promyelozytenleukämie - ein hämatologischer Notfall. **2022**, 25, 10-15 ○
- 357 c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche. **2022**, 8, e11998 ○
- 356 Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. 1
- 355 Case report: Chronic neutrophilic leukemia associated with monoclonal gammopathies. A case series and review of genetic characteristics and practical management. 12, ○
- 354 Diagnostic and therapeutic challenges in mast cell sarcoma. ○
- 353 Essential Thrombocythemia: One-Center Data in a Changing Disease. **2022**, 58, 1798 ○
- 352 Impact of mutations on pregnancy outcome in patients with myeloproliferative neoplasms. ○
- 351 Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts. **2022**, 2022, 218-224 ○

- 350 Coagulation status and determinants of possible aspirin resistance in patients with essential thrombocythemia. 9, ○
- 349 GSK3 inhibitor suppresses cell growth and metabolic process in FLT3-ITD leukemia cells. **2023**, 40, ○
- 348 Comparison of demographics, disease characteristics, and outcomes between Black and White patients with myelodysplastic syndromes: A population-based study. **2022**, 107006 ○
- 347 Prevalence, patterns and outcomes of cardiac involvement in Erdheim-Chester disease. ○
- 346 Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm. **2023**, 12, 105 1
- 345 Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms. **2022**, 14, 6080 ○
- 344 Single cell guided deconvolution of bulk transcriptomics recapitulates differentiation stages of acute myeloid leukemia and predicts drug response. ○
- 343 Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective. **2022**, 23, 15256 ○
- 342 Clinical response to upfront targeted tyrosine kinase inhibitors among patients with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusion.. **2022**, ○
- 341 Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience. 13, ○
- 340 Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts. ○
- 339 Effects of post-transplant maintenance therapy with decitabine prophylaxis on the relapse for acute lymphoblastic leukemia.. ○
- 338 Clinical screening for Ph-like ALL and the developing role of TKIs. **2022**, 2022, 594-602 ○
- 337 Cytogenetic evolution predicts a poor prognosis in acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation. ○
- 336 Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component. **2022**, 14, 6244 ○
- 335 SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia. **2022**, 14, ○
- 334 Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms. ○
- 333 Case report: First report of haploidentical allogeneic hematopoietic stem cell transplantation from donors with mild alpha-thalassemia for acute leukemia. 12, ○

- 332 High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial. 12, 1
- 331 Risk stratifying MDS in the time of precision medicine. **2022**, 2022, 375-381 0
- 330 Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy. 0
- 329 Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia. 0
- 328 Myelofibrosis progression grading based on type I and type III collagen and fibrillin 1 expression boosted by whole slide image analysis. 0
- 327 A treatment-refractory aggressive MDS-MLD with multiple highly complex chromosome 5 intrachromosomal rearrangements: a case report. **2022**, 15, 0
- 326 CD34 negative HLA-DR negative acute myeloid leukaemia: A higher association with NPM1 and FLT3-ITD mutations. 0
- 325 A Rare Case of p190 BCR-ABL B-cell Acute Lymphocytic Leukemia With Excellent Response to Hyper-CVAD and Ponatinib. **2022**, 0
- 324 A Rare Case of Aggressive Systemic Mastocytosis With Skeletal Osteosclerotic Lesions on Presentation: A Diagnostic Conundrum. **2022**, 0
- 323 Clinical characteristics, pathology features and outcomes of pediatric myeloid sarcoma: A retrospective case series. 10, 0
- 322 Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML. 12, 0
- 321 Dissecting the cell of origin of aberrant SALL4 expression in myelodysplastic syndrome. 0
- 320 Clinical and Prognostic Impact of STAG2 Mutations in Myeloid Neoplasms: The Mayo Clinic Experience. 0
- 319 Intraoral myeloid sarcoma presenting as toothache and gingival mass. **2022**, 15, e251452 0
- 318 Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. 0
- 317 Monocytosis in primary care and risk of haematological malignancies. 0
- 316 Clinical characteristics and management of headache in patients with myeloproliferative neoplasms. 13, 0
- 315 Enhanced MCM5 Level Predicts Bad Prognosis in Acute Myeloid Leukemia. 0

314	Early-onset venous thromboembolisms in newly diagnosed non-promyelocytic acute myeloid leukemia patients undergoing intensive induction chemotherapy.	0
313	Splenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival.	0
312	Moving Toward More Molecular Classifications of Myelodysplastic Syndrome and Acute Myeloid Leukemia.	0
311	Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients.	3
310	Ginsenoside Rk3 Inhibits the Extramedullary Infiltration of Acute Monocytic Leukemia Cell via miR-3677-5p/CXCL12 Axis. <b>2022</b> , 2022, 1-17	0
309	Structural variants drive context-dependent oncogene activation in cancer. <b>2022</b> , 612, 564-572	2
308	Comparison of characteristics and outcomes on ETP-ALL/LBL and non-ETP ALL patients receiving allogeneic hematopoietic stem cell transplantation. 12,	0
307	Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor. <b>2023</b> , 13,	1
306	Antitumor Effects of Poplar Propolis on DLBCL SU-DHL-2 Cells. <b>2023</b> , 12, 283	0
305	Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia.	1
304	Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.	0
303	Re-induction therapy in patients with acute myeloid leukemia not in complete remission after the first course of treatment.	0
302	Mechanisms associated with t(7;12) acute myeloid leukaemia: from genetics to potential treatment targets.	0
301	Primary Blastic Plasmacytoid Dendritic Cell Neoplasm: a US Population-Based Study.	0
300	Trends in overall mortality among US veterans with primary myelofibrosis. <b>2023</b> , 23,	0
299	Sex disparities in myelodysplastic syndromes: genotype, phenotype, and outcomes. <b>2023</b> ,	0
298	Early response evaluation by single cell signaling profiling in acute myeloid leukemia. <b>2023</b> , 14,	1
297	Relative Bioavailability and Food Effect of Asciminib Pediatric Mini-tablet Formulation Compared to the Reference Tablet Formulation in Healthy Adult Participants.	0

- 296 Cardiac involvement in a patient with B-cell lymphoblastic lymphoma/acute lymphoblastic leukemia and a history of allogeneic hematopoietic stem cell transplantation and CAR T-cell therapy: A case report. **13,** ○
- 295 Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision Oncology. **2023, 13, 163** ○
- 294 Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study. **2023, 100016** ○
- 293 Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97). **12,** ○
- 292 ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms. ○
- 291 Splicing factor-mediated regulation patterns reveals biological characteristics and aid in predicting prognosis in acute myeloid leukemia. **2023, 21,** ○
- 290 Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML. **2023, 13,** ○
- 289 "Losing the Brakes" - Suppressed Inhibitors Triggering Uncontrolled Wnt/ $\beta$ Catenin Signaling May Provide a Potential Therapeutic Target in Elderly Acute Myeloid Leukemia. **2023, 45, 604-613** ○
- 288 Masked Polycythemia Vera and Iron Deficiency in a Fertile-Age Woman. **2023,** ○
- 287 A Case of Acute T/Myeloid Mixed Phenotype Leukemia. **2023, 13, 213-217** ○
- 286 Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management. ○
- 285 Characterization of myeloproliferative neoplasms in the paediatric and young adult population. ○
- 284 BCR :: ABL1 -positive chronic myeloid leukemia with CALR mutation. ○
- 283 Enkurin: A novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens. ○
- 282 Immunophenotypical profiling of myeloid neoplasms with erythroid predominance using mass cytometry (CyTOF). ○
- 281 Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. ○
- 280 Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes. ○
- 279 CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results. **12,** ○

278	Recurrent sideroblastic anemia during pregnancy. <b>2023</b> , 11,	0
277	Analysis of Immune-Cell Distribution of Bone Marrow in Patients with Myelodysplastic Syndrome. <b>2023</b> , 15, 50-56	0
276	Current Understanding of DDX41 Mutations in Myeloid Neoplasms. <b>2023</b> , 15, 344	0
275	Portal vein thrombosis as the presenting manifestation of JAK2 positive myeloproliferative neoplasm. <b>2023</b> ,	0
274	Real-world treatments and thrombotic events in polycythemia vera patients in the USA.	0
273	Splenic irradiation prior to allogeneic hematopoietic cell transplantation for patients with myelofibrosis.	1
272	The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions. 12,	0
271	MPN-Related Mutations and JAK2 Inhibitor Therapy. <b>2023</b> , 13, 238-245	0
270	N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia. <b>2023</b> , 98, 290-299	0
269	Myeloid-derived suppressor cells inhibit natural killer cells in myelodysplastic syndromes through the TIGIT/CD155 pathway. <b>2023</b> , 28,	0
268	Epigenetically silenced DACT3 promotes tumor growth via affecting Wnt/beta-catenin signaling and supports chidamide plus azacitidine therapy in acute myeloid leukemia.	0
267	MarrowQuant 2.0: a digital pathology workflow assisting bone marrow evaluation in experimental and clinical hematology. <b>2023</b> , 100088	0
266	CircZBTB46 Protects Acute Myeloid Leukemia Cells from Ferroptotic Cell Death by Upregulating SCD. <b>2023</b> , 15, 459	0
265	Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis. <b>2023</b> , 55, 348-360	0
264	Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia. <b>2023</b> , 15, 352	0
263	Rare case of pediatric trilineal mixed-phenotype acute leukemia with t(11;19)(q23.3;p13)/KMT2A::ELL. <b>2023</b> , 125, 107018	1
262	Clinical significance of prognostic nutritional index in myelodysplastic syndrome. <b>2023</b> , 28,	0
261	Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management.	2

260	SETD2 detection may reveal response to induction therapy and survival profile in acute myeloid leukemia patients. <b>2023</b> , 28,	0
259	Treatment patterns in older patients with myelodysplastic syndromes: A population-based analysis reflecting the real world. <b>2023</b> , 14, 101418	0
258	Germline Predisposition to Myeloid Neoplasms in Inherited Bone Marrow Failure Syndromes, Inherited Thrombocytopenias, Myelodysplastic Syndromes and Acute Myeloid Leukemia: Diagnosis and Progression to Malignancy. 8, 11-38	1
257	Roads of Drug Resistance in Acute Myeloid Leukemia—It Dead End?.	0
256	Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia: an appraisal of the new WHO and IC classifications and ELN risk stratification.	0
255	Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission.	0
254	Isquemia arterial, mñ allñ de la aterosclerosis y la embolia. <b>2022</b> , 7, 45-47	0
253	Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy.	0
252	Isolated intracranial recurrence in the long-term survival of acute myeloid leukemia: A case report. <b>2022</b> ,	0
251	Impact of the International Consensus Classification of myelodysplastic syndromes.	0
250	Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes. <b>2023</b> , 24, 463	1
249	NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia.	0
248	How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms.	1
247	Genomics and Diagnostics in Acute Myeloid Leukaemia. <b>2019</b> , 161-185	0
246	The Application of Morphogo in the Detection of Megakaryocytes from Bone Marrow Digital Images with Convolutional Neural Networks. <b>2023</b> , 22, 153303382211500	0
245	Clinical and molecular characteristics of forty Chinese children with essential thrombocythemia: A single-center, retrospective analysis.	0
244	Typing of acute leukemia by intelligent optical time-stretch imaging flow cytometry on a chip.	0
243	WHO-Klassifikation 2022 chronischer myeloproliferativer Erkrankungen.	0



- 242 Association of lifestyle behaviors with health-related quality of life among patients with hematologic diseases. ○
- 241 Are the current guidelines for identification of myelodysplastic syndrome with germline predisposition strong enough?. ○
- 240 Downregulation of IRAIN long non-coding RNA predicts unfavourable clinical outcome in acute myeloid leukaemia patients. 1-18 ○
- 239 Impact of Advanced External Beam Radiotherapy on Second Haematological Cancer Risk in Prostate Cancer Survivors. **2023**, ○
- 238 Clinical Impact of c-KIT and CEBPA Mutations in 33 Patients with Corebinding Factor (Non-M3)Acute Myeloid Leukemia. **2023**, ○
- 237 Myelodysplastic syndromes, thy name is heterogeneity. ○
- 236 The effect of granulocyte-colony stimulating factor, decitabine, and busulfanâ€¦yclophosphamide versus busulfanâ€¦yclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, ○
- 235 MUTATIONAL PROFILE ENABLES THE IDENTIFICATION OF A HIGH RISK SUBGROUP IN MYELOYDYSPLASTIC SYNDROMES WITH ISOLATED TRISOMY 8. ○
- 234 Whole-exome sequencing identified recurrent and novel variants in benzene-induced leukemia. **2023**, 16, ○
- 233 Chronic myeloid leukemia diagnosed from the course of diabetic retinopathy. **2023**, ○
- 232 Dasatinib for chronic myelomonocytic leukemia with ZMIZ1-ABL1 fusion gene: a case report. ○
- 231 Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations. ○
- 230 Pediatric Philadelphia-Negative Myeloproliferative Neoplasms in the Era of WHO Classification: A Systematic Review. **2023**, 13, 377 ○
- 229 A potential area of use for immune checkpoint inhibitors: Targeting bone marrow microenvironment in acute myeloid leukemia. 14, ○
- 228 Comprehensive mastocytosis data analysis from a single center. **2023**, 23, ○
- 227 Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL. **2023**, 22, 153303382311540 ○
- 226 Evaluation of the HOXA9 and MEIS1 genes as a potential biomarker in adult acute myeloid leukemia. **2023**, 24, ○
- 225 TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis. ○

- 224 Utilizing digital pathology and immunohistochemistry of p53 as an adjunct to molecular testing in myeloid disorders. **2023**, 10, 100064 ○
- 223 Comparable Outcomes of Pre- Versus Post-Tyrosine Kinase Inhibitor Era Treatment in Chronic Myeloid Leukemia: A Retrospective Cohort Study With Long-term Follow-up. **2023**, 32, 096368972311632 ○
- 222 Epidemiology, clinical presentation, and outcomes of 620 patients with eosinophilia in the intensive care unit. **2023**, 49, 291-301 ○
- 221 Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression. ○
- 220 Detection of acute promyelocytic leukemia in peripheral blood and bone marrow with annotation-free deep learning. **2023**, 13, ○
- 219 The Philadelphia Chromosome, from Negative to Positive: A Case Report of Relapsed Acute Lymphoblastic Leukemia Following Allogeneic Stem Cell Transplantation. **2023**, 59, 671 ○
- 218 A Case Report of Ropoginterferon Alfa-2b for Polycythemia Vera during Pregnancy. **2023**, 15, 172-179 ○
- 217 Epidemiological Features and Outcomes of HTLV-1 Carriers Diagnosed With Cancer: A Retrospective Cohort Study in an Endemic Country. **2023**, ○
- 216 Recognizing Minor Leukemic Populations with Monocytic Features in Mixed-Phenotype Acute Leukemia by Flow Cell Sorting Followed by Cytogenetic and Molecular Studies: Report of Five Exemplary Cases. **2023**, 24, 5260 ○
- 215 Donor-derived myeloid leukemia. **2023**, ○
- 214 Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores. ○
- 213 Incidence, prognostic factors, and survival outcomes in patients with blastic plasmacytoid dendritic cell neoplasm: A retrospective study in the Surveillance, Epidemiology, and End Results database. ○
- 212 High plateletcrit may be associated with thrombotic risk in polycythemia vera. ○
- 211 Intestinal Microbes and Hematological Malignancies. **2023**, 15, 2284 ○
- 210 Identification and validation of a prognostic Risk-Scoring Model based on LATS2 expression in acute myeloid leukemia. ○
- 209 Uptake of COVID-19 vaccination in people with blood cancer: Population-level cohort study of 12 million patients in England. **2023**, 183, 162-170 ○
- 208 Adult Philadelphia-Positive Acute Lymphoblastic Leukemia: A Single-Institution Experience in Limited-Resource Setting. ○
- 207 10-year nationwide trends in incidence, treatment patterns, and mortality of patients with myelodysplastic syndromes in Denmark. **2023**, 128, 107056 ○

- 206 An insight on the role of genetic testing of RUNX1: A key transcriptional gene in familial platelet disorder with predisposition to acute myeloid leukemia. **2023**, 8, 80-84 ○
- 205 Cytotoxic and immunomodulatory potential of a novel [2-(4-(2,5-dimethyl-1H-pyrrol-1-yl)H-pyrazol-3-yl)pyridine] in myeloid leukemia. **2023**, 162, 114701 ○
- 204 The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia. **2023**, 212, 115539 ○
- 203 The prognostic and therapeutic potential of HO-1 in leukemia and MDS. **2023**, 21, ○
- 202 A Review on the Role of Molecular Genetics in the Diagnostic Workup of BCR::ABL1-Negative Myeloproliferative Neoplasms. ○
- 201 Epigenomic machinery regulating pediatric AML: Clonal expansion mechanisms, therapies, and future perspectives. **2023**, 92, 84-101 ○
- 200 High incidence of disseminated intravascular coagulation and acute cerebral infarction in acute myeloid leukemia with cup-like nuclei. **2022**, 62, 249-252 ○
- 199 Persistent decreased bone marrow CD3 + CD56 + T lymphocytes are inversely associated with mature granulocytes in myelodysplastic syndromes. **2023**, 110, 575-577 ○
- 198 Enfermedad mínima residual por citometría de flujo en pacientes con leucemia linfoblástica aguda. **2022**, 20, ○
- 197 Lymphoid aggregates in the bone marrow biopsies of patients with myelodysplastic syndromes: a potential prognostic marker?. **2022**, 12, ○
- 196 Essential Thrombocythemia. **2023**, 19, 104514 ○
- 195 Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review. **2023**, 16, 131-140 ○
- 194 Enteropathy-Associated T-Cell Lymphoma: Epidemiology, Natural History, and Management in the Current Era. **2023**, ○
- 193 Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma. **2023**, 11, 14 ○
- 192 Intracranial Myeloid Sarcoma Mimicking Hypertensive Intracerebral Hemorrhage. **2023**, ○
- 191 A Practical Approach to Systemic Mastocytosis Complications in Cardiac Surgery: A Case Report and Systematic Review of the Literature. **2023**, 12, 1156 ○
- 190 Mutational Profile Enables the Identification of a High Risk Subgroup in Myelodysplastic Syndromes With Isolated Trisomy 8. ○
- 189 Risk prediction in MDS: independent validation of the IPSS-M: ready for routine?. **2023**, 37, 938-941 ○

- 188 The heat shock protein DNAJB2 as a novel biomarker for essential thrombocythemia diagnosis associated with immune infiltration. **2023**, 223, 131-138 ○
- 187 Development of Auer bodies from giant inclusions associated with rough endoplasmic reticulum in acute promyelocytic leukemia. Publish Ahead of Print, ○
- 186 Incidence and risk factors for second malignancies among patients with myeloproliferative neoplasms. ○
- 185 Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication. **2023**, 30, 30-37 1
- 184 Somatic genetic alterations predict haematological progression in GATA2 deficiency. ○
- 183 The fifth edition of the World Health Organization Classification and the International Consensus Classification of myeloid neoplasms: evolving guidelines in the molecular era with practical implications. **2023**, 30, 53-63 ○
- 182 Novel Candidate loci and Pathogenic Germline Variants Involved in Familial Hematological Malignancies Revealed by Whole-Exome Sequencing. **2023**, 15, 944 ○
- 181 Hämatologische Neoplasien und solide Tumore. **2022**, 85-151 ○
- 180 Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic eventsâA population based cohort study. ○
- 179 Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia. **2023**, 30, 153-170.e9 2
- 178 Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL). **2023**, 24, 2962 ○
- 177 Primary extranodal soft tissue Lennert lymphoma (lymphoepithelioid variant of peripheral T-cell lymphoma, unspecified): a case report and review of the literature. **2023**, 18, ○
- 176 Cytokine levels in patients with non-M3 myeloid leukemia are key indicators of how well the disease responds to chemotherapy.. ○
- 175 Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease. **2023**, 64, 846-855 ○
- 174 Sellar B lymphoblastic lymphoma mimics pituitary apoplexy with newly discovered gene mutations in TP53 and PAX5: A case report. 13, ○
- 173 Clinical Features and Genomic Landscape of Myeloproliferative Neoplasm (MPN) Patients with Autoimmune and Inflammatory Diseases (AID). ○
- 172 DNMT activation, TdT-aided gene length mutation, and better prognosis in ATG-based regimen allo-HSCT in AML. **2023**, 62, 665-675 ○
- 171 High Co-Expression of PDCD1/TIGIT/CD47/KIR3DL2 in Bone Marrow Is Associated with Poor Prognosis for Patients with Myelodysplastic Syndrome. **2023**, 2023, 1-11 ○

- 170 European standard clinical practice – Key issues for the medical care of individuals with familial leukemia. **2023**, 66, 104727 ○
- 169 Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS. **2023**, 101056 ○
- 168 Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes. **2023**, 13, ○
- 167 Elevaci3n de SPINK2 en leucemia mieloide aguda. **2023**, 4, 98-104 ○
- 166 Investigation of distinct gene expression profile patterns that can improve the classification of intermediate-risk prognosis in AML patients. 14, ○
- 165 Genomics of clonal evolution in a rare essential thrombocythemia with coexisting Type 2 CALR and MPL S204P mutations. **2023**, 34, ○
- 164 TP53 in AML and MDS: The new (old) kid on the block. **2023**, 101055 ○
- 163 Transcriptionally imprinted glycomic signatures of acute myeloid leukemia. **2023**, 13, ○
- 162 Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Cancer Genetics Group ( UKCGG ), CanGene-CanVar , NHS England Genomic Laboratory Hub ( GLH ) Haematological Malignancies Working Group and the Brit. **2023**, 201, 35-44 ○
- 161 Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression. **2023**, 37, 680-690 ○
- 160 Incidence and predisposing factors of infection in patients treated with hypomethylating agents. **2023**, 127, 107043 ○
- 159 Molecular Drivers of Myelodysplastic Neoplasms (MDS) – Classification and Prognostic Relevance. **2023**, 12, 627 ○
- 158 How I manage anemia related to myelofibrosis and its treatment regimens. **2023**, 102, 689-698 ○
- 157 Palpable spleen size is differently prognostic in primary and secondary myelofibrosis. **2023**, 64, 893-896 ○
- 156 Upregulation of SPINK2 in acute myeloid leukemia. **2023**, 4, 92-97 ○
- 155 Exploration and identification of anoikis-related genes in polycythemia vera. 14, ○
- 154 Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A review. **2023**, 102, e32904 ○
- 153 Blastic Plasmacytoid Dendritic Cell Neoplasm Mimicking Erythema Nodosum: A Case Report. **2023**, 2, ○

- 152 Proteomic and transcriptomic screening demonstrates increased mast cell-derived CCL23 in systemic mastocytosis. **2023**, ○
- 151 Differences between aquagenic and non-aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients. ○
- 150 Decitabine may effectively treat CMML/MDS-associated inflammatory bowel disease by regulating the Th17/Treg balance. ○
- 149 Prognostication refinement in NPM1 -mutated acute myeloid leukemia stratified by FLT3 -ITD status with different induction doses of cytarabine. ○
- 148 Genetic diagnostics and treatment of young adult acute myelomonoblastic leukemia patient using double haploidentical bone marrow transplantation. **2020**, 15, 70-74 ○
- 147 Genomic Alterations, Gene Expression Profiles and Functional Enrichment of Normal-Karyotype Acute Myeloid Leukaemia Based on Targeted Next-Generation Sequencing. **2023**, 15, 1386 ○
- 146 MDS subclassification—do we still have to count blasts?. **2023**, 37, 942-945 ○
- 145 Identification of putative noncanonical driver mutations in patients with essential thrombocythemia. ○
- 144 Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities. **2023**, 37, 843-853 ○
- 143 An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial. 14, ○
- 142 Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine—A Prospective Cohort Study by the AGMT. **2023**, 15, 1388 ○
- 141 Impact of Mutational Status and Prognostic Factors on Survival in Chronic Myelomonocytic Leukemia With Systemic Inflammation and Autoimmune Disorders. **2023**, 7, e847 ○
- 140 Evolving Risk Classifications in AML in a Real-Life Scenario: After Changes upon Changes, Is It More and More Adverse?. **2023**, 15, 1425 ○
- 139 Design and Validation of a Custom Next-Generation Sequencing Panel in Pediatric Acute Lymphoblastic Leukemia. **2023**, 24, 4440 ○
- 138 Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia. ○
- 137 Multilineage Lymphoblastic Lymphoma as an Initial Presentation of Mixed Phenotype Acute Leukemia. **2023**, 2023, 1-6 ○
- 136 Emergency Department Utilization Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Longitudinal Analysis of 557 Patients. **2023**, ○
- 135 The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw. **2023**, 15, 1483 ○

- 134 Hereditary predisposition to malignant myeloid hemopathies: Caution in use of saliva and guideline based on our experience. **2023**, 13, ○
- 133 Pediatric Myeloid Sarcoma, More than Just a Chloroma: A Review of Clinical Presentations, Significance, and Biology. **2023**, 15, 1443 ○
- 132 CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70 Retrospective Study. **2023**, 15, 1479 ○
- 131 Essenzielle Thrombozythämie und Polycythaemia vera. **2023**, 29, 296-304 ○
- 130 Review: JAK2V617F Allele Burden in Diagnosis and Therapeutic Monitoring of Myeloproliferative Neoplasms. **2023**, 5, 35-40 ○
- 129 Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan. ○
- 128 The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes. **2023**, 24, 4708 ○
- 127 Flow cytometry in acute leukemia diagnostics. Guidelines of Russian-Belarusian multicenter group for pediatric leukemia studies. **2023**, 22, 165-177 1
- 126 Mixed-phenotype acute leukemia, T/megakaryoblastic: does it really exist?. **2023**, 16, 49-55 ○
- 125 Chronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report. **2023**, 85, 257-260 ○
- 124 Sepsis-related outcomes of patients with Philadelphia-negative myeloproliferative neoplasms. 1-20 ○
- 123 Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia. **2023**, 98, 760-769 1
- 122 Association of serum polyfluoroalkyl substances (PFAS) with anemia and erythrocytosis in Korean adults: Data from Korean National Environmental Health Survey cycle 4 (2018-2020). **2023**, 249, 114136 ○
- 121 Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies. **2023**, 98, 794-800 ○
- 120 Targeting BCR-ABL1-positive leukaemias: a review article. **2023**, 1, ○
- 119 Prospective Identification of Prognostic Hot-Spot Mutant Gene Signatures for Leukemia: A Computational Study Based on Integrative Analysis of TCGA and cBioPortal Data. ○
- 118 Heterogeneity analysis of the CEBPAdm AML based on bZIP region mutations. Publish Ahead of Print, ○
- 117 Efficacy of Contrast-Enhanced Endoscopic Ultrasonography for the Differentiation of Non-Hodgkin Lymphoma: A Single-Center Retrospective Cohort Study. **2023**, 12, 2054 ○

- 116 Appropriate pre-transplant strategy for patients with myelodysplastic syndromes receiving allogeneic haematopoietic stem cell transplantation after myeloablative conditioning. 14, ○
- 115 Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia. **2023**, 24, 5018 ○
- 114 Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases. **2023**, 15, 180-187 ○
- 113 The Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency. **2023**, 15, 1590 ○
- 112 Decreased transthyretin predicts a poor prognosis in primary myelodysplastic syndrome. 10, ○
- 111 Sequential vs Myeloablative vs Reduced Intensity Conditioning for Patients with Myelodysplastic Syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: A Retrospective Study by the Chronic Malignancies Working Party of the EBMT. ○
- 110 Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells. ○
- 109 In vivo interrogation of regulatory genomes reveals extensive quasi-insufficiency in cancer evolution. **2023**, 3, 100276 ○
- 108 Sepsis-Related Outcomes of Patients with Philadelphia-Negative Myeloproliferative Neoplasms. 1-9 ○
- 107 Editorial: Hybrid or mixed myelodysplastic/myeloproliferative disorders: Current trends in diagnosis and treatment. 13, ○
- 106 Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany. ○
- 105 Faktenblatt: Epidemiologie der myeloproliferativen Neoplasien und des myelodysplastischen Syndroms in Deutschland 2017 bis 2019. **2023**, 29, 281-286 ○
- 104 Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes. **2023**, 28, ○
- 103 Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy. ○
- 102 Isolated meningeal myeloid sarcoma with recurrent MLL-AF6 translocation: a case report. **2023**, 51, 030006052811593 ○
- 101 Prognostic value of PET / CT and CT in T-cell lymphoblastic lymphoma/leukaemia patients: A retrospective cohort study of 145 patients. **2023**, 201, ○
- 100 Comparison of flowcytometry-based scoring system for the diagnosis of early T precursor-acute lymphoblastic leukemia. ○
- 99 The Combination of JAK2V617F Allele Burden and WT1 Expression can Be Helpful in Distinguishing the Subtype of MPN Patients. **2023**, 30, 107327482311636 ○



- 98 Structural and Dynamic Differences between Calreticulin Mutants Associated with Essential Thrombocythemia. **2023**, 13, 509 ○
- 97 Chemotherapy-Induced Oxidative Stress in Pediatric Acute Lymphoblastic Leukemia. **2023**, ○
- 96 Optical Genome Mapping for Cytogenetic Diagnostics in AML. **2023**, 15, 1684 ○
- 95 Wilms's Tumor 1 expression combined with genetic mutations for prognostic assessment in MDS. **2023**, 64, 856-864 ○
- 94 Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). **2023**, 101072 ○
- 93 LSD1 inhibition modulates transcription factor networks in myeloid malignancies. 13, ○
- 92 Changes in retinal circulation and choroidal thickness in patients with acute myeloid leukemia detected by optical coherence tomography angiography. 10, ○
- 91 Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). **2023**, 13, ○
- 90 Case report: Germline RECQL mutation potentially involved in hereditary predisposition to acute leukemia. 13, ○
- 89 Tocotrienols-enriched Self-nanoemulsifying Drug Delivery System Enhances the Antileukemic Activity of All-trans Retinoic Acid but not Electrocardiogram Alterations Evoked by Its Combination with Arsenic Trioxide. **2023**, 24, ○
- 88 Explainable AI identifies diagnostic cells of genetic AML subtypes. **2023**, 2, e0000187 ○
- 87 The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. **2023**, 16, ○
- 86 Combination of NeuX and NeuZ can predict neutrophil dysplasia features of myelodysplastic neoplasms in peripheral blood. ○
- 85 Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model. ○
- 84 Applications of Artificial Intelligence in Philadelphia-Negative Myeloproliferative Neoplasms. **2023**, 13, 1123 ○
- 83 GAISBOCK'S SYNDROME: A CASE STUDY. **2023**, 9-10 ○
- 82 The effect of antinuclear antibody titre and its variation on outcomes in children with primary immune thrombocytopenia. ○
- 81 The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia. **2023**, 24, 5734 ○

- 80 Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. ○
- 79 Erythroleukemia: Classification. ○
- 78 Therapy-related MDS dissected based on primary disease and treatmentâ nationwide perspective. ○
- 77 SOME ASPECTS OF EPIDEMIOLOGY, PATHOGENESIS, DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA. **2021**, 23, 395-409 ○
- 76 m6A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis. **2023**, 83, 1165-1179.e11 ○
- 75 Teufel mit Engelsflgeln âwenn Vitamin A Leben rettet. **2023**, 148, 396-399 ○
- 74 Clinical presentation, treatment patterns, and outcomes of pulmonary embolism in patients with chronic myeloproliferative neoplasms. **2023**, ○
- 73 Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices. **2023**, 102, 985-993 ○
- 72 Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology. **2023**, 12, 946 ○
- 71 Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration. ○
- 70 Inhibition of Integrin  $\alpha 5$ -FAK-MAPK signaling constrains the invasion of T-ALL cells. **2023**, 17, 1-14 ○
- 69 Translocation t(6;7) in AML-M4 cell line GDM-1 results in MNX1 activation through enhancer-hijacking. ○
- 68 Identifying prognostic gene panels in acute myeloid leukemia. **2023**, 16, 277-287 ○
- 67 An Updated Overview of the Role of CYP450 during Xenobiotic Metabolization in Regulating the Acute Myeloid Leukemia Microenvironment. **2023**, 24, 6031 ○
- 66 Prognostic value of cross-lineage expression of the myeloid-associated antigens CD13 and CD33 in adult B-lymphoblastic leukemia: A large real-world study of 1005 patients. ○
- 65 Does leukocytosis remain a predictive factor for survival outcomes in patients with acute promyelocytic leukemia receiving ATRA plus a chemotherapy-based regimen? A prospective multicenter analysis from TALWG. **2023**, 28, ○
- 64 A novel subclonal rearrangement of the STRN3::PDGFRB genes in de novo acute myeloid leukemia with NPM1 mutation and its leukemogenic effects. ○
- 63 Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group. 1-9 ○

- 62 Effects of post-transplant maintenance therapy with decitabine prophylaxis on the relapse for acute lymphoblastic leukemia. ○
- 61 Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma. **2023**, 91, 337-344 ○
- 60 Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study. **2023**, 102, 1099-1109 ○
- 59 Single cell proteogenomic analysis of aberrant monocytosis in TET2 mutant premalignant and malignant hematopoiesis. ○
- 58 RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia. 1-11 ○
- 57 Evaluation of diagnostic efficacy of NRP -1/ CD304 in hematological diseases. ○
- 56 Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia. **2023**, 14, ○
- 55 Cell damage evaluation by intelligent imaging flow cytometry. ○
- 54 JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management. ○
- 53 Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12). ○
- 52 Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. **2023**, 10, e272-e283 ○
- 51 A new combination of monocytic scores to support diagnosis of chronic myelomonocytic leukemia according to novel classifications. ○
- 50 Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience. **2023**, 15, 1983 ○
- 49 Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia. 13, ○
- 48 Development of rapidly fatal TAFRO syndrome-like features in a patient with essential thrombocythemia. **2023**, 63, 32-36 ○
- 47 The expression level of ARF and p53 in AML patients, and their relation to patients' outcome. **2023**, 24, ○
- 46 Prediction of thrombosis in polycythemia vera: Development and validation of a multiple factor-based prognostic score system. **2023**, 7, 100132 ○
- 45 Consensus for Flow Cytometry Clinical Report on Multiple Myeloma: A Multicenter Harmonization Process Merging Laboratory Experience and Clinical Needs. **2023**, 15, 2060 ○

- 44 What's New in the Classification, Diagnosis and Therapy of Myeloid Leukemias. **2023**, 4, 112-134 ○
- 43 The spectrum of biopsy-proven renal disease among Tibetan inhabitants: A survey of 429 patients at a single Chinese center. ○
- 42 The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study. ○
- 41 Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report. **2023**, ○
- 40 Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study. ○
- 39 Applications of Machine Learning in Chronic Myeloid Leukemia. **2023**, 13, 1330 ○
- 38 Polycythemia vera: aspects of its current diagnosis and initial treatment. **2023**, 16, 253-266 ○
- 37 Intravascular Complications of Central Venous Catheterization by Insertion Site in Acute Leukemia during Remission Induction Chemotherapy Phase: Lower Risk with Peripherally Inserted Catheters in a Single-Center Retrospective Study. **2023**, 15, 2147 ○
- 36 TALLSorts: a T-cell acute lymphoblastic leukaemia subtype classifier using RNA-seq expression data. ○
- 35 Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review. Volume 14, 261-277 ○
- 34 Place des outils moléculaires dans les leucémies aiguës myéloïdes en 2023. **2023**, 2023, 52-63 ○
- 33 Actualités des classifications des leucémies aiguës myéloïdes. **2023**, 2023, 22-33 ○
- 32 La leucémie aiguë myéloïde pédiatrique, une entité clinico-biologique ?. **2023**, 2023, 40-51 ○
- 31 Diagnostic et prise en charge des prédispositions génétiques aux hémopathies malignes. **2023**, 2023, 34-39 ○
- 30 Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS-mutated chronic myelomonocytic leukemia. ○
- 29 Increased reactive oxygen species lead to overactivation of platelets in essential thrombocythemia. **2023**, 226, 18-29 ○
- 28 Netrin-1 inducing antiapoptotic effect of acute myeloid leukemia cells in a concentration-dependent manner through the Unc-5 netrin receptor B-focal adhesion kinase axis. **2023**, 24, ○
- 27 The effect of the time from diagnosis to induction therapy on prognosis in patients with acute leukemia undergoing leukapheresis for symptomatic hyperleukocytosis. ○

- 26 Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis. **2023**, 33,
- 25 Therapy-related myeloid neoplasms after <sup>177</sup>Lu-DOTATATE therapy for metastatic neuroendocrine neoplasia: CPX-351 consolidated by allogeneic stem cells transplantation as applicable therapeutic strategy. 1-3
- 24 Genomics of myelodysplastic/myeloproliferative neoplasm. **2023**,
- 23 Kimura disease as an uncommon cause of persistent hypereosinophilia: a diagnostic challenge. **2023**, 33,
- 22 Acute myeloid leukemia cells and MSC-derived exosomes inhibiting transformation in myelodysplastic syndrome.
- 21 Erythroid differentiation intensifies RNA mis-splicing in SF3B1-mutant myelodysplastic syndromes with ring sideroblasts.
- 20 Multifaceted Pt Nanoclusters for Targeting Recognition, Cellular Uptake, and Therapy In Vivo and In Vitro in Chronic Myeloid Leukemia Cells.
- 19 Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
- 18 A novel risk model for predicting early relapse in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem-cell transplantation.
- 17 Neurofibromatosis Symptom-Lacking B-Cell Lineage Acute Lymphoblastic Leukemia with Only an NF1 Gene Pathogenic Variant. **2023**, 13, 1486
- 16 Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression. **2023**, 13,
- 15 Acute myeloid leukemia with RAM immunophenotype: A new underdiagnosed entity.
- 14 Myeloid sarcoma cases with varied presentations leading to diagnostic delay: A case series. 1-5
- 13 Editorial for Preliminary Study of Confounder-Corrected Fat Fraction and R2 \* Mapping of Bone Marrow in Children With Acute Leukemia.
- 12 STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 antibody (MBG453) + azacitidine in higher risk MDS and CMML-2.
- 11 Improving the diagnosis of myelodysplastic syndrome by red blood cell parameters.
- 10 Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. 1-19
- 9 The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients. **2023**,

- 8 Clinical implications of myeloid malignancy-related somatic mutations in aplastic anemia. ○
- 7 NEXT-GENERATION SEQUENCING-BASED GENOMIC PROFILING OF CHILDREN WITH ACUTE MYELOID LEUKEMIA. **2023**, ○
- 6 CNL and aCML should be considered as a single entity based on molecular profiles and outcomes. **2023**, 7, 1672-1681 ○
- 5 Cerebral Sinus Vein Thrombosis and Gender: A Not Entirely Casual Relationship. **2023**, 11, 1280 ○
- 4 Eosinophilia: hypereosinophilic syndrome vs. eosinophilic granulomatosis with polyangiitis. **2023**, 82, 307-320 ○
- 3 Sox13 and M2-like leukemia-associated macrophages contribute to endogenous IL-34 caused accelerated progression of acute myeloid leukemia. **2023**, 14, ○
- 2 Multifunctional targetable liposomal drug delivery system in the management of leukemia: Potential, opportunities, and emerging strategies. **2023**, 325, 121771 ○
- 1 Testicular dysfunction at diagnosis in children and teenagers with haematopoietic malignancies improves after initial chemotherapy. 14, ○